WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, April 22, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L12	= 2001	519
☐	L11	L10 AND L8	937
☐	L10	coronary artery disease	9074
☐	L9	L7 AND L8	158
☐	L8	FGF-1 OR aFGF OR FGF-2 OR bFGF OR VEGF	14483
☐	L7	L6 AND coronary artery disease	467
☐	L6	514/2,8,12,14.CCLS.	15126
☐	L5	Franco.IN.	6857
☐	L4	Franco-W.IN.	4
☐	L3	Franco-Wayne.IN.	0
☐	L2	Franco-W-P.IN.	3
☐	L1	(Franco-Wayne-P.IN.)	7

END OF SEARCH HISTORY

NCBI PubMed National Library of Medicine NIH My NC [Sign In] [Regis

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for coronary artery disease AND FGF-2 Go Clear Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

All: 38 Review: 7

Items 1 - 38 of 38 One page.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Related Articles, Links

Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.
Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.
PMID: 15184289 [PubMed - indexed for MEDLINE]

2: van Royen N, Voskuil M, Hoefer I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST. Related Articles, Links

CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization.
Circulation. 2004 Apr 6;109(13):1647-52. Epub 2004 Mar 15.
PMID: 15023889 [PubMed - indexed for MEDLINE]

3: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Related Articles, Links

Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]

4: Biswas SS, Hughes GC, Scarborough JE, Domkowski PW, Diodato L, Smith ML, Landolfo C, Lowe JE, Annex BH, Landolfo KP. Related Articles, Links

Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
J Thorac Cardiovasc Surg. 2004 Jan;127(1):34-43.
PMID: 14752410 [PubMed - indexed for MEDLINE]

5: Aviles RJ, Annex BH, Lederman RJ. Related Articles, Links

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
Br J Pharmacol. 2003 Oct;140(4):637-46.
PMID: 14534147 [PubMed - indexed for MEDLINE]

6: Ruel M, Sellke FW. Related Articles, Links

Angiogenic protein therapy.
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]

7: Ruel M, Wu GF, Khan TA, Voisine P, Bianchi C, Li J, Li J, Laham RJ, Sellke FW. Related Articles, Links

Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model.
Circulation. 2003 Sep 9;108 Suppl 1:II335-40.
PMID: 12970256 [PubMed - indexed for MEDLINE]

8: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
PMID: 12907464 [PubMed - indexed for MEDLINE]

9: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M. Related Articles, Links

Toward surgical angiogenesis using slow-released basic fibroblast growth factor.
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]

10: Sellke FW, Ruel M. Related Articles, Links

Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

11: Zhang C, Yang J, Feng J, Jennings LK. Related Articles, Links

Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction.
J Lab Clin Med. 2002 Aug;140(2):119-25.
PMID: 12228768 [PubMed - indexed for MEDLINE]

12: Katinioti AA, Tousoulis D, Economou E, Stefanadis C, Trikas A, Tentolouris C, Pitsavos C, Androulakis A, Toutouzas P. Related Articles, Links

Basic fibroblast growth factor changes in response to coronary angioplasty in patients with stable angina.
Int J Cardiol. 2002 Aug;84(2-3):195-9.
PMID: 12127372 [PubMed - indexed for MEDLINE]

13: Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. Related Articles, Links

The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis.
Clin Cardiol. 2002 Jun;25(6):271-8.
PMID: 12058790 [PubMed - indexed for MEDLINE]

14: Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P. Related Articles, Links

Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]

15: Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, Chronos NA. Related Articles, Links

Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
Circulation. 2002 Feb 19;105(7):788-93.
PMID: 11854116 [PubMed - indexed for MEDLINE]

☐ 16: Wilke NM, Zenovich AG, Jerosch-Herold M, Henry TD. Related Articles, Links

Cardiac Magnetic Resonance Imaging for the Assessment of Myocardial Angiogenesis.
Curr Interv Cardiol Rep. 2001 Aug;3(3):205-212.
PMID: 11485690 [PubMed - as supplied by publisher]

☐ 17: Bush MA, Samara E, Whitehouse MJ, Yoshizawa C, Novicki DL, Pike M, Laham RJ, Simons M, Chronos NA. Related Articles, Links

Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease.
J Clin Pharmacol. 2001 Apr;41(4):378-85.
PMID: 11304894 [PubMed - indexed for MEDLINE]

☐ 18: Rosengart TK, Hillebrand K. Related Articles, Links

Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

☐ 19: Lambiase P, Edwards R, Bucknall CA, Marber MS. Related Articles, Links

Physiologically assessed collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 2001 Jan 30;103(4):E22. No abstract available.
PMID: 11157734 [PubMed - indexed for MEDLINE]

☐ 20: Schumacher B, Hannekum A, Pecher P. Related Articles, Links

[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

☐ 21: Udelson JE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M, Galt JR, Pike M, Yoshizawa C, Simons M. Related Articles, Links

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease.
Circulation. 2000 Oct 3;102(14):1605-10.
PMID: 11015335 [PubMed - indexed for MEDLINE]

☐ 22: Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon RO 3rd, Quyyumi AA. Related Articles, Links

Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris.
Am J Cardiol. 2000 Jun 15;85(12):1414-9.
PMID: 10856385 [PubMed - indexed for MEDLINE]

☐ 23: Lucassen AM, de Waal RM, Verheugt FW. Related Articles, Links

[Therapeutic angiogenesis as a new experimental treatment for vascular disease]
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch.

PMID: 10774292 [PubMed - indexed for MEDLINE]

24: Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Related Articles, Links

Expression and function of PPARgamma in rat and human vascular smooth muscle cells.
Circulation. 2000 Mar 21;101(11):1311-8.
PMID: 10725292 [PubMed - indexed for MEDLINE]

25: Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Related Articles, Links

Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]

26: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. Related Articles, Links

Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

27: Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Related Articles, Links

Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]

28: Laham RJ, Simons M, Tofukuji M, Hung D, Sellke FW. Related Articles, Links

Modulation of myocardial perfusion and vascular reactivity by pericardial basic fibroblast growth factor: insight into ischemia-induced reduction in endothelium-dependent vasodilatation.
J Thorac Cardiovasc Surg. 1998 Dec;116(6):1022-8.
PMID: 9832695 [PubMed - indexed for MEDLINE]

29: Iwakura A, Komeda M, Fujita M. Related Articles, Links

[Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]

30: Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Related Articles, Links

Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results.
Ann Thorac Surg. 1998 Jun;65(6):1540-4.
PMID: 9647055 [PubMed - indexed for MEDLINE]

31: Hasdai D, Barak V, Leibovitz E, Herz I, Sclarovsky S, Eldar M, Scheinowitz M. Related Articles, Links

Serum basic fibroblast growth factor levels in patients with ischemic heart disease.
Int J Cardiol. 1997 Apr 18;59(2):133-8.
PMID: 9158164 [PubMed - indexed for MEDLINE]

☐ 32: Ito A, Shimokawa H, Fukumoto Y, Kadokami T, Nakaike R, Takayanagi T, Egashira K, Sueishi K, Takeshita A. Related Articles, Links

The role of fibroblast growth factor-2 in the vascular effects of interleukin-1 beta in porcine coronary arteries in vivo.
Cardiovasc Res. 1996 Sep;32(3):570-9.
PMID: 8881517 [PubMed - indexed for MEDLINE]

☐ 33: Taylor AJ, Farb AA, Angello DA, Burwell LR, Virmani R. Related Articles, Links

Proliferative activity in coronary atherectomy tissue. Clinical, histopathologic, and immunohistochemical correlates.
Chest. 1995 Sep;108(3):815-20.
PMID: 7656639 [PubMed - indexed for MEDLINE]

☐ 34: Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Related Articles, Links

Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?
Circulation. 1994 Apr;89(4):1511-7.
PMID: 7908609 [PubMed - indexed for MEDLINE]

☐ 35: Wilcox JN. Related Articles, Links

Molecular biology: insight into the causes and prevention of restenosis after arterial intervention.
Am J Cardiol. 1993 Oct 18;72(13):88E-95E. Review.
PMID: 8213576 [PubMed - indexed for MEDLINE]

☐ 36: Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. Related Articles, Links

A cascade model for restenosis. A special case of atherosclerosis progression.
Circulation. 1992 Dec;86(6 Suppl):III47-52. Review.
PMID: 1424051 [PubMed - indexed for MEDLINE]

☐ 37: Gordon D. Related Articles, Links

Growth factors and cell proliferation in human transplant arteriosclerosis.
J Heart Lung Transplant. 1992 May-Jun;11(3 Pt 2):S7. No abstract available.
PMID: 1623005 [PubMed - indexed for MEDLINE]

☐ 38: Heidemann P, Hofling B, Heimerl J, Emberger C, Meyer G, Kandolf R, Bauriedel G. Related Articles, Links

[Proliferative response of smooth muscle cells from human arteriosclerosis lesions to PDGF, bFGF and EGF]
Vasa Suppl. 1992;35:137-9. German. No abstract available.
PMID: 1481019 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

NCBI PubMed National Library of Medicine [Sign In] [Regis

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for coronary artery disease AND FGF-1 Go Clear Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

All: 7 Review: 1

Items 1 - 7 of 7 One page.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
PMID: 12907464 [PubMed - indexed for MEDLINE]

2: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C. Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
PMID: 12692004 [PubMed - indexed for MEDLINE]

3: Sellke FW, Ruel M. Related Articles, Links

Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

4: Schumacher B, Hannekum A, Pecher P. Related Articles, Links

[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

5: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC. Related Articles, Links

Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.
Microvasc Res. 1999 Nov;58(3):238-49.
PMID: 10527767 [PubMed - indexed for MEDLINE]

6: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. Related Articles, Links

Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

7: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.
Surgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

NCBI PubMed National Library of Medicine [Sign In] [Regis

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for coronary artery disease AND VEGF Go Clear Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

About Entrez

Text Version

All: 113 Review: 38

Items 1 - 113 of 113 One page.

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Matsunaga T, Chilian WM, March K. Related Articles, Links

Angiostatin is negatively associated with coronary collateral growth in patients with coronary artery disease.
Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2042-6.
PMID: 15840902 [PubMed - in process]

2: Urbich C, Dimmeler S. Related Articles, Links

Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Kidney Int. 2005 May;67(5):1672-6.
PMID: 15840010 [PubMed - in process]

3: Urbich C, Knau A, Fichtlscherer S, Walter DH, Bruhl T, Potente M, Hofmann WK, de Vos S, Zeiher AM, Dimmeler S. Related Articles, Links

FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.
FASEB J. 2005 Apr 11; [Epub ahead of print]
PMID: 15824087 [PubMed - as supplied by publisher]

4: Gupta K, Zhang J. Related Articles, Links

Angiogenesis: a curse or cure?
Postgrad Med J. 2005 Apr;81(954):236-42.
PMID: 15811887 [PubMed - in process]

5: Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, Wakhloo AK, Webster KA. Related Articles, Links

Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle.
Gene Ther. 2005 May;12(9):762-71.
PMID: 15772688 [PubMed - in process]

6: Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, Spandidos DA. Related Articles, Links

Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions.
Int J Mol Med. 2005 Apr;15(4):603-10.
PMID: 15754021 [PubMed - in process]

7: Alber HF, Frick M, Dulak J, Dorler J, Zwick RH, Dichtl W, Pachinger O, Weidinger F. Related Articles, Links

Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease.

Heart. 2005 Mar;91(3):365-6. No abstract available.
PMID: 15710722 [PubMed - indexed for MEDLINE]

8: Czekalski S. Related Articles, Links

[What is new in the treatment of diabetes?--The importance of nephro- and cardioprotective management]
Pol Arch Med Wewn. 2004 Oct;112 Spec No:65-9. Polish.
PMID: 15669203 [PubMed - indexed for MEDLINE]

9: Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM; CAPTURE Study Investigators. Related Articles, Links

Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis.
J Am Coll Cardiol. 2005 Jan 18;45(2):229-37.
PMID: 15653020 [PubMed - indexed for MEDLINE]

10: Yoon YS, Johnson IA, Park JS, Diaz L, Losordo DW. Related Articles, Links

Therapeutic myocardial angiogenesis with vascular endothelial growth factors.
Mol Cell Biochem. 2004 Sep;264(1-2):63-74. Review.
PMID: 15544036 [PubMed - indexed for MEDLINE]

11: Maulik N. Related Articles, Links

Angiogenic signal during cardiac repair.
Mol Cell Biochem. 2004 Sep;264(1-2):13-23. Review.
PMID: 15544031 [PubMed - indexed for MEDLINE]

12: Pawlak J, Klim B, Szkudlarek M, Dzieciol J. Related Articles, Links

[The formation of new blood vessels in coronary artery disease: where we are now]
Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.
PMID: 15536393 [PubMed - in process]

13: Suzuki A, Miyagawa-Tomita S, Komatsu K, Nakazawa M, Fukaya T, Baba K, Yutani C. Related Articles, Links

Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease.
Pediatr Int. 2004 Oct;46(5):590-6.
PMID: 15491390 [PubMed - indexed for MEDLINE]

14: Crawford SE, Mavroudis C, Backer CL, Huang X, Mu Y, Volpert OV, Stellmach V, Pahl E, Huang L. Related Articles, Links

Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels.
J Heart Lung Transplant. 2004 Jun;23(6):666-73.
PMID: 15366425 [PubMed - indexed for MEDLINE]

15: Celec P, Yonemitsu Y. Related Articles, Links

Vascular endothelial growth factor - basic science and its clinical implications.
Pathophysiology. 2004 Oct;11(2):69-75.
PMID: 15364116 [PubMed - as supplied by publisher]

16: Tio RA, Tan ES, Jessurun GA, Veeger N, Jager PL, Slart RH, de Jong RM, Pruim J, Hospers GA, Willemsen AT, de Jongste MJ, Related Articles, Links

van Boven AJ, van Veldhuisen DJ, Zijlstra F.

PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease.
J Nucl Med. 2004 Sep;45(9):1437-43.
PMID: 15347709 [PubMed - indexed for MEDLINE]

17: Kolsut P, Malecki M, Firek B, Teresinska A, Janik P, Religa Z. Related Articles, Links

[Gene therapy with phVEGF165 plasmid--preliminary report]
Kardiol Pol. 2004 Feb;60 Suppl 1:I-82-9. Polish. No abstract available.
PMID: 15247953 [PubMed - indexed for MEDLINE]

18: Depre C, Kim SJ, John AS, Huang Y, Rimoldi OE, Pepper JR, Dreyfus GD, Gaussin V, Pennell DJ, Vatner DE, Camici PG, Vatner SF. Related Articles, Links

Program of cell survival underlying human and experimental hibernating myocardium.
Circ Res. 2004 Aug 20;95(4):433-40. Epub 2004 Jul 8.
PMID: 15242971 [PubMed - indexed for MEDLINE]

19: Nakajima K, Tabata S, Yamashita T, Kusuhara M, Arakawa K, Ohmori R, Yonemura A, Higashi K, Ayaori M, Nakamura H, Ohsuzu F. Related Articles, Links

Plasma vascular endothelial growth factor level is elevated in patients with multivessel coronary artery disease.
Clin Cardiol. 2004 May;27(5):281-6.
PMID: 15188944 [PubMed - indexed for MEDLINE]

20: Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Related Articles, Links

Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support.
Circulation. 2004 Jun 22;109(24):2986-92. Epub 2004 Jun 7.
PMID: 15184289 [PubMed - indexed for MEDLINE]

21: Lemstrom KB, Nykanen AI, Tikkanen JM, Krebs R, Sihvola RK, Kallio EA, Olivier R, Koskinen PK. Related Articles, Links

Role of angiogenic growth factors in transplant coronary artery disease.
Ann Med. 2004;36(3):184-93. Review.
PMID: 15181974 [PubMed - indexed for MEDLINE]

22: Panchal VR, Rehman J, Nguyen AT, Brown JW, Turrentine MW, Mahomed Y, March KL. Related Articles, Links

Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease.
J Am Coll Cardiol. 2004 Apr 21;43(8):1383-7.
PMID: 15093871 [PubMed - indexed for MEDLINE]

23: Gouni-Berthold I, Sachinidis A. Related Articles, Links

Molecular mechanisms explaining the preventive effects of catechins on the development of proliferative diseases.
Curr Pharm Des. 2004;10(11):1261-71. Review.
PMID: 15078140 [PubMed - indexed for MEDLINE]

24: Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D. Related Articles, Links

Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).
Gene Ther. 2004 Mar;11(6):512-21.
PMID: 14999223 [PubMed - indexed for MEDLINE]

25: Syed IS, Sanborn TA, Rosengart TK. Related Articles, Links

Therapeutic angiogenesis: a biologic bypass.
Cardiology. 2004;101(1-3):131-43. Review.
PMID: 14988635 [PubMed - indexed for MEDLINE]

26: Adams V, Lenk K, Linke A, Lenz D, Erbs S, Sandri M, Tarnok A, Gielen S, Emmrich F, Schuler G, Hambrecht R. Related Articles, Links

Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia.
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):684-90. Epub 2004 Feb 26.
PMID: 14988094 [PubMed - indexed for MEDLINE]

27: Chong AY, Caine GJ, Lip GY. Related Articles, Links

Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?
Eur J Clin Invest. 2004 Jan;34(1):9-13.
PMID: 14984432 [PubMed - indexed for MEDLINE]

28: Schalch P, Rahman GF, Patejunas G, Goldschmidt RA, Carbray J, Retuerto MA, Kim D, Esser K, Crystal RG, Rosengart TK. Related Articles, Links

Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.
J Thorac Cardiovasc Surg. 2004 Feb;127(2):535-40.
PMID: 14762365 [PubMed - indexed for MEDLINE]

29: Symes JF. Related Articles, Links

Gene therapy for ischemic heart disease: therapeutic potential.
Am J Cardiovasc Drugs. 2001;1(3):159-66. Review.
PMID: 14728030 [PubMed - indexed for MEDLINE]

30: Calvi C, Dentelli P, Pagano M, Rosso A, Pegoraro M, Giunti S, Garbarino G, Camussi G, Pegoraro L, Brizzi MF. Related Articles, Links

Angiopoietin 2 induces cell cycle arrest in endothelial cells: a possible mechanism involved in advanced plaque neovascularization.
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):511-8. Epub 2004 Jan 15.
PMID: 14726409 [PubMed - indexed for MEDLINE]

31: Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G. Related Articles, Links

Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis.
Circulation. 2004 Jan 20;109(2):220-6. Epub 2003 Dec 22.
PMID: 14691039 [PubMed - indexed for MEDLINE]

32: Scheubel RJ, Zorn H, Silber RE, Kuss O, Morawietz H, Holtz J, Simm A. Related Articles, Links

Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery bypass grafting.
J Am Coll Cardiol. 2003 Dec 17;42(12):2073-80.
PMID: 14680729 [PubMed - indexed for MEDLINE]

33: Kolsut P, Malecki M, Zelazny P, Teresinska A, Firek B, Janik P, Religa Z. Related Articles, Links

Gene therapy of coronary artery disease with phvegf165--early outcome.
Kardiol Pol. 2003 Nov;59(11):373-84. English, Polish.
PMID: 14668888 [PubMed - indexed for MEDLINE]

34: Baklanov D, Simons M. Related Articles, Links

Arteriogenesis: lessons learned from clinical trials.
Endothelium. 2003;10(4-5):217-23. Review.
PMID: 14660081 [PubMed - indexed for MEDLINE]

35: Roguin A, Resar JR. Related Articles, Links

Genetics and susceptibility of coronary collateral formation.
Circulation. 2003 Nov 25;108(21):e149; author reply e149. No abstract available.
PMID: 14638531 [PubMed - indexed for MEDLINE]

36: Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY. Related Articles, Links

Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease.
Heart. 2003 Dec;89(12):1411-5.
PMID: 14617549 [PubMed - indexed for MEDLINE]

37: Panutsopulos D, Zafiropoulos A, Krambovitis E, Kochiadakis GE, Igoumenidis NE, Spandidos DA. Related Articles, Links

Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression.
J Transl Med. 2003 Oct 6;1(1):6.
PMID: 14585103 [PubMed - as supplied by publisher]

38: Juan-Babot JO, Martinez-Gonzalez J, Berrozpe M, Badimon L. Related Articles, Links

[Neovascularization in human coronary arteries with lesions of different severity]
Rev Esp Cardiol. 2003 Oct;56(10):978-86. Spanish.
PMID: 14563292 [PubMed - indexed for MEDLINE]

39: Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H, Hamasaki Y. Related Articles, Links

A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki disease.
J Pediatr. 2003 Sep;143(3):357-62.
PMID: 14517520 [PubMed - indexed for MEDLINE]

40: Fujita M, Ikemoto M, Tanaka T, Tamaki S, Yamazato A, Sawamura T, Hasegawa K, Kihara Y, Nohara R, Sasayama S. Related Articles, Links

Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
Angiogenesis. 1998;2(1):105-8.
PMID: 14517380 [PubMed]

41: Crottogini A, Meckert PC, Vera Janavel G, Lascano E, Negroni J, Del Valle H, Dulbecco E, Werba P, Cuniberti L, Martinez V, De Lorenzi A, Telayna J, Mele A, Fernandez JL, Marangunich L, Criscuolo M, Capogrossi MC, Laguens R. Related Articles, Links

Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs.
Hum Gene Ther. 2003 Sep 20;14(14):1307-18.
PMID: 14503966 [PubMed - indexed for MEDLINE]

42: Ruel M, Sellke FW. Related Articles, Links

Angiogenic protein therapy.
Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):222-35. Review.
PMID: 12973700 [PubMed - indexed for MEDLINE]

43: Hedman M, Yla-Herttuala S. Related Articles, Links

Gene therapy for the treatment of peripheral vascular disease and coronary artery disease.
Drugs Today (Barc). 2000 Sep;36(9):609-17.
PMID: 12847566 [PubMed]

44: Chung NA, Makin AJ, Lip GY. Related Articles, Links

Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay.
Eur J Clin Invest. 2003 Jul;33(7):529-35.
PMID: 12814387 [PubMed - indexed for MEDLINE]

45: Kastrup J. Related Articles, Links

Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?
Curr Gene Ther. 2003 Jun;3(3):197-206. Review.
PMID: 12762479 [PubMed - indexed for MEDLINE]

46: Rasmussen HS, Rasmussen CS, Macko J. Related Articles, Links

VEGF gene therapy for coronary artery disease and peripheral vascular disease.
Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.
PMID: 12699842 [PubMed - indexed for MEDLINE]

47: Kusumanto YH, Hospers GA, Mulder NH, Tio RA. Related Articles, Links

Therapeutic angiogenesis with vascular endothelial growth factor in peripheral and coronary artery disease: a review.
Int J Cardiovasc Intervent. 2003;5(1):27-34. Review.
PMID: 12623562 [PubMed - indexed for MEDLINE]

48: Sellke FW, Ruel M. Related Articles, Links

Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

49: Khan TA, Sellke FW, Laham RJ. Related Articles, Links

Therapeutic angiogenesis: protein-based therapy for coronary artery disease.
Expert Opin Pharmacother. 2003 Feb;4(2):219-26. Review.
PMID: 12562312 [PubMed - indexed for MEDLINE]

50: Sim EK, Zhang L, Shim WS, Lim YL, Ge R. Related Articles, Links

Therapeutic angiogenesis for coronary artery disease.
J Card Surg. 2002 Jul-Aug;17(4):350-4. Review.

PMID: 12546086 [PubMed - indexed for MEDLINE]

☐ 51: Kutryk MJ, Stewart DJ. Related Articles, Links

Angiogenesis of the heart.
Microsc Res Tech. 2003 Feb 1;60(2):138-58. Review.
PMID: 12539168 [PubMed - indexed for MEDLINE]

☐ 52: Lenihan DJ, Osman A, Sriram V, Aitsebaomo J, Patterson C. Related Articles, Links

Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary disease.
Am J Physiol Heart Circ Physiol. 2003 May;284(5):H1507-12. Epub 2003 Jan 9.
PMID: 12521946 [PubMed - indexed for MEDLINE]

☐ 53: Lee CH, Smits PC. Related Articles, Links

Vascular growth factors for coronary angiogenesis.
J Interv Cardiol. 2002 Dec;15(6):511-8. Review.
PMID: 12476656 [PubMed - indexed for MEDLINE]

☐ 54: Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G. Related Articles, Links

Angiogenic gene therapy strategies for the treatment of cardiovascular disease.
Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.
PMID: 12435049 [PubMed - indexed for MEDLINE]

☐ 55: Ben-Gary H, McKinney RL, Rosengart T, Lesser ML, Crystal RG. Related Articles, Links

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Mol Ther. 2002 Aug;6(2):287-97.
PMID: 12349828 [PubMed - indexed for MEDLINE]

☐ 56: Freedman SB, Vale P, Kalka C, Kearney M, Pieczek A, Symes J, Losordo D, Isner JM. Related Articles, Links

Plasma vascular endothelial growth factor (VEGF) levels after intramuscular and intramyocardial gene transfer of VEGF-1 plasmid DNA.
Hum Gene Ther. 2002 Sep 1;13(13):1595-603.
PMID: 12228014 [PubMed - indexed for MEDLINE]

☐ 57: Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Related Articles, Links

Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?
Stroke. 2002 Sep;33(9):2187-91.
PMID: 12215585 [PubMed - indexed for MEDLINE]

☐ 58: Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF. Related Articles, Links

A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
Clin Pharmacol Ther. 2002 Jul;72(1):20-32.
PMID: 12152001 [PubMed - indexed for MEDLINE]

☐ 59: Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. Related Articles, Links

Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.
J Am Coll Cardiol. 2002 Jun 19;39(12):1951-5.
PMID: 12084593 [PubMed - indexed for MEDLINE]

60: Cotton JM, Mathur A, Hong Y, Brown AS, Martin JF, Erusalimsky JD. Related Articles, Links

Acute rise of circulating vascular endothelial growth factor-A in patients with coronary artery disease following cardiothoracic surgery.
Eur Heart J. 2002 Jun;23(12):953-9.
PMID: 12069450 [PubMed - indexed for MEDLINE]

61: Vale PR, Isner JM, Rosenfield K. Related Articles, Links

Therapeutic angiogenesis in critical limb and myocardial ischemia.
J Interv Cardiol. 2001 Oct;14(5):511-28. Review.
PMID: 12053643 [PubMed - indexed for MEDLINE]

62: Byzova TV, Goldman CK, Jankau J, Chen J, Cabrera G, Achen MG, Stacker SA, Carnevale KA, Siemionow M, Deitcher SR, DiCorleto PE. Related Articles, Links

Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo.
Blood. 2002 Jun 15;99(12):4434-42.
PMID: 12036873 [PubMed - indexed for MEDLINE]

63: Herrmann J, Best PJ, Ritman EL, Holmes DR, Lerman LO, Lerman A. Related Articles, Links

Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia.
J Am Coll Cardiol. 2002 May 1;39(9):1555-61.
PMID: 11985922 [PubMed - indexed for MEDLINE]

64: Rosen LS. Related Articles, Links

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44. Review.
PMID: 11965229 [PubMed - indexed for MEDLINE]

65: Zimmerman MA, Selzman CH, Raeburn CD, Calkins CM, Barsness K, Harken AH. Related Articles, Links

Clinical applications of cardiovascular angiogenesis.
J Card Surg. 2001 Nov-Dec;16(6):490-7. Review.
PMID: 11925031 [PubMed - indexed for MEDLINE]

66: Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB, van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C. Related Articles, Links

Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
J Intern Med. 2001 Nov;250(5):373-81.
PMID: 11887971 [PubMed - indexed for MEDLINE]

67: Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Related Articles, Links

Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of

patients with coronary or peripheral atherosclerosis, or Type II diabetes.
Clin Sci (Lond). 2002 Feb;102(2):187-94.
PMID: 11834138 [PubMed - indexed for MEDLINE]

68: Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, Dryota V, Islam KB. Related Articles, Links

Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression.
J Cardiovasc Pharmacol. 2002 Feb;39(2):215-24.
PMID: 11791007 [PubMed - indexed for MEDLINE]

69: Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Related Articles, Links

Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.
Hum Gene Ther. 2002 Jan 1;13(1):65-100.
PMID: 11779413 [PubMed - indexed for MEDLINE]

70: Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Related Articles, Links

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Hum Gene Ther. 2002 Jan 1;13(1):15-63.
PMID: 11779412 [PubMed - indexed for MEDLINE]

71: Freedman SB, Isner JM. Related Articles, Links

Therapeutic angiogenesis for coronary artery disease.
Ann Intern Med. 2002 Jan 1;136(1):54-71. Review.
PMID: 11777364 [PubMed - indexed for MEDLINE]

72: Dulak J, Jozkowicz A, Frick M, Alber HF, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. Related Articles, Links

Vascular endothelial growth factor: angiogenesis, atherogenesis or both?
J Am Coll Cardiol. 2001 Dec;38(7):2137-8. No abstract available.
PMID: 11738334 [PubMed - indexed for MEDLINE]

73: Huwer H, Welter C, Ozbek C, Seifert M, Straub U, Greilach P, Kalweit G, Isringhaus H. Related Articles, Links

Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.
Eur J Cardiothorac Surg. 2001 Dec;20(6):1128-34.
PMID: 11717016 [PubMed - indexed for MEDLINE]

74: Davda J, Labhasetwar V. Related Articles, Links

An update on angiogenesis therapy.
Crit Rev Eukaryot Gene Expr. 2001;11(1-3):1-21. Review.
PMID: 11693956 [PubMed - indexed for MEDLINE]

75: Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER. Related Articles, Links

Intracoronary administration of recombinant human vascular endothelial

growth factor to patients with coronary artery disease.
Am Heart J. 2001 Nov;142(5):872-80.
PMID: 11685177 [PubMed - indexed for MEDLINE]

76: Choukroun G. Related Articles, Links

[Prevention and treatment of type 1 diabetes]
Presse Med. 2001 Sep 1;30(24 Pt 2):21-3. French.
PMID: 11577580 [PubMed - indexed for MEDLINE]

77: Basara N. Related Articles, Links

AdGVVEGF121.10 (GenVec).
Curr Opin Investig Drugs. 2001 Jun;2(6):792-5. Review.
PMID: 11572658 [PubMed - indexed for MEDLINE]

78: Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. Related Articles, Links

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
J Clin Invest. 2001 Aug;108(3):391-7.
PMID: 11489932 [PubMed - indexed for MEDLINE]

79: Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Related Articles, Links

Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Heart Vessels. 2000;15(3):105-11.
PMID: 11289497 [PubMed - indexed for MEDLINE]

80: Ray S, Panja M. Related Articles, Links

Current understanding of pathogenesis of coronary artery disease and its future implications.
J Indian Med Assoc. 2000 Nov;98(11):710-1, 714, 718.
PMID: 11265801 [PubMed - indexed for MEDLINE]

81: Brizzi MF, Formato L, Bonamini R. Related Articles, Links

The molecular mechanisms of angiogenesis: a new approach to cardiovascular diseases.
Ital Heart J. 2001 Feb;2(2):81-92. Review.
PMID: 11256548 [PubMed - indexed for MEDLINE]

82: Morse MA. Related Articles, Links

Technology evaluation: VEGF165 gene therapy, Valentis Inc.
Curr Opin Mol Ther. 2001 Feb;3(1):97-101. Review.
PMID: 11249737 [PubMed - indexed for MEDLINE]

83: Rosengart TK, Hillebrand K. Related Articles, Links

Gene therapy for coronary artery disease.
Adv Card Surg. 2001;13:107-20. Review. No abstract available.
PMID: 11209652 [PubMed - indexed for MEDLINE]

84: Freedman SB, Isner JM. Related Articles, Links

Therapeutic angiogenesis for ischemic cardiovascular disease.
J Mol Cell Cardiol. 2001 Mar;33(3):379-93. Review.
PMID: 11181008 [PubMed - indexed for MEDLINE]

85: Durairaj A, Mehra A, Singh RP, Faxon DP. Related Articles, Links

Therapeutic angiogenesis.
Cardiol Rev. 2000 Sep-Oct;8(5):279-87. Review.
PMID: 11174906 [PubMed - indexed for MEDLINE]

86: Rutanen J, Rissanen TT, Kivela A, Vajanto I, Yla-Herttuala S. Related Articles, Links

Clinical applications of vascular gene therapy.
Curr Cardiol Rep. 2001 Jan;3(1):29-36. Review.
PMID: 11139796 [PubMed - indexed for MEDLINE]

87: Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM. Related Articles, Links

Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
Anesth Analg. 2001 Jan;92(1):19-25.
PMID: 11133594 [PubMed - indexed for MEDLINE]

88: Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF, Isner JM. Related Articles, Links

Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia.
Circulation. 2000 Aug 29;102(9):965-74.
PMID: 10961959 [PubMed - indexed for MEDLINE]

89: Mukherjee D, Ellis SG. Related Articles, Links

New options for untreatable coronary artery disease: angiogenesis and laser revascularization.
Cleve Clin J Med. 2000 Aug;67(8):577-83.
PMID: 10946453 [PubMed - indexed for MEDLINE]

90: O'Brien T, Simari RD. Related Articles, Links

Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution.
Mayo Clin Proc. 2000 Aug;75(8):831-4. Review.
PMID: 10943238 [PubMed - indexed for MEDLINE]

91: Lucassen AM, de Waal RM, Verheugt FW. Related Articles, Links

[Therapeutic angiogenesis as a new experimental treatment for vascular disease]
Ned Tijdschr Geneeskd. 2000 Apr 1;144(14):650-5. Review. Dutch.
PMID: 10774292 [PubMed - indexed for MEDLINE]

92: Lazarous DF, Shou M, Stiber JA, Hodge E, Thirumurti V, Goncalves L, Unger EF. Related Articles, Links

Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
Cardiovasc Res. 1999 Nov;44(2):294-302.
PMID: 10690306 [PubMed - indexed for MEDLINE]

93: Chawla PS, Keelan MH, Kipshidze N. Related Articles, Links

Angiogenesis for the treatment of vascular diseases.
Int Angiol. 1999 Sep;18(3):185-92. Review.
PMID: 10688416 [PubMed - indexed for MEDLINE]

94: Moussa I, Moses JW. Related Articles, Links

Angiogenesis for treatment of ischemic heart disease: should we worry about progression of atherosclerosis?
Circulation. 1999 Nov 30;100(22):e109. No abstract available.
PMID: 10578010 [PubMed - indexed for MEDLINE]

95: Fleisch M, Billinger M, Eberli FR, Garachemani AR, Meier B, Seiler C. Related Articles, Links

Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.
Circulation. 1999 Nov 9;100(19):1945-50.
PMID: 10556219 [PubMed - indexed for MEDLINE]

96: Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. Related Articles, Links

Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Ann Surg. 1999 Oct;230(4):466-70; discussion 470-2.
PMID: 10522716 [PubMed - indexed for MEDLINE]

97: Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isner JM. Related Articles, Links

Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
Ann Thorac Surg. 1999 Sep;68(3):830-6; discussion 836-7.
PMID: 10509970 [PubMed - indexed for MEDLINE]

98: Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, Lavie P, Roguin A, Levy AP. Related Articles, Links

Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation.
Circulation. 1999 Aug 3;100(5):547-52.
PMID: 10430770 [PubMed - indexed for MEDLINE]

99: Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG. Related Articles, Links

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Circulation. 1999 Aug 3;100(5):468-74.
PMID: 10430759 [PubMed - indexed for MEDLINE]

100: Losordo DW, Vale PR, Isner JM. Related Articles, Links

Gene therapy for myocardial angiogenesis.
Am Heart J. 1999 Aug;138(2 Pt 2):S132-41. Review.
PMID: 10426872 [PubMed - indexed for MEDLINE]

101: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. Related Articles, Links

Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.

Clin Chim Acta. 1999 May;283(1-2):171-82.
PMID: 10404741 [PubMed - indexed for MEDLINE]

☐ **102:** Patterson C, Runge MS. Related Articles, Links

Therapeutic angiogenesis: the new electrophysiology?
Circulation. 1999 May 25;99(20):2614-6. Review. No abstract available.
PMID: 10338451 [PubMed - indexed for MEDLINE]

☐ **103:** Okada M, Matsumori A, Ono K, Miyamoto T, Takahashi M, Sasayama S. Related Articles, Links

Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Biochem Biophys Res Commun. 1999 Feb 5;255(1):80-7.
PMID: 10082659 [PubMed - indexed for MEDLINE]

☐ **104:** Chen YX, Nakashima Y, Tanaka K, Shiraishi S, Nakagawa K, Sueishi K. Related Articles, Links

Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.
Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):131-9.
PMID: 9888875 [PubMed - indexed for MEDLINE]

☐ **105:** Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Related Articles, Links

Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
Circulation. 1998 Dec 22-29;98(25):2800-4.
PMID: 9860779 [PubMed - indexed for MEDLINE]

☐ **106:** Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K. Related Articles, Links

Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.
Circulation. 1998 Nov 17;98(20):2108-16.
PMID: 9815864 [PubMed - indexed for MEDLINE]

☐ **107:** Iwakura A, Komeda M, Fujita M. Related Articles, Links

[Coronary stenosis and mechanisms of collateral vessel growth]
Nippon Rinsho. 1998 Oct;56(10):2504-8. Review. Japanese.
PMID: 9796310 [PubMed - indexed for MEDLINE]

☐ **108:** Komatsu R, Ueda M. Related Articles, Links

[Plaque progression and destabilization in human coronary arteries]
Nippon Rinsho. 1998 Oct;56(10):2477-82. Review. Japanese.
PMID: 9796305 [PubMed - indexed for MEDLINE]

☐ **109:** Goalstone ML, Natarajan R, Standley PR, Walsh MF, Leitner JW, Carel K, Scott S, Nadler J, Sowers JR, Draznin B. Related Articles, Links

Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells.
Endocrinology. 1998 Oct;139(10):4067-72.
PMID: 9751484 [PubMed - indexed for MEDLINE]

☐ **110:** Metais C, Li J, Li J, Simons M, Sellke FW. Related Articles, Links



Effects of coronary artery disease on expression and microvascular response to VEGF.
Am J Physiol. 1998 Oct;275(4 Pt 2):H1411-8.
PMID: 9746492 [PubMed - indexed for MEDLINE]

☐ **111:** Brilla CG, Rybinski L, Gehrke D, Rupp H. Related Articles, Links



[Transmyocardial laser revascularization--an innovative pathophysiologic concept]
Herz. 1997 Aug;22(4):183-9. Review. German.
PMID: 9378452 [PubMed - indexed for MEDLINE]

☐ **112:** Labarrere CA, Faulk WP. Related Articles, Links



Antithrombin determinants of coronary artery disease in transplanted human hearts.
Semin Hematol. 1995 Oct;32(4 Suppl 2):61-6. Review. No abstract available.
PMID: 8821212 [PubMed - indexed for MEDLINE]

☐ **113:** Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA. Related Articles, Links



Regulation of vascular endothelial growth factor in cardiac myocytes.
Circ Res. 1995 May;76(5):758-66.
PMID: 7728992 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

NCBI PubMed National Library of Medicine [Sign In] [Regis

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for coronary artery disease AND aFGF Go Clear Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

All: 8 Review: 1

Items 1 - 8 of 8 One page.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Pawlak J, Klim B, Szkudlarek M, Dzieciol J. Related Articles, Links

[The formation of new blood vessels in coronary artery disease: where we are now]
Postepy Hig Med Dosw (Online). 2004 Oct 6;58:358-63. Polish.
PMID: 15536393 [PubMed - in process]

2: Ghiselli G, Chen J, Kaou M, Hallak H, Rubin R. Related Articles, Links

Ethanol inhibits fibroblast growth factor-induced proliferation of aortic smooth muscle cells.
Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1808-13. Epub 2003 Aug 7.
PMID: 12907464 [PubMed - indexed for MEDLINE]

3: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C. Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
PMID: 12692004 [PubMed - indexed for MEDLINE]

4: Sellke FW, Ruel M. Related Articles, Links

Vascular growth factors and angiogenesis in cardiac surgery.
Ann Thorac Surg. 2003 Feb;75(2):S685-90. Review.
PMID: 12607713 [PubMed - indexed for MEDLINE]

5: Schumacher B, Hannekum A, Pecher P. Related Articles, Links

[Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease]
Z Kardiol. 2000;89 Suppl 7:23-30. German.
PMID: 11098556 [PubMed - indexed for MEDLINE]

6: Safi J Jr, DiPaula AF Jr, Riccioni T, Kajstura J, Ambrosio G, Becker LC, Anversa P, Capogrossi MC. Related Articles, Links

Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart.
Microvasc Res. 1999 Nov;58(3):238-49.
PMID: 10527767 [PubMed - indexed for MEDLINE]

7: Ikemoto M, Hasegawa K, Kihara Y, Iwakura A, Komeda M, Yamazato A, Fujita M. Related Articles, Links

Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
Clin Chim Acta. 1999 May;283(1-2):171-82.

PMID: 10404741 [PubMed - indexed for MEDLINE]

8: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.

u S rgery. 1996 Aug;120(2):182-8.

PMID: 8751581 [PubMed - indexed for MEDLINE]

Display Summary Show 500 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

NCBI PubMed National Library of Medicine [Sign In] [Regis

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for coronary artery disease AND acidic FGF Go Clear Save Sea

Limits Preview/Index History Clipboard Details

Display Summary Show 500 Sort by Send to

All: 2 Review: 0

Items 1 - 2 of 2 One page.

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: Ananyeva N, Tjurmin A, Saenko E, Haudenschild C. Related Articles, Links

Low density lipoproteins interact with acidic fibroblast growth factor and modify its function.
Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):601-7. Epub 2003 Mar 6.
PMID: 12692004 [PubMed - indexed for MEDLINE]

2: Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M. Related Articles, Links

Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia.
Surgery. 1996 Aug;120(2):182-8.
PMID: 8751581 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

NCBI PubMed National Library of Medicine NIH
My NC
[Sign In] [Regis
All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Bool
Search PubMed for coronary artery disease AND basic FGF Go Clear Save Sea
Limits Preview/Index History Clipboard Details
Display Summary Show 500 Sort by Send to
All: 4 Review: 0

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 4 of 4 One page.

1: Aviles RJ, Annex BH, Lederman RJ. Related Articles, Links

Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
Br J Pharmacol. 2003 Oct;140(4):637-46.
PMID: 14534147 [PubMed - indexed for MEDLINE]

2: Sakakibara Y, Tambara K, Sakaguchi G, Lu F, Yamamoto M, Nishimura K, Tabata Y, Komeda M. Related Articles, Links

Toward surgical angiogenesis using slow-released basic fibroblast growth factor.
Eur J Cardiothorac Surg. 2003 Jul;24(1):105-11; discussion 112.
PMID: 12853053 [PubMed - indexed for MEDLINE]

3: Campuzano R, Barrios V, Cuevas B, Asin-Cardiel E, Muela A, Castro JM, Fernandez-Ayerdi A, Cuevas P. Related Articles, Links

Serum basic fibroblast growth factor levels in exercise-induced myocardial ischemia more likely a marker of endothelial dysfunction than a marker of ischemia?
Eur J Med Res. 2002 Mar 28;7(3):93-7.
PMID: 11953278 [PubMed - indexed for MEDLINE]

4: Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ. Related Articles, Links

Localization of insulin-like growth factor I and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. A potential treatment for restenosis?
Circulation. 1994 Apr;89(4):1511-7.
PMID: 7908609 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Apr 18 2005 07:10:12

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:09:39 ON 22 APR 2005

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'ANABSTR' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (c) 2005 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT 2005 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:09:47 ON 22 APR 2005
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:09:47 ON 22 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'CAPLUS' ENTERED AT 15:09:47 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:09:47 ON 22 APR 2005
```

FILE 'CEN' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:09:47 ON 22 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DRUGB' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'FOMAD' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'HEALSAFE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (c) 2005 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:09:47 ON 22 APR 2005

FILE 'NIOSHTIC' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:09:47 ON 22 APR 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'NUTRACEUT' ENTERED AT 15:09:47 ON 22 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:09:47 ON 22 APR 2005
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2005 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 WIPO

FILE 'PHAR' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 15:09:47 ON 22 APR 2005
Copyright 2005 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 T&F Informa UK Ltd.

FILE 'PHIN' ENTERED AT 15:09:47 ON 22 APR 2005

```
FILE 'PROMT' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:09:47 ON 22 APR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 15:09:47 ON 22 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:09:47 ON 22 APR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 15:09:47 ON 22 APR 2005
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s coronary artery disease OR acute coronary artery disease OR chronic corona
  11 FILES SEARCHED...
  12 FILES SEARCHED...
  22 FILES SEARCHED...
  25 FILES SEARCHED...
  32 FILES SEARCHED...
  45 FILES SEARCHED...
  53 FILES SEARCHED...
  65 FILES SEARCHED...
L1      323642 CORONARY ARTERY DISEASE OR ACUTE CORONARY ARTERY DISEASE OR
               CHRONIC CORONARY ARTERY DISEASE

=> S FGF-1 OR FGF-2 OR aFGF OR bFGF OR VEGF
  14 FILES SEARCHED...
  29 FILES SEARCHED...
  40 FILES SEARCHED...
  53 FILES SEARCHED...
```

```
  71 FILES SEARCHED...
L2      251553 FGF-1 OR FGF-2 OR AFGF OR BFGF OR VEGF

=> S L1 AND L2
  59 FILES SEARCHED...
L3         2609 L1 AND L2

=> DUP REM L3
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE,
SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  62% COMPLETE FOR L3
PROCESSING COMPLETED FOR L3
L4          2003 DUP REM L3 (606 DUPLICATES REMOVED)

=> S L4 AND PY<=2000
'2000' NOT A VALID FIELD CODE
   5 FILES SEARCHED...
  10 FILES SEARCHED...
  12 FILES SEARCHED...
  15 FILES SEARCHED...
  20 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  31 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
'2000' NOT A VALID FIELD CODE
  40 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  47 FILES SEARCHED...
  49 FILES SEARCHED...
  53 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  59 FILES SEARCHED...
'2000' NOT A VALID FIELD CODE
  65 FILES SEARCHED...
  71 FILES SEARCHED...
L5          549 L4 AND PY<=2000

=> D L5 1-549

L5   ANSWER 1 OF 549  ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
     STN
AN   2000:14563  ADISCTI
DN   800836302
TI   Effects of a single intracoronary injection of basic fibroblast growth
     factor in stable angina pectoris.
     ADIS TITLE: Fibroblast growth factor: therapeutic use.
     Angina pectoris
     Intracoronary administration in patients with   ***coronary***
       ***artery***     ***disease***  .
AU   Unger E F; Goncalves L; Epstein S E; Chew E Y; Trapnell C B; et al.
CS   National Heart, Lung, and Blood Institute, Rockville, Maryland, USA.
SO   American Journal of Cardiology (Jun 15, 2000), Vol. 85, pp. 1414-1419
DT   Study
RE   Ischaemic Heart Disease
FS   Summary
LA   English
WC   663

L5   ANSWER 2 OF 549  ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on
```

AN 2000:3823 ADISCTI
DN 800813542
TI Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect.
ADIS TITLE: Vascular endothelial growth factor: pharmacodynamics.
Effect on myocardial perfusion
In patients with ***coronary*** ***artery*** ***disease*** .
AU Hendel R C; Henry T D; Rocha Singh K; Isner J M; Kereiakes D J; et al.
CS Northwestern University Medical School, Chicago, Illinois, USA.
SO Circulation (Jan 18, 2000), Vol. 101, pp. 118-121
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 524

L5 ANSWER 3 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1999:45637 ADISCTI
DN 800786553
TI Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant ***coronary*** ***artery*** ***disease*** .
ADIS TITLE: Vascular endothelial growth factor gene therapy: therapeutic use.
Coronary disorders
A phase I study.
AU Rosengart T K; Lee L Y; Patel S R; Sanborn T A; Parikh M; et al.
CS Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York, USA; GenVec, Inc, Rockville, Maryland, USA.
SO Circulation (Aug 3, 1999), Vol. 100, pp. 468-474
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 691

L5 ANSWER 4 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1999:45634 ADISCTI
DN 800788334
TI Gene therapy for myocardial angiogenesis.
ADIS TITLE: Vascular endothelial growth factor gene therapy: therapeutic use.
Coronary disorders
In patients refractory to conventional therapies.
AU Losordo D W; Vale P R; Isner J M.
CS St. Elizabeth's Medical Center, Boston, Massachusetts, USA.
SO American Heart Journal (Aug 1, 1999), Vol. 138, pp. 132-141
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 450

L5 ANSWER 5 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1999:11635 ADISCTI
DN 800742050
TI The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results.

Stimulation of neoangiogenesis
In patients undergoing coronary artery bypass graft surgery.
AU Schumacher B; Stegmann Th; Pecher P.
CS University of Ulm, Ulm, Germany.
SO Journal of Cardiovascular Surgery (Dec 1, 1998), Vol. 39, pp. 783-789
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 518

L5 ANSWER 6 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1999:2247 ADISCTI
DN 800734037
TI Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
ADIS TITLE: Vascular endothelial growth factor gene therapy: therapeutic use.
Angina pectoris.
AU Losordo D W; Vale P R; Symes J F; Dunnington C H; Esakof D D; et al.
CS St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
SO Circulation (Dec 29, 1998), Vol. 98, pp. 2800-2804
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 482

L5 ANSWER 7 OF 549 ADISCTI COPYRIGHT (C) 2005 Adis Data Information BV on STN
AN 1996:43031 ADISCTI
DN 800469793
TI Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina.
ADIS TITLE: Unstable angina pectoris: pathogenesis.
Role of fibroblast growth factor.
AU Fujita M; Ikemoto M; Kishishita M; Otani H; Nohara R; et al.
CS Kyoto University, Kyoto, Japan.
SO Circulation (Aug 15, 1996), Vol. 94, pp. 610-613
DT Study
RE Ischaemic Heart Disease
FS Summary
LA English
WC 249

L5 ANSWER 8 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on STN
ACCESSION NUMBER: 2000:2372 ED: 8 Aug 2001 UP: 8 Aug 2001
DOCUMENT NUMBER: 11738324-800840069
TITLE: Product news: ***VEGF*** gene therapy appears beneficial in myocardial ischaemia.
SOURCE: INPHARMA ***21 Sep 2000*** ISSN: 1173-8324
DOCUMENT TYPE: (MIX)
WORD COUNT: 344

L5 ANSWER 9 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on STN
ACCESSION NUMBER: 2000:197 ED: 8 Aug 2001 UP: 8 Aug 2001
DOCUMENT NUMBER: 11738324-800763516

the American College of Cardiology.
SOURCE: INPHARMA ***20 Apr 2000*** ISSN: 1173-8324
DOCUMENT TYPE: (MIX)
WORD COUNT: 1210

L5 ANSWER 10 OF 549 ADISNEWS COPYRIGHT (C) 2005 Adis Data Information BV on STN
ACCESSION NUMBER: 1999:2132 ED: 8 Aug 2001 UP: 8 Aug 2001
DOCUMENT NUMBER: 11738324-800786553
TITLE: Product news: Gene therapy shows promise in CAD.
SOURCE: INPHARMA ***20 Aug 1999*** ISSN: 1173-8324
DOCUMENT TYPE: (MIX)
WORD COUNT: 283

L5 ANSWER 11 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 1998:31898 BIOBUSINESS
DN 0983721
TI ***FGF*** - ***1*** promotes neoangiogenesis in the ischaemic heart.
AU Anon
SO European Biotechnology Newsletter, (***1998***) No.263, March 11, p.10-11.
ISSN: 0765-2046.
DT ARTICLE
FS UNIQUE
LA English

L5 ANSWER 12 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 97:80150 BIOBUSINESS
DN 0937685
TI GenVec/Parke-Davis BioByPass to begin clinicals in First Quarter 1998.
AU Anon
SO F-D-C Reports - "The Pink Sheet", (***1997***) Vol.59, No.38, Sept. 22, p.t&g11-t&g12.
ISSN: 1068-5324.
DT ARTICLE
FS UNIQUE
LA English

L5 ANSWER 13 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 96:65393 BIOBUSINESS
DN 0830254
TI European Patent Office rules in favor of Scios in growth factor patent opposition.
AU Anon
SO Biotech Patent News, (***1996***) Vol.10, No.7, July, P.1.
ISSN: 0898-2813.
FS UNIQUE
LA ENGLISH

L5 ANSWER 14 OF 549 BIOBUSINESS COPYRIGHT (c) 1998 The Thomson Corporation. on STN
AN 96:47439 BIOBUSINESS
DN 0812300
TI Scios to patent method of producing human basic fibroblast growth factor.
AU Anon
SO Biotech Patent News, (***1996***) Vol.10, No.5, May, P.5-6.
ISSN: 0898-2813.
FS UNIQUE
LA ENGLISH

L5 ANSWER 15 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0187890 BIOCOMMERCE FS Abstract
CO Valentis Inc (51189), USA
SO Valentis Press Release, 01 JUN 2000
TC (Company information)

L5 ANSWER 16 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0187333 BIOCOMMERCE FS Abstract
CO GenVec Inc (28772), USA
Scios Inc (25945), USA
SO GenVec Press Release, 26 APR 2000, vol. 2541, Page(s) 22.
Scrip, 19 MAY 2000
TC (Company information)

L5 ANSWER 17 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0186685 BIOCOMMERCE FS Abstract
CO Vascular Genetics Inc (VGI) (44457), USA
Food and Drug Administration (FDA) (815), USA
Johnson & Johnson (1565), USA
SO Clinica, 20 MAR 2000, vol. 900, Page(s) 15.
TC (Company information)

L5 ANSWER 18 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0186500 BIOCOMMERCE FS Abstract
CO Chiron Corp (1282), USA
SO Chiron Press Release, 12 MAR 2000, vol. 2523, Page(s) 10.
Scrip, 17 MAR 2000
TC (Company information)

L5 ANSWER 19 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0181030 BIOCOMMERCE FS Abstract
CO Vascular Genetics Inc (VGI) (44457), USA
Human Genome Sciences Inc (HGSI) (26897), USA
SO Human Genome Sciences Press Release, 17 JUN 1999, vol. 2626, Page(s) 28.
Marketletter, 28 JUN 1999
TC (Company information)

L5 ANSWER 20 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0176027 BIOCOMMERCE FS Abstract
CO Chiron Corp (1282), USA
Beth Israel-Deaconess Medical Center (42698), USA
SO Chiron Press Release, 09 NOV 1998, vol. 9217, Page(s) 4.
BioWorld Today, 10 NOV 1998, vol. 358, Page(s) 6.
Medical Technology Stock Letter, 12 NOV 1998
TC (Company information)

L5 ANSWER 21 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0169197 BIOCOMMERCE FS Abstract
CO GeneMedicine Inc (28725), USA
Kuopio, University of (8514), Finland
Valentis Inc (51189), USA
SO Marketletter, 30 MAR 1998, vol. 2513, Page(s) 20.
Genetic Technology News, 01 APR 1998, vol. 1813, Page(s) 1.
Medical Technology Stock Letter, 26 MAR 1998, vol. 342, Page(s) 5.
Pharmaceutical Ventures, 23 MAR 1998, vol. 812, Page(s) 7.
Genetic Engineering News, 15 APR 1998, vol. 188, Page(s) 43.
TC (Company information)

L5 ANSWER 22 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0167113 BIOCOMMERCE FS Abstract
CO Fulda Medical Centre (45021), Germany
SO BioWorld Today, 24 FEB 1998, vol. 935, Page(s) 1,3.

European Biotechnology Newsletter, 11 MAR 1998, vol. 263, Page(s) 10-11.
TC (Institute information)

L5 ANSWER 23 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0164669 BIOCOMMERCE FS Abstract
CO Collateral Therapeutics Inc (36627), USA
Schering AG (161), Germany
SO R&D Focus Drug News, 01 DEC 1997, vol. 647, Page(s) 13.
Scrip, 16 JAN 1998, vol. 2301, Page(s) 17.
Biotechnology Newswatch, 05 JAN 1998, Page(s) 14.
TC (Company information)

L5 ANSWER 24 OF 549 BIOCOMMERCE COPYRIGHT 2005 BioCommerce Data Ltd. on STN
AN 0161264 BIOCOMMERCE FS Abstract
CO GenVec Inc (28772), USA
Parke-Davis Co (3379), USA
SO Scrip, 16 SEP 1997, vol. 2267, Page(s) 9.
R&D Focus Drug News, 22 SEP 1997, vol. 637, Page(s) 10.
BioWorld Financial Watch, 29 SEP 1997, vol. 539, Page(s) 8.
Genetic Technology News, 24 SEP 1997, vol. 1719, Page(s) 3.
BioVenture View, OCT 1997, vol. 1210, Page(s) 24.
Scrip, 16 JAN 1998, vol. 2301, Page(s) 17.
Nature Biotechnology, OCT 1997, vol. 1510, Page(s) 930.
Genetic Engineering News, 01 OCT 1997, vol. 1717, Page(s) 27.
Genetic Engineering News, 15 OCT 1997, vol. 1718, Page(s) 45.
In Vivo, OCT 1997, vol. 159, Page(s) 74-75.
Business Week International, 24 NOV 1997, vol. 3538868, Page(s) 44.
TC (Company information)

L5 ANSWER 25 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:257278 BIOSIS
DN PREV200100257278
TI Rat sponge implant model: A new system for evaluating angiogenic gene transfer.
AU Wang, H. [Reprint author]; Gordon, D.; Olszewski, B.; Song, Y. L.; Kovesdi, I.; Keiser, J. A.
CS Cardiovascular Therapeutics, Parke-Davis Pharmaceutical Research, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA
he.wang@wl.com
SO International Journal of Molecular Medicine, (December, 2000) Vol. 6, No. 6, pp. 645-653. print.
ISSN: 1107-3756.
DT Article
LA English
ED Entered STN: 30 May 2001
Last Updated on STN: 19 Feb 2002

L5 ANSWER 26 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:223300 BIOSIS
DN PREV200100223300
TI Cardiovascular gene therapy.
AU Yla-Herttuala, Seppo [Reprint author]; Martin, John F.
CS Department of Medicine, A I Virtanen Institute, University of Kuopio, 70211, Kuopio, Finland
Seppo.YlaHerttuala@uku.fi
SO Lancet (North American Edition), (15 January, 2000) Vol. 355, No. 9199, pp. 213-222. print.
ISSN: 0099-5355.
DT Article
General Review; (Literature Review)

ED Entered STN: 9 May 2001
Last Updated on STN: 18 Feb 2002

L5 ANSWER 27 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:158874 BIOSIS
DN PREV200100158874
TI Atorvastatin reduces vascular endothelial growth factor (***VEGF***) concentrations in the plasma of patients with ***coronary*** ***artery*** ***disease*** .
AU Alber, H. [Reprint author]; Dulak, J. [Reprint author]; Frick, M. [Reprint author]; Seidel, L. [Reprint author]; Schwarzacher, S. [Reprint author]; Pachinger, O. [Reprint author]; Weidinger, F. [Reprint author]
CS Department of Cardiology, Innsbruck University, Innsbruck, Austria
SO Zeitschrift fuer Kardiologie, (September, 2000) Vol. 89, No. 9, pp. 888. print.
Meeting Info.: Update in Thrombolysis 2000 Meeting on Arteriosclerosis, Thrombosis and Cardiovascular Biology. Vienna, Austria. October 12-14, 2000.
CODEN: ZKRDAX. ISSN: 0300-5860.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 28 Mar 2001
Last Updated on STN: 15 Feb 2002

L5 ANSWER 28 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:150039 BIOSIS
DN PREV200100150039
TI Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with ***coronary*** ***artery*** ***disease*** .
AU Soeki, Takeshi [Reprint author]; Tamura, Yoshiyuki; Shinohara, Hisanori; Tanaka, Hideji; Bando, Kanji; Fukuda, Nobuo
CS Department of Cardiology and Clinical Research Institute, National Zentsuji Hospital, 2-1-1 Senyu-cho, Zentsuji, Kagawa, 765-8507, Japan
tsoeki@jun.ncvc.go.jp
SO Heart and Vessels, (2000) Vol. 15, No. 3, pp. 105-111. print.
CODEN: HEVEEO. ISSN: 0910-8327.
DT Article
LA English
ED Entered STN: 28 Mar 2001
Last Updated on STN: 15 Feb 2002

L5 ANSWER 29 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:112482 BIOSIS
DN PREV200100112482
TI Shock waves upregulate vascular endothelial growth factor M-RNA in human umbilical vascular endothelial cells.
AU Gutersohn, Achim [Reprint author]; Caspari, Guido H. [Reprint author]
CS Univ of Essen, Essen, Germany
SO Circulation, (October 31, 2000) Vol. 102, No. 18 Supplement, pp. II.432. print.
Meeting Info.: Abstracts from American Heart Association Scientific Sessions 2000. New Orleans, Louisiana, USA. November 12-15, 2000. American Heart Association.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English

Last Updated on STN: 15 Feb 2002

L5 ANSWER 30 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:60987 BIOSIS
DN PREV200100060987
TI Plasma ***VEGF*** levels after intramyocardial and intramuscular ***VEGF*** gene transfer in patients with coronary artery and peripher artery disease.
AU Freedman, Ben [Reprint author]; Vale, Peter R. [Reprint author]; Kalka, Christoph [Reprint author]; Losordo, Douglas W. [Reprint author]; Kearney, Marianne [Reprint author]; Symes, James F. [Reprint author]
CS St Elizabeth's Medical Ctr, Boston, MA, USA
SO Circulation, (October 31, 2000) Vol. 102, No. 18 Supplement, pp. II.10. print.
Meeting Info.: Abstracts from American Heart Association Scientific Sessions 2000. New Orleans, Louisiana, USA. November 12-15, 2000. American Heart Association.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 Jan 2001
Last Updated on STN: 12 Feb 2002

L5 ANSWER 31 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:14963 BIOSIS
DN PREV200100014963
TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the treatment of ***coronary*** ***artery*** ***disease*** .
Original Title: Neoangiogenese durch lokale Gentherapie: Ein neues therapeutisches Konzept in der Behandlung der koronaren Herzkrankheit.
AU Schumacher, B. [Reprint author]; Hannekum, A.; Pecher, P.
CS Abt. Chirurgie IV, Herzchirurgie, Universitaetsklinik Ulm, Steinhoevelstr. 9, D-89075, Ulm, Germany
SO Zeitschrift fuer Kardiologie, (2000) Vol. 89, No. Supplement 7, pp. VII.23-VII.30. print.
CODEN: ZKRDAX. ISSN: 0300-5860.
DT Article
LA German
ED Entered STN: 27 Dec 2000
Last Updated on STN: 27 Dec 2000

L5 ANSWER 32 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:526436 BIOSIS
DN PREV200000526436
TI Vascular endothelial growth factor (***VEGF***) and soluble Flt-1 (sFlt-1) in patients with atherosclerotic vascular disease.
AU Belgore, F. M. [Reprint author]; Lip, G. Y. H. [Reprint author]; McCollum, C. N. [Reprint author]; Blann, A. D. [Reprint author]
CS Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK
SO Clinical Science (London), (August, 2000) Vol. 99, No. 2, pp. 19P-20P. print.
Meeting Info.: Communications for the Spring Meeting of the Medical Research Society. London, England, UK. May 22, 2000.
CODEN: CSCIAE. ISSN: 0143-5221.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English

Last Updated on STN: 11 Jan 2002

L5 ANSWER 33 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:517402 BIOSIS
DN PREV200000517402
TI Induction of myocardial neoangiogenesis by human growth factors. A new therapeutic option in coronary heart disease.
AU Stegmann, Thomas J. [Reprint author]; Hoppert, Thomas; Schneider, Andre; Gemeinhardt, Stefan; Koecher, Michael; Ibing, Rainer; Strupp, Gerhard
CS Klinik fuer Thorax-, Herz- und Gefaesschirurgie, Klinikum Fulda, Pacelliallee 4, D-36043, Fulda, Germany
SO Herz, (September, 2000) Vol. 25, No. 6, pp. 589-599. print.
ISSN: 0340-9937.
DT Article
LA German
ED Entered STN: 29 Nov 2000
Last Updated on STN: 11 Jan 2002

L5 ANSWER 34 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:443484 BIOSIS
DN PREV200000443484
TI Role of vascular endothelial growth factor in diabetic vascular complications.
AU Aiello, Lloyd Paul [Reprint author]; Wong, Jun-Shyan
CS Joslin Diabetes Center, One Joslin Place, Boston, MA, 02215, USA
SO Kidney International Supplement, (September, 2000) No. 77, pp. S.113-S.119. print.
CODEN: KISUDF. ISSN: 0098-6577.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 18 Oct 2000
Last Updated on STN: 10 Jan 2002

L5 ANSWER 35 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:415902 BIOSIS
DN PREV200000415902
TI Vascular endothelial growth factor (***VEGF***) and its soluble receptor (sFlt-1) in peripheral and ***coronary*** ***artery*** ***disease*** .
AU Blann, A. D. [Reprint author]; Belgore, F. M. [Reprint author]; McCollum, C. N.; Lip, G. Y. H. [Reprint author]
CS University Department of Medicine, City Hospital, Birmingham, UK
SO Haemostasis, (May, 2000) Vol. 30, No. 1-2, pp. 60. print.
Meeting Info.: 1st North Sea Conference on Thrombosis and Haemostasis. Maastrich, Netherlands. June 12-14, 2000.
CODEN: HMTSB7. ISSN: 0301-0147.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 27 Sep 2000
Last Updated on STN: 8 Jan 2002

L5 ANSWER 36 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:385286 BIOSIS
DN PREV200000385286
TI Alcohol and catechin increase ***VEGF*** expression in cultured human endothelial cells.

E. M. [Reprint author]; Barchuc, J. P. [Reprint author]; Wheeler, C. G. [Reprint author]; Booyse, F. M. [Reprint author]
CS University of Alabama at Birmingham, Birmingham, AL, 35294, USA
SO Alcoholism Clinical and Experimental Research, (May, 2000) Vol. 24, No. 5 Supplement, pp. 128A. print.
Meeting Info.: Scientific Meeting of the Research Society on Alcoholism. Santa Barbara, California, USA. June 24-29, 2000. Research Society on Alcoholism.
CODEN: ACRSDM. ISSN: 0145-6008.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 6 Sep 2000
Last Updated on STN: 8 Jan 2002

L5 ANSWER 37 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:157247 BIOSIS
DN PREV200000157247
TI Angiogenesis for the treatment of vascular diseases.
AU Chawla, P. S.; Keelan, M. H.; Kipshidze, N. [Reprint author]
CS Department of Cardiovascular Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI, 53226, USA
SO International Angiology, (Ssept., 1999) Vol. 18, No. 3, pp. 185-192. print.
ISSN: 0392-9590.
DT Article
Editorial
LA English
ED Entered STN: 26 Apr 2000
Last Updated on STN: 4 Jan 2002

L5 ANSWER 38 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:139832 BIOSIS
DN PREV200000139832
TI Vascular endothelial growth factor (***VEGF***) and soluble ***VEGF*** receptor (sFlt-1) levels in ***coronary*** ***artery*** ***disease*** and peripheral artery disease.
AU Belgore, F. [Reprint author]; Lip, G.Y.H. [Reprint author]; McCollum, C. N. [Reprint author]; Blann, A. D. [Reprint author]
CS Haemostasis, Thrombosis and Vascular Biology Unit, City Hospital, University Department of Medicine, Birmingham, B18 7QH, UK
SO Blood Coagulation and Fibrinolysis, (Dec., 1999) Vol. 10, No. 8, pp. 536. print.
Meeting Info.: Autumn Meeting of the British Society for Haemostasis and Thrombosis. Cambridge, England, UK. September 22-24, 1999. British Society for Haemostasis and Thrombosis.
CODEN: BLFIE7. ISSN: 0957-5235.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 19 Apr 2000
Last Updated on STN: 4 Jan 2002

L5 ANSWER 39 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:24118 BIOSIS
DN PREV200000024118
TI Adenoviral-mediated gene transfer induces sustained pericardial ***VEGF*** expression in dogs: Effect on myocardial angiogenesis.
AU Lazarous, Daisy F. [Reprint author]; Shou, Matie; Stiber, Jonathan A.;

CS Division of Cardiology, A1 East, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD, 21224, USA
SO Cardiovascular Research, (Nov., 1999) Vol. 44, No. 2, pp. 294-302. print. CODEN: CVREAU. ISSN: 0008-6363.
DT Article
LA English
ED Entered STN: 29 Dec 1999
Last Updated on STN: 31 Dec 2001

L5 ANSWER 40 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:17089 BIOSIS
DN PREV200000017089
TI Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel ***coronary*** ***artery*** ***disease*** .
AU Fleisch, Martin; Billinger, Michael; Eberli, Franz R.; Garachemani, Ali R.; Meier, Bernhard; Seiler, Christian [Reprint author]
CS Swiss Cardiovascular Centre Bern, Cardiology, University Hospital, CH-3010, Bern, Switzerland
SO Circulation, (Nov. 9, 1999) Vol. 100, No. 19, pp. 1945-1950. print. CODEN: CIRCAZ. ISSN: 0009-7322.
DT Article
LA English
ED Entered STN: 29 Dec 1999
Last Updated on STN: 31 Dec 2001

L5 ANSWER 41 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:514644 BIOSIS
DN PREV199900514644
TI Therapeutic angiogenesis in patients with advanced ***coronary*** ***artery*** ***disease*** .
AU Lal, Parshotam [Reprint author]; Sahota, Harry; Nikolaychik, Victora; Chakanov, Valeri; Keelan, Michael H.; Kipshidze, Nicholas N.
CS Metro Hosp. Heart Inst., New Delhi, India
SO Circulation, (Oct. 27, 1998) Vol. 98, No. 17 SUPPL., pp. I352-I353. print. Meeting Info.: 71st Scientific Sessions of the American Heart Association. Dallas, Texas, USA. November 8-11, 1998. The American Heart Association. CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Dec 1999
Last Updated on STN: 5 Jun 2000

L5 ANSWER 42 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:425938 BIOSIS
DN PREV199900425938
TI Results of a randomized, double-blind, placebo-controlled study of local perivascular basic fibroblast growth factor (***bFGF***) treatment in patients undergoing coronary artery bypass surgery.
AU Laham, Roger J. [Reprint author]; Sellke, Frank W. [Reprint author]; Ware, J. Anthony [Reprint author]; Pearlman, Justin D. [Reprint author]; Edelman, Elazar R. [Reprint author]; Simons, Michael [Reprint author]
CS BIDMC/Harvard Medical School, Boston, MA, USA
SO Journal of the American College of Cardiology, (Feb., 1999) Vol. 33, No. 2 SUPPL. A, pp. 383A-384A. print.
Meeting Info.: 48th Annual Scientific Session of the American College of Cardiology. New Orleans, Louisiana, USA. March 7-10, 1999. American

CODEN: JACCDI. ISSN: 0735-1097.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 18 Oct 1999
Last Updated on STN: 18 Oct 1999

L5 ANSWER 43 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:406399 BIOSIS
DN PREV199900406399
TI Interindividual heterogeneity in the hypoxic regulation of ***VEGF*** : Significance for the development of the coronary artery collateral circulation.
AU Schultz, Aylit; Lavie, Lena; Hochberg, Irit; Beyar, Rafael; Stone, Tzachi; Skorecki, Karl; Lavie, Peretz; Roguin, Ariel; Levy, Andrew P. [Reprint author]
CS Rappaport Faculty of Medicine, Bat Galim, Israel
SO Circulation, (Aug. 3, 1999) Vol. 100, No. 5, pp. 547-552. print.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Article
LA English
ED Entered STN: 8 Oct 1999
Last Updated on STN: 8 Oct 1999

L5 ANSWER 44 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:406390 BIOSIS
DN PREV199900406390
TI Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe ***coronary*** ***artery*** ***disease*** .
AU Rosengart, Todd K.; Lee, Leonard Y.; Patel, Shailen R.; Sanborn, Timothy A.; Parikh, Manish; Bergman, Geoffrey W.; Hachamovitch, Rory; Szulc, Massimiliano; Kligfield, Paul D.; Okin, Peter M.; Hahn, Rebecca T.; Devereux, Richard B.; Post, Martin R.; Hackett, Neil R.; Foster, Taliba; Grasso, Tina M.; Lesser, Martin L.; Isom, O. Wayne; Crystal, Ronald G. [Reprint author]
CS New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, 10021, USA
SO Circulation, (Aug. 3, 1999) Vol. 100, No. 5, pp. 468-474. print.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Article
LA English
ED Entered STN: 8 Oct 1999
Last Updated on STN: 8 Oct 1999

L5 ANSWER 45 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:321681 BIOSIS
DN PREV199900321681
TI Development of enzyme-linked immunosorbent assay for acidic fibroblast growth factor and its clinical application.
AU Ikemoto, Masaki [Reprint author]; Hasegawa, Koji; Kihara, Yasuki; Iwakura, Atsushi; Komeda, Masashi; Yamazato, Ario; Fujita, Masatoshi
CS College of Medical Technology, Kyoto University, Kyoto, 606-8507, Japan
SO Clinica Chimica Acta, (May, 1999) Vol. 283, No. 1-2, pp. 171-182. print.
CODEN: CCATAR. ISSN: 0009-8981.
DT Article
LA English
ED Entered STN: 24 Aug 1999

L5 ANSWER 46 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:134228 BIOSIS
DN PREV199900134228
TI Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
AU Okada, Masaharu; Matsumori, Akira [Reprint author]; Ono, Koh; Miyamoto, Tadashi; Takahashi, Mamoru; Sasayama, Shigetake
CS Dep. Cardiovasc. Med., Kyoto Univ., 54 Kawaracho Shogoin, Sakyo-ku, Kyoto 606-8397, Japan
SO Biochemical and Biophysical Research Communications, (Feb. 5, 1999) Vol. 255, No. 1, pp. 80-87. print.
CODEN: BBRCA9. ISSN: 0006-291X.
DT Article
LA English
ED Entered STN: 31 Mar 1999
Last Updated on STN: 31 Mar 1999

L5 ANSWER 47 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:3267 BIOSIS
DN PREV199900003267
TI Perspectives of gene therapy for the treatment of ***coronary*** ***artery*** ***disease*** .
AU Waltenberger, J. [Reprint author]
CS Abteilung Innere Med. II, Med. Klinik Poliklinik, Univ. Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany
SO Zeitschrift fuer Kardiologie, (1998) Vol. 87, No. SUPPL. 2, pp. 152-156. print.
CODEN: ZKRDAX. ISSN: 0300-5860.
DT Article
LA German
ED Entered STN: 11 Jan 1999
Last Updated on STN: 11 Jan 1999

L5 ANSWER 48 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1998:492503 BIOSIS
DN PREV199800492503
TI Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF*** .
AU Metais, Caroline; Li, Jianyi; Simons, Michael; Sellke, Frank W. [Reprint author]
CS Div. Cardiothorac. Surg., Dep. Surg., Beth Isr.-Deaconess Med. Cent., East Campus, Dana 905, 330 Brookline Ave., Boston, MA 02215, USA
SO American Journal of Physiology, (Oct., 1998) Vol. 275, No. 4 PART 2, pp. H1411-H1418. print.
CODEN: AJPHAP. ISSN: 0002-9513.
DT Article
LA English
ED Entered STN: 18 Nov 1998
Last Updated on STN: 18 Nov 1998

L5 ANSWER 49 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1997:435367 BIOSIS
DN PREV199799734570
TI Transmyocardial laser revascularization: A novel pathophysiological concept.
AU Brilla, C. G. [Reprint author]; Rybinski, L.; Gehrke, D.; Rupp, H.
CS Zentrum Innere Med.-Kardiol., Philipps-Univ., Baldingerstr., D-35033

SO Herz, (1997) Vol. 22, No. 4, pp. 183-189.
ISSN: 0340-9937.
DT Article
General Review; (Literature Review)
LA German
ED Entered STN: 8 Oct 1997
Last Updated on STN: 8 Oct 1997

L5 ANSWER 50 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1997:270129 BIOSIS
DN PREV199799561847
TI Serum basic fibroblast growth factor levels in patients with ischemic heart disease.
AU Hasdai, David; Barak, Vivian; Leibovitz, Eyal; Herz, Itzhak; Sclarovsky, Samuel; Eldar, Michael; Scheinowitz, Mickey [Reprint author]
CS Neufeld Cardiac Res. Inst., Sheba Med. Cent., Tel Hashomer 52621, Israel
SO International Journal of Cardiology, (1997) Vol. 59, No. 2, pp. 133-138.
CODEN: IJCDD5. ISSN: 0167-5273.
DT Article
LA English
ED Entered STN: 24 Jun 1997
Last Updated on STN: 24 Jun 1997

L5 ANSWER 51 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1996:321934 BIOSIS
DN PREV199699044290
TI Vascular endothelial growth factor administration in chronic myocardial ischemia.
AU Harada, Kazumasa; Friedman, Menachem; Lopez, John J.; Wang, Steven Y.; Li, Jian; Prasad, Pottumarthi V.; Pearlman, Justin D.; Edelman, Elazer R.; Sellke, Frank W.; Simons, Michael [Reprint author]
CS Cardiovasc. Div., Beth Israel Hosp., 330 Brookline Ave., Boston, MA 02115, USA
SO American Journal of Physiology, (1996) Vol. 270, No. 5 PART 2, pp. H1791-1802.
CODEN: AJPHAP. ISSN: 0002-9513.
DT Article
LA English
ED Entered STN: 11 Jul 1996
Last Updated on STN: 11 Jul 1996

L5 ANSWER 52 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1996:146019 BIOSIS
DN PREV199698718154
TI ***VEGF*** -induced angiogenesis as an alternate method of revascularization for chronic myocardial ischemia: Improved perfusion and vascular reactivity.
AU Sellke, Frank W.; Wang, Steven Y.; Harada, Kazumasa; Lopez, John J.; Simons, Michael
CS Beth Israel Hosp., Boston, MA, USA
SO Journal of the American College of Cardiology, (1996) Vol. 27, No. 2 SUPPL. A, pp. 92A-93A.
Meeting Info.: 45th Annual Scientific Session of the American College of Cardiology. Orlando, Florida, USA. March 24-27, 1996.
CODEN: JACCDI. ISSN: 0735-1097.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English

Last Updated on STN: 26 Apr 1996

L5 ANSWER 53 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1995:388125 BIOSIS
DN PREV199598402425
TI Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro.
AU Chen, Chu-Huang; Nguyen, Hai Hoang; Weibaeccher, Don; Luo, Sherry; Gotto., Antonio M., Jr.; Henry, Philip D.
CS Dep. Med., M.S. A-601, Baylor Coll. Med., 6565 Fannin St., Houston, TX 77030, USA
SO Atherosclerosis, (1995) Vol. 116, No. 2, pp. 261-268.
CODEN: ATHSBL. ISSN: 0021-9150.
DT Article
LA English
ED Entered STN: 13 Sep 1995
Last Updated on STN: 13 Sep 1995

L5 ANSWER 54 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1995:263157 BIOSIS
DN PREV199598277457
TI Regulation of vascular endothelial growth factor in cardiac myocytes.
AU Levy, Andrew P.; Levy, Nina S.; Loscalzo, Joseph; Calderone, Angelino; Takahashi, Nobuyuki; Yeo, Kiang-Teck; Koren, Gideon; Colucci, Wilson S.; Goldberg, Mark A. [Reprint author]
CS Brigham and Women's Hosp., 221 Longwood Ave., Boston, MA 02115, USA
SO Circulation Research, (1995) Vol. 76, No. 5, pp. 758-766.
CODEN: CIRUAL. ISSN: 0009-7330.
DT Article
LA English
ED Entered STN: 26 Jun 1995
Last Updated on STN: 26 Jun 1995

L5 ANSWER 55 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1995:8448 BIOSIS
DN PREV199598022748
TI Angiogenic therapy of acute myocardial infarction (AMI) by intrapericardial injection of basic fibroblast growth factor (***bFGF***) and heparan sulfate (HS): An experimental study.
AU Uchida, Yasumi; Yanagisawa-Miwa, Atsuko; Ikuta, Makoto; Makamura, Fumitaka; Tomaru, Takanobu; Fujimori, Yoshiharu; Morita, Toshihiro
CS Second Dep. Intenral Med., Univ. Tokyo, Tokyo, Japan
SO Circulation, (1994) Vol. 90, No. 4 PART 2, pp. I296.
Meeting Info.: 67th Scientific Sessions of the American Heart Association. Dallas, Texas, USA. November 14-17, 1994.
CODEN: CIRCAZ. ISSN: 0009-7322.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Jan 1995
Last Updated on STN: 23 Feb 1995

L5 ANSWER 56 OF 549 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1994:432142 BIOSIS
DN PREV199497445142
TI Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts.
AU Harada, Kazumasa; Grossman, William; Friedman, Menachem; Edelman, Elazer

Sellke, Frank W.; Simons, Michael [Reprint author]
CS Cardiovascular Div., Beth Israel Hosp., 330 Brookline Ave., Boston, MA 02215, USA
SO Journal of Clinical Investigation, (1994) Vol. 94, No. 2, pp. 623-630. CODEN: JCINAO. ISSN: 0021-9738.
DT Article
LA English
ED Entered STN: 11 Oct 1994
Last Updated on STN: 11 Oct 1994

L5 ANSWER 57 OF 549 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN 2001-03887 BIOTECHDS
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits;
vascular endothelial cell growth factor dimer for use in therapy
AU Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA Scios
LO Sunnyvale, CA, USA.
PI WO 2000071716 ***30 Nov 2000***
AI WO 2000-US13636 18 May 2000
PRAI US 2000-177407 20 Jan 2000; US 1999-135312 20 May 1999
DT Patent
LA English
OS WPI: 2001-041064 [05]

L5 ANSWER 58 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:32044206 BIOTECHNO
TI Gene therapy for ***coronary*** ***artery*** ***disease*** . Perspectives and limitations of the therapeutic induction of a collateral circulation
GENTHERAPIE BEI KORONARER HERZKRANKHEIT: MOGLICHKEITEN UND GRENZEN EINER THERAPEUTISCHEN INDUKTION VON KOLLATERALEN
AU Waltenberger J.
CS Dr. J. Waltenberger, Universitatsklinikum Ulm, Robert-Koch-Strasse 8, D-89081 Ulm, Germany.
E-mail: johannes.waltenberger@medizin.uni-ulm.de
SO Hamostaseologie, (***2000***), 20/4 (162-166), 24 reference(s) CODEN: HAEMD2 ISSN: 0720-9355
DT Journal; Conference Article
CY Germany, Federal Republic of
LA German
SL English; German

L5 ANSWER 59 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30812493 BIOTECHNO
TI Neoangiogenesis by local gene therapy: A new therapeutic approach in the treatment of ***coronary*** ***artery*** ***disease***
NEOANGIOGENESE DURCH LOKALE GENTHERAPIE: EIN NEUES THERAPEUTISCHES KONZEPT IN DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT
AU Schumacher B.; Hannekum A.; Pecher P.
CS Dr. B. Schumacher, Universitatsklinik Ulm, Abt. Chirurgie IV, Herzchirurgie, Steinhovelstr. 9, D-89075 Ulm, Germany.
SO Zeitschrift fur Kardiologie, (***2000***), 89/SUPPL. 7 (VII23-VII30), 29 reference(s)
CODEN: ZKRDAX ISSN: 0300-5860
DT Journal; Article
CY Germany, Federal Republic of
LA German
SL English; German

L5 ANSWER 60 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30808017 BIOTECHNO
TI Intravascular adenovirus-mediated ***VEGF*** -C gene transfer reduces neointima formation in balloon-denuded rabbit aorta
AU Hiltunen M.O.; Laitinen M.; Turunen M.P.; Jeltsch M.; Hartikainen J.; Rissanen T.T.; Laukkanen J.; Niemi M.; Kossila M.; Hakkinen T.P.; Kivela A.; Enholm B.; Mansukoski H.; Turunen A.-M.; Alitalo K.; Yla-Herttuala S.
CS Dr. S. Yla-Herttuala, Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, PO Box 1627, FIN-70211 Kuopio, Finland. E-mail: seppo.ylaherttuala@uku.fi
SO Circulation, ***(31 OCT 2000)*** , 102/18 (2262-2268), 37 reference(s)
CODEN: CIRCAZ ISSN: 0009-7322
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 61 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30782871 BIOTECHNO
TI Gene therapy for the treatment of peripheral vascular disease and ***coronary*** ***artery*** ***disease***
AU Hedman M.; Yla-Herttuala S.
CS Dr. S. Yla-Herttuala, A.I. Virtanen Institute, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland.
SO Drugs of Today, (***2000***), 36/9 (609-617), 60 reference(s)
CODEN: MDACAP ISSN: 0025-7656
DT Journal; General Review
CY Spain
LA English
SL English

L5 ANSWER 62 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30751013 BIOTECHNO
TI ***VEGF*** gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease
AU Kalka C.; Tehrani H.; Laudenberg B.; Vale P.R.; Isner J.M.; Asahara T.; Symes J.F.
CS Dr. J.F. Symes, Division of Cardiothoracic Surgery, St. Elizabeth's Medical Center, MOB 306, 11 Nevins St, Boston, MA 02135, United States. E-mail: jsymes@semc.org
SO Annals of Thoracic Surgery, (***2000***), 70/3 (829-834), 20 reference(s)
CODEN: ATHSAK ISSN: 0003-4975
PUI S0003497500016337
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 63 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30644583 BIOTECHNO
TI Gene therapy in cardiovascular diseases
GENTHERAPIE BEI KARDIOVASKULAREN ERKRANKUNGEN
AU Stegmann Th.J.; Hoppert Th.
CS Dr. Th.J. Stegmann, Klinik Thorax Herz-/Gefasschirurgie, Klinikum Fulda, Pacelliallee 4, D-36043 Fulda, Germany.
E-mail: heart.stegmann@klinikum-fulda.de
SO Journal fur Kardiologie, (***2000***), 7/7-8 (292-295), 30 reference(s)
CODEN: JKARFN ISSN: 1024-0098
DT Journal; (Short Survey)
CY Austria

SL English; German

L5 ANSWER 64 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 2000:30210343 BIOTECHNO
TI Angiogenesis and arteriogenesis - Not yet for prescription
AU Helisch A.; Schaper W.
CS Dr. A. Helisch, Abt. fur Experimentelle Kardiologie, Max-Planck-Inst. fur Physiologische, Klinische Forschung, Benekestr. 2, D-61231 Bad Nauheim, Germany.
E-mail: a.helisch@kerckhoff.mpg.de
SO Zeitschrift fur Kardiologie, (***2000***), 89/3 (239-244), 37 reference(s)
CODEN: ZKRDAX ISSN: 0300-5860
DT Journal; Article
CY Germany, Federal Republic of
LA English
SL English; German

L5 ANSWER 65 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:30191841 BIOTECHNO
TI Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of ***coronary*** ***artery*** ***disease*** using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA
AU Rosengart T.K.; Lee L.Y.; Patel S.R.; Kligfield P.D.; Okin P.M.; Hackett N.R.; Isom O.W.; Crystal R.G.; Folkman M.J.; Moore T.C.; Meyer A.A.; Kaiser L.R.; Greenfield L.J.
CS Dr. T.K. Rosengart, Dept. of Cardiothoracic Surgery, Weill Med. Coll. of Cornell Univ., New York Presbyterian Hospital, New York, NY 10021, United States.
SO Annals of Surgery, (***1999***), 230/4 (466-472), 19 reference(s)
CODEN: ANSUA5 ISSN: 0003-4932
DT Journal; Conference Article
CY United States
LA English
SL English

L5 ANSWER 66 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29531873 BIOTECHNO
TI Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart
AU Safi J. Jr.; DiPaula A.F. Jr.; Riccioni T.; Kajstura J.; Ambrosio G.; Becker L.C.; Anversa P.; Capogrossi M.C.
CS J. Safi Jr., Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, Baltimore, MD 21224, United States.
SO Microvascular Research, (***1999***), 58/3 (238-249), 28 reference(s)
CODEN: MIVRA6 ISSN: 0026-2862
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 67 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29526847 BIOTECHNO
TI Gene therapy with vascular endothelial growth factor for inoperable ***coronary*** ***artery*** ***disease***
AU Symes J.F.; Losordo D.W.; Vale P.R.; Lathi K.G.; Esakof D.D.; Mayskiy M.; Isner J.M.; Schaff H.V.; Atkinson A.W.; Vincent C.K.; Pham S.M.; Stanbridge R.D.L.; Horowitz S.; Thomas N.J.
CS Dr. J.F. Symes, 11 Nevins St/306, Boston, MA 02135, United States.
E-mail: jsymes@semc.org
SO Annals of Thoracic Surgery, (***1999***), 68/3 (830-837), 21

CODEN: ATHSAK ISSN: 0003-4975
PUI S0003497599008073
DT Journal; Conference Article
CY United States
LA English
SL English

L5 ANSWER 68 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29411709 BIOTECHNO
TI Role of vascular endothelial growth factor in the regulation of angiogenesis
AU Ferrara N.
CS Dr. N. Ferrara, Dept. of Cardiovascular Research, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
E-mail: nf@gene.com
SO Kidney International, (***1999***), 56/3 (794-814), 285 reference(s)
CODEN: KDYIA5 ISSN: 0085-2538
DT Journal; General Review
CY United States
LA English
SL English

L5 ANSWER 69 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29379654 BIOTECHNO
TI Gene therapy for myocardial angiogenesis
AU Losordo D.W.; Vale P.R.; Isner J.M.
CS Dr. D.W. Losordo, Department of Medicine, Division of Cardiovascular Research, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135, United States.
SO American Heart Journal, (***1999***), 138/2 II (S132-S141), 47 reference(s)
CODEN: AHJOA2 ISSN: 0002-8703
DT Journal; General Review
CY United States
LA English
SL English

L5 ANSWER 70 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29230015 BIOTECHNO
TI Novel vascularization strategies
AU Simons M.
CS M. Simons, Angiogenesis Research Center, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, United States.
E-mail: msimons@caregroup.harvard.edu
SO IDrugs, (***1999***), 2/5 (396-397)
CODEN: IDRUFN ISSN: 1369-7056
DT Journal; Conference Article
CY United Kingdom
LA English
SL English

L5 ANSWER 71 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1999:29094086 BIOTECHNO
TI Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno- ***VEGF***
AU Rivard A.; Silver M.; Chen D.; Kearney M.; Magner M.; Annex B.; Peters K.; Isner J.M.
CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, United States.
E-mail: jisner@opal.tufts.edu
SO American Journal of Pathology, (***1999***), 154/2 (355-363), 50 reference(s)

DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 72 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:29003959 BIOTECHNO
TI Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF.sub.1.sub.6.sub.5 as sole therapy for myocardial ischemia
AU Losordo D.W.; Vale P.R.; Symes J.F.; Dunnington C.H.; Esakof D.D.; Maysky M.; Ashare A.B.; Lathi K.; Isner J.M.
CS Dr. J.M. Isner, St. Elizabeth's Medical Center, 736 Cambridge St., Boston, MA 02135, United States.
SO Circulation, ***(29 DEC 1998)*** , 98/25 (2800-2804), 19 reference(s)
CODEN: CIRCAZ ISSN: 0009-7322
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 73 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28510806 BIOTECHNO
TI Basic fibroblast growth factor: A potential therapeutic agent for the treatment of acute neurodegenerative disorders and vascular insufficiency
AU Moyer J.A.; Wood A.; Zaleska M.M.; Ay I.; Finklestein S.P.; Protter A.A.
CS J.A. Moyer, CNS Disorders Division, Wyeth-Ayerst Research, CN 8000, Princeton, NJ 08543-8000, United States.
SO Expert Opinion on Therapeutic Patents, (***1998***), 8/11 (1425-1445), 142 reference(s)
CODEN: EOTPEG ISSN: 1354-3776
DT Journal; General Review
CY United Kingdom
LA English
SL English

L5 ANSWER 74 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28491904 BIOTECHNO
TI Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF***
AU Metais C.; Li J.; Li J.; Simons M.; Sellke F.W.
CS F.W. Sellke, Division of Cardiothoracic Surgery, Beth Israel-Deaconess Medical Center, East Campus, 330 Brookline Ave., Boston, MA 02215, United States.
SO American Journal of Physiology - Heart and Circulatory Physiology, (***1998***), 275/4 44-4 (H1411-H1418), 48 reference(s)
CODEN: AJPPDI ISSN: 0363-6135
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 75 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1998:28368703 BIOTECHNO
TI Comparison of ***VEGF*** delivery techniques on collateral-dependent microvascular reactivity
AU Sellke F.W.; Tofukuji M.; Laham R.J.; Li J.; Hariawala M.D.; Bunting S.; Simons M.
CS F.W. Sellke, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, East Campus, 330 Brookline Avenue, Boston, MA 02215, United States.
E-mail: fsellke@bidmc.harvard.edu

CODEN: MIVRA6 ISSN: 0026-2862
DT Journal; Article
CY United States
LA English

L5 ANSWER 76 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1997:27418032 BIOTECHNO
TI Enhanced angiogenesis and unfavorable remodeling in injured porcine coronary artery lesions: Effects of local basic fibroblast growth factor delivery
AU Staab M.E.; Simari R.D.; Srivatsa S.S.; Hasdai D.; Pompili V.J.; Holmes D.R. Jr.; Schwartz R.S.
CS Dr. R.S. Schwartz, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, United States.
SO Angiology, (***1997***), 48/9 (753-760), 29 reference(s)
CODEN: ANGIAB ISSN: 0003-3197
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 77 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1996:26349307 BIOTECHNO
TI Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model
AU Horrigan M.C.G.; MacIsaac A.I.; Nicolini F.A.; Vince D.G.; Lee P.; Ellis S.G.; Topol E.J.
CS Department of Cardiology (F-25), Cleveland Clinic Foundation, 9500 Euclid Ave,Cleveland, OH 44195, United States.
SO Circulation, (***1996***), 94/8 (1927-1933)
CODEN: CIRCAZ ISSN: 0009-7322
DT Journal; Article
CY United States
LA English
SL English

L5 ANSWER 78 OF 549 BIOTECHNO COPYRIGHT 2005 Elsevier Science B.V. on STN
AN 1996:26160120 BIOTECHNO
TI Human recombinant insulin-like growth factor I and -II stimulate the expression of basic fibroblast growth factor but suppress the division of bovine coronary smooth muscle cells
AU Schriever C.; Schmidt A.; Breithardt G.; Buddecke E.
CS Inst. of Arteriosclerosis Research, Division of Molecular Cardiology, University of Munster, Domagkstrasse 315,D-48149 Munster, Germany.
SO Atherosclerosis, (***1996***), 122/2 (255-263)
CODEN: ATHSBL ISSN: 0021-9150
DT Journal; Article
CY Ireland
LA English
SL English

L5 ANSWER 79 OF 549 CANCERLIT on STN
AN 2001163550 CANCERLIT
DN 21163550 PubMed ID: 11265801
TI Current understanding of pathogenesis of ***coronary*** ***artery*** ***disease*** and its future implications.
AU Ray S; Panja M
CS Ruby General Hospital, Calcutta.
SO JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, ***(2000 Nov)*** 98 (11) 710-1, 714, 718.
Journal code: 7505608. ISSN: 0019-5847.
CY India

LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001164719
EM 200105
ED Entered STN: 20010614
Last Updated on STN: 20010614

L5 ANSWER 80 OF 549 CANCERLIT on STN
AN 2000550038 CANCERLIT
DN 20550038 PubMed ID: 11098556
TI [Neoangiogenesis by local gene therapy: a new therapeutic concept in the treatment of coronary disease].
Neoangiogenese durch lokale Gentherapie: Ein neues therapeutisches Konzept in der Behandlung der koronaren Herzkrankheit.
AU Schumacher B; Hannekum A; Pecher P
CS Universitatsklinik Ulm, Abt. Chirurgie IV Herzchirurgie.
SO ZEITSCHRIFT FUR KARDIOLOGIE, ***(2000)*** 89 Suppl 7 23-30.
Journal code: 0360430. ISSN: 0300-5860.
CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LA German
FS MEDLINE; Priority Journals
OS MEDLINE 2001057653
EM 200012
ED Entered STN: 20010423
Last Updated on STN: 20010423

L5 ANSWER 81 OF 549 CANCERLIT on STN
AN 2000151124 CANCERLIT
DN 20151124 PubMed ID: 10688416
TI Angiogenesis for the treatment of vascular diseases.
AU Chawla P S; Keelan M H; Kipshidze N
SO INTERNATIONAL ANGIOLOGY, ***(1999 Sep)*** 18 (3) 185-92. Ref: 66
Journal code: 8402693. ISSN: 0392-9590.
CY Italy
DT Editorial
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2000151124
EM 200004
ED Entered STN: 20000515
Last Updated on STN: 20000515

L5 ANSWER 82 OF 549 CANCERLIT on STN
AN 1999012402 CANCERLIT
DN 99012402 PubMed ID: 9796310
TI Coronary stenosis and mechanisms of collateral vessel growth.
AU Iwakura A; Komeda M; Fujita M
CS Department of Cardiovascular Surgery, Kyoto University.
SO NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, ***(1998 Oct)***
56 (10) 2504-8. Ref: 19
Journal code: 0420546. ISSN: 0047-1852.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA Japanese
FS MEDLINE; Priority Journals

AU Biswas, Shankha S.; Hughes, G. Chad; Yin, Bangliang; Baklanov, Dmitri V.; Lowe, James E.; Annex, Brian H.; Landolfo, Kevin P.
CS Division of Thoracic and Cardiovascular Surgery, Duke University Medical Center, Durham, NC, USA
SO Surgical Forum (***1999***), 50, 122-124
CODEN: SUFOAX; ISSN: 0071-8041
PB American College of Surgeons
DT Journal
LA English
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 86 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:645432 CAPLUS
DN 132:31013
TI Angiogenic therapy of acute myocardial infarction by intramyocardial injection of basic fibroblast growth factor
AU Nagamine, Hiroshi
CS Department of Surgery (I), School of Medicine, Kanazawa University, Kanazawa, 920-8640, Japan
SO Kanazawa Daigaku Juzen Igakkai Zasshi (***1999***), 108(3), 336-348
CODEN: JUZIAG; ISSN: 0022-7226
PB Juzen Igakkai
DT Journal
LA Japanese

L5 ANSWER 87 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:641878 CAPLUS
DN 131:252631
TI Angiogenesis in cardiovascular disease: current status and therapeutic potential
AU Sellke, Frank W.; Simons, Michael
CS Beth Israel Deaconess Medical Center, Division of Cardiothoracic Surgery and Cardiovascular Division, Harvard Medical School, Boston, MA, USA
SO Drugs (***1999***), 58(3), 391-396
CODEN: DRUGAY; ISSN: 0012-6667
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:48639 CAPLUS
DN 130:76613
TI Novel composition for treating, preventing and/or delaying ischemic cell death using proteins having the function of ***aFGF*** or activators of stress-activated protein kinases
IN Schaper, Wolfgang; Htun, Patrik
PA Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V., Germany
SO PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9901150	A1	19990114	WO 1998-EP4134	19980703 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ,

EM 199902
ED Entered STN: 19990405
Last Updated on STN: 19990405

L5 ANSWER 83 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:158191 CAPLUS
DN 134:173434
TI sFlt-1, a potential antagonist for exogenous ***VEGF*** . Comments
AU Belgore, Funmi M.; Blann, Andrew D.; Lip, Gregory Y. H.
CS Haemostasis, Thrombosis, and Vascular Biol. Unit, Univ. Dep. Med. City Hosp., Birmingham, B18 7QH, UK
SO Circulation (***2000***), 102(15), E108
CODEN: CIRCAZ; ISSN: 0009-7322
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 84 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:175692 CAPLUS
DN 132:227446
TI Angiogenically effective unit dose of fibroblast growth factor-2 and method of use
IN Whitehouse, Martha Jo
PA Chiron Corporation, USA
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000013701	A2	20000316	WO 1999-US19770	19990827 <--
	WO 2000013701	A3	20000803		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9960223	A1	20000327	AU 1999-60223	19990827 <--
	EP 1121142	A2	20010808	EP 1999-968630	19990827
	EP 1121142	B1	20041020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002524420	T2	20020806	JP 2000-568509	19990827
	AT 279937	E	20041115	AT 1999-968630	19990827
	US 2002165160	A1	20021107	US 2002-131965	20020425
PRAI	US 1998-145743P	P	19980903		
	US 1998-104102P	P	19981013		
	US 1998-104103P	P	19981013		
	WO 1999-US19770	W	19990827		
	US 1999-417721	A1	19991013		

L5 ANSWER 85 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:15114 CAPLUS
DN 132:161488
TI Effects of low-dose basic fibroblast growth factor on regional blood flow

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9888557 A1 19990125 AU 1998-88557 19980703 <--
PRAI US 1997-888112 A 19970703
WO 1998-EP4134 W 19980703
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:539034 CAPLUS
DN 129:288788
TI Elastase and elastase inhibitors and pulmonary and ***coronary*** ***artery*** ***disease***
AU Rabinovitch, Marlene
CS Division of Cardiovascular Research, University of Toronto, Toronto, Can.
SO International Congress Series (***1998***), 1155(Atherosclerosis XI), 317-326
CODEN: EXMDA4; ISSN: 0531-5131
PB Elsevier Science B.V.
DT Journal; General Review
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:658352 CAPLUS
DN 127:302847
TI Gene therapy for ***coronary*** ***artery*** ***disease***
AU Morishita, Ryuichi; Higaki, Jitsuo; Ogihara, Toshio
CS Med. Sch., Osaka Univ., Suita, 565, Japan
SO Saishin Igaku (***1997***), 52(10), 2452-2456
CODEN: SAIGAK; ISSN: 0370-8241
PB Saishin Igakusha
DT Journal; General Review
LA Japanese

L5 ANSWER 91 OF 549 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:804532 CAPLUS
DN 123:276007
TI Method for treating diseases mediated by cellular proliferation in response to PDGF, EGF, FGF and ***VEGF***
IN Brown, Paul A.; Bursten, Stuart L.; Rice, Glenn C.; Singer, Jack W.
PA Cell Therapeutics, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9519171	A1	19950720	WO 1995-US520	19950113	<--
	W: AU, CA, JP					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	CA 2192470	AA	19950720	CA 1995-2192470	19950113	<--
	AU 9518313	A1	19950801	AU 1995-18313	19950113	<--
	EP 739203	A1	19961030	EP 1995-910088	19950113	<--
	R: AT, DE, ES, FR, GB, IE, IT					
	US 5795898	A	19980818	US 1995-485325	19950607	<--
	US 5859018	A	19990112	US 1995-485322	19950607	<--
	US 5929081	A	19990727	US 1995-485320	19950607	<--
PRAI	US 1994-181947	A	19940114			

OS MARPAT 123:276007

L5 ANSWER 92 OF 549 CEABA-VTB COPYRIGHT 2005 DECHEMA on STN
AN 1999(06):4967 CEABA-VTB FS B
DN CEABA: 1999:3174891
TI Blood vessel growth factor genes seen as aid for failing hearts
CS St Elizabeth s Medical Center, Cambridge, MA, USA
SO Biotechnol. Newswatch (***1999***), p.4
ISSN: 0275-3685
DT Journal
LA English

L5 ANSWER 93 OF 549 CEABA-VTB COPYRIGHT 2005 DECHEMA on STN
AN 1997(06):6385 CEABA-VTB FS B
DN CEABA: 1997:2511890
TI Scios-Wyeth-Ayerst sign Fiblast deal
CS Scios, Mountain View, CA, USA
SO Biotechnol. Bus. News (***1996***) 6(137), p.9
CODEN: BBUNER ISSN: 0965-9595
DT Journal
LA English

L5 ANSWER 94 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(49):49406Z CIN
TI Clinical results
SO BioCentury, 20 Nov 2000 (20001120), 8(51, Pt. 2), p. B11. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 95 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(14):13961N CIN
TI Clinical results
SO BioCentury, 20 Mar 2000 (20000320), 8(13, Pt. 2), p. B11-B12. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 96 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(14):13915A CIN
TI Clinical results
SO BioCentury, 20 Mar 2000 (20000320), 8(13, Pt. 2), p. B9. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 97 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(12):12386S CIN
TI The bottleneck at Vascular Genetics
SO BioCentury, 6 Mar 2000 (20000306), 8(11), p. A8. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 98 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 29(3):2019K CIN
TI ACE inhibitor promotes angiogenesis in rabbits
SO Emerging Pharm., Aug 1999 (19990800), 8(8), p. 7. ISSN: 1061-6098; CODEN: EMPHFR.
LA English

L5 ANSWER 99 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(34):34201J CIN
TI Clinical results
SO BioCentury, 9 Aug 1999 (19990809), 7(48, Pt. 2), p. B8. ISSN: 1097-7201; CODEN: BICEFS.

L5 ANSWER 100 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(27):27212K CIN
TI Clinical status
SO BioCentury, 21 Jun 1999 (19990621), 7(37, Pt. 2), p. B14. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 101 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(13):12771T CIN
TI Clinical results
SO BioCentury, 15 Mar 1999 (19990315), 7(18, Pt. 2), p. B7-B8. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 102 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 28(10):9559Z CIN
TI Clinical results
SO BioCentury, 22 Feb 1999 (19990222), 7(12, Pt. 2), p. B7. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 103 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(48):54736V CIN
TI Clinical Status
SO BioCentury, 16 Nov 1998 (19981116), 6(97, Pt. 2), p. B15. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 104 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(16):18097D CIN
TI Clinical results
SO BioCentury, 6 Apr 1998 (19980406), 6(30, Pt. 2), p. B9. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 105 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(14):15671A CIN
TI Clinical Status
SO BioCentury, 23 Mar 1998 (19980323), 6(25, Pt. 2), p. B10. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 106 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(11):12285S CIN
TI Making angiogenesis work for the heart
SO BioCentury, 2 Mar 1998 (19980302), 6(18), p. A4. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 107 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(5):4580U CIN
TI Clinical status
SO BioCentury, 12 Jan 1998 (19980112), 6(2, Pt. 2), p. B12. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L5 ANSWER 108 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 27(4):3316A CIN
TI Clinical status
SO BioCentury, 5 Jan 1998 (19980105), 6(1, Pt. 2), p. B7. CODEN: BICEFS.
LA English

L5 ANSWER 109 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 26(23):25804Q CIN
TI Companies aim novel therapeutic strategies at dual nature of angiogenesis
SO Genet. Eng. News, 1 May 1997 (970501), 17(9), p. 6, 33. ISSN: 0270-6377; CODEN: GENNDX.
LA English

L5 ANSWER 110 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 26(15):17282C CIN
TI Angiogenic factors put to the test in bypassing blocked arteries
SO Biotechnol. News, 27 Mar 1997 (970327), 17(8), p. 7. ISSN: 0273-3226; CODEN: BINWEY.
LA English

L5 ANSWER 111 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 25(51):55796K CIN
TI Scios/Wyeth-Ayerst sign fiblast deal
SO Biotechnol. Bus. News, 13 Nov 1996 (961113), 6(137), p. 9. ISSN: 0965-9595; CODEN: BBUNER.
LA English

L5 ANSWER 112 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 25(28):30596G CIN
TI Scios to patent method of producing human basic fibroblast growth factor
SO Biotech Pat. News, May 1996 (960500), 10(5), p. 5-6. ISSN: 0898-2813; CODEN: BPANEP.
LA English

L5 ANSWER 113 OF 549 CIN COPYRIGHT 2005 ACS on STN
AN 23(9):8931Z CIN
TI Relieving angina using ***bFGF***
SO Biotechnol. News, 3 Feb 1994 (940203), 14(3), p. 4-5. ISSN: 0273-3226; CODEN: BINWEY.
LA English

L5 ANSWER 114 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50436 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
DESC Human VEGF110.

L5 ANSWER 115 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50435 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520

LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90481
DESC Human VEGF206.

L5 ANSWER 116 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50434 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90480
DESC Human VEGF189.

L5 ANSWER 117 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50433 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90479
DESC Human VEGF165.

L5 ANSWER 118 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50432 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90478
DESC Human VEGF145.

L5 ANSWER 119 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50431 Protein DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -

PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR N-PSDB: AAC90477
DESC Human VEGF121.

L5 ANSWER 120 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50428 Protein DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]
CR N-PSDB: AAC90473
DESC Mature human vascular endothelial growth factor polypeptide.

L5 ANSWER 121 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAB50427 Protein DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]
CR N-PSDB: AAC90473
DESC Human vascular endothelial growth factor polypeptide.

L5 ANSWER 122 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY81942 Peptide DGENE
TI Composition for inducing angiogenesis or treating ***coronary*** ***artery*** ***disease*** comprises fibroblast growth factor-2 o angiogenically active fragment or mutein -
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000013701 A2 20000316 60***
AI WO 1999-US19770 19990827
PRAI US 1998-145743 19980903
US 1998-104102 19981013
US 1998-104103 19981013
DT Patent
LA English

DESC Recombinant bovine ***FGF*** - ***2*** protein sequence fragment.

L5 ANSWER 123 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY81941 Protein DGENE
TI Composition for inducing angiogenesis or treating ***coronary*** ***artery*** ***disease*** comprises fibroblast growth factor-2 o:
angiogenically active fragment or mutein -
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000013701 A2 20000316 60***
AI WO 1999-US19770 19990827
PRAI US 1998-145743 19980903
US 1998-104102 19981013
US 1998-104103 19981013
DT Patent
LA English
OS 2000-256860 [22]
CR N-PSDB: AAA07355
DESC Recombinant bovine ***FGF*** - ***2*** protein sequence.

L5 ANSWER 124 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY92777 Protein DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.
PI ***WO 2000025805 A1 20000511 76***
AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
DESC PDGF/ ***VEGF*** family characteristic motif.

L5 ANSWER 125 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY92776 Protein DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.
PI ***WO 2000025805 A1 20000511 76***
AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
DESC Orf virus strain NZ10 vascular endothelial growth factor-like protein.

L5 ANSWER 126 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY92775 Protein DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.

AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
CR N-PSDB: AAA28493
DESC Orf virus strain NZ2 vascular endothelial growth factor-like protein.

L5 ANSWER 127 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87849 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
DESC ***FGF*** - ***2*** protein fragment.

L5 ANSWER 128 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87848 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
CR N-PSDB: AAA39555
DESC Bovine ***FGF*** - ***2*** protein.

L5 ANSWER 129 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87847 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
DESC Human ***FGF*** - ***2*** protein.

L5 ANSWER 130 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN

TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
DESC Bovine ***FGF*** - ***1*** protein.

L5 ANSWER 131 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAY87845 protein DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
DESC Human ***FGF*** - ***1*** protein.

L5 ANSWER 132 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAW53244 Protein DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D) peptide.

L5 ANSWER 133 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAW53243 Protein DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F

(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR N-PSDB: AAV20809
DESC Mus musculus vascular endothelial growth factor D2 (***VEGF*** -D2).

L5 ANSWER 134 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAW53242 Protein DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR N-PSDB: AAV20808
DESC Mus musculus vascular endothelial growth factor D1 (***VEGF*** -D1).

L5 ANSWER 135 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAW53241 Protein DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]

DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D).

L5 ANSWER 136 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAW53240 Protein DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR N-PSDB: AAV20806
DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D).

L5 ANSWER 137 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90483 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
DESC Human VEGF121 gene mutagenic reverse primer oligo 2524.

L5 ANSWER 138 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90482 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
DESC Human VEGF121 gene mutagenic forward primer oligo 1612.

L5 ANSWER 139 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90481 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating

tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50435
DESC Human VEGF206 DNA.

L5 ANSWER 140 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90480 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50434
DESC Human VEGF189 DNA.

L5 ANSWER 141 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90479 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50433
DESC Human VEGF165 DNA.

L5 ANSWER 142 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90478 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50432
DESC Human VEGF145 DNA.

L5 ANSWER 143 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90477 DNA DGENE
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections -
IN Pollitt N S; Abraham J A
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071713 A1 20001130 62***
AI WO 2000-US13536 20000518
PRAI US 1999-135312 19990520
DT Patent
LA English
OS 2001-025162 [03]
CR P-PSDB: AAB50431
DESC Human VEGF121 DNA.

L5 ANSWER 144 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAC90473 cDNA DGENE
TI Vascular endothelial growth factor dimer, useful for treating essential hypertension, polycystic kidney diseases, microvascular angiopathy and ***coronary*** ***artery*** ***disease*** , comprising two monomeric subunits -
IN Jue R A; Schellenberger U; Stathis P A; Adriaenssens P I; Abraham J A; Baldwin P A; Pollitt N S
PA (SCIO-N) SCIOS INC.
PI ***WO 2000071716 A2 20001130 61***
AI WO 2000-US13636 20000518
PRAI US 1999-135312 19990520
US 2000-177407 20000120
DT Patent
LA English
OS 2001-041064 [05]
CR P-PSDB: AAB50427; AAB50428
DESC Human vascular endothelial growth factor cDNA.

L5 ANSWER 145 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA07355 DNA DGENE
TI Composition for inducing angiogenesis or treating ***coronary*** ***artery*** ***disease*** comprises fibroblast growth factor-2 o
angiogenically active fragment or mutein -
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000013701 A2 20000316 60***
AI WO 1999-US19770 19990827
PRAI US 1998-145743 19980903
US 1998-104102 19981013
US 1998-104103 19981013
DT Patent
LA English
OS 2000-256860 [22]
CR P-PSDB: AAY81941
DESC Recombinant bovine ***FGF*** - ***2*** coding sequence.

L5 ANSWER 146 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA28494 DNA DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.

AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
CR P-PSDB: AAY92776
DESC ORFV10- ***VEGF*** coding sequence.

L5 ANSWER 147 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA28493 DNA DGENE
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis
IN Wise L M; Mercer A A; Savory L J; Fleming S B; Stacker S A
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYOT-N) UNIV OTAGO.
PI ***WO 2000025805 A1 20000511 76***
AI WO 1999-US25869 19991102
PRAI US 1998-106689 19981102
US 1998-106800 19981103
DT Patent
LA English
OS 2000-365394 [31]
CR P-PSDB: AAY92775
DESC ORFV2- ***VEGF*** coding sequence.

L5 ANSWER 148 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAA39555 DNA DGENE
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury -
IN Kavanaugh W M
PA (CHIR) CHIRON CORP.
(WHIT-I) WHITEHOUSE M J.
PI ***WO 2000021548 A2 20000420 67***
AI WO 1999-US22936 19991013
PRAI US 1998-104103 19981013
DT Patent
LA English
OS 2000-317840 [27]
CR P-PSDB: AAY87848
DESC Bovine ***FGF*** - ***2*** DNA fragment.

L5 ANSWER 149 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20811 DNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210

DT Patent
LA English
OS 1998-179057 [16]
DESC Homo sapiens ***VEGF*** -D gene PCR primer.

L5 ANSWER 150 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20810 DNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
DESC Homo sapiens ***VEGF*** -D gene PCR primer.

L5 ANSWER 151 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20809 cDNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR P-PSDB: AAW53243
DESC Mus musculus vascular endothelial growth factor D2 (***VEGF*** -D2) gene.

L5 ANSWER 152 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20808 cDNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***

PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR P-PSDB: AAW53242
DESC Mus musculus vascular endothelial growth factor D1 (***VEGF*** -D1) gene.

L5 ANSWER 153 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20807 cDNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR P-PSDB: AAW53241
DESC Homo sapiens vascular endothelial growth factor D (***VEGF*** -D) gene.

L5 ANSWER 154 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV20806 cDNA DGENE
TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders
IN Achen M G; Alitalo K; Stacker S A; Wilks A F
PA (LUDW-N) LUDWIG INST CANCER RES.
(UYHE-N) UNIV HELSINKI LICENSING LTD.
PI ***WO 9807832 A1 19980226 101***
AI WO 1997-US14696 19970821
PRAI US 1997-51426 19970701
AU 1996-1825 19960823
US 1996-23751 19960823
AU 1996-3554 19961111
US 1996-31097 19961114
AU 1997-4954 19970205
US 1997-38814 19970210
AU 1997-7435 19970619
DT Patent
LA English
OS 1998-179057 [16]
CR P-PSDB: AAW53240

gene.

L5 ANSWER 155 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV08945 DNA DGENE
TI Treatment of congestive heart failure - by delivering a vector comprising a gene encoding an angiogenic protein linked to a promoter to the heart of a patient
IN Hammond H K; Kelly T L
PA (REGC) UNIV CALIFORNIA.
PI ***WO 9850079 A2 19981112 87***
AI WO 1998-US8848 19980430
PRAI US 1997-852779 19970506
DT Patent
LA English
OS 1998-610127 [51]
DESC PCR primer for ***FGF*** - ***1*** coding sequence.

L5 ANSWER 156 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV08944 DNA DGENE
TI Treatment of congestive heart failure - by delivering a vector comprising a gene encoding an angiogenic protein linked to a promoter to the heart of a patient
IN Hammond H K; Kelly T L
PA (REGC) UNIV CALIFORNIA.
PI ***WO 9850079 A2 19981112 87***
AI WO 1998-US8848 19980430
PRAI US 1997-852779 19970506
DT Patent
LA English
OS 1998-610127 [51]
DESC PCR primer for ***FGF*** - ***1*** coding sequence.

L5 ANSWER 157 OF 549 DGENE COPYRIGHT 2005 The Thomson Corp on STN
AN AAV08942 DNA DGENE
TI Treatment of congestive heart failure - by delivering a vector comprising a gene encoding an angiogenic protein linked to a promoter to the heart of a patient
IN Hammond H K; Kelly T L
PA (REGC) UNIV CALIFORNIA.
PI ***WO 9850079 A2 19981112 87***
AI WO 1998-US8848 19980430
PRAI US 1997-852779 19970506
DT Patent
LA English
OS 1998-610127 [51]
DESC PCR primer for ***FGF*** - ***1*** coding sequence.

L5 ANSWER 158 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-41526 DRUGU T P B
TI Atorvastatin therapy reduces vascular endothelial growth factor (***VEGF***) in patients with ***coronary*** ***artery*** ***disease*** .
AU Alber H; Dulak J; Schwarzacher S; Pachinger O; Weidinger F
CS Univ.Innsbruck; Univ.Jagiellonian
LO Innsbruck, Austria; Cracow, Pol.
SO Atherosclerosis (151, No. 1, 191, 2000)
CODEN: ATHSBL ISSN: 0021-9150
AV Department of Cardiology, University of Innsbruck, Austria.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 159 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-32505 DRUGU T
TI Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with ***coronary*** ***artery*** ***disease*** (CAD): ***FGF*** - ***2*** initiating revascularization support trial (FIRST).
AU Simons M
LO Boston, Mass., USA
SO J.Am.Coll.Cardiol. (36, No. 1, 310-11, 2000)
CODEN: JACCDI ISSN: 0735-1097
AV Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 160 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-18652 DRUGU T P
TI Unique kinetics and hemodynamics of vascular endothelial growth factor (rhVEGF) following intracoronary and intravenous infusion in humans.
AU Eppler S M; McCluskey E R; Henry T D; Simons M; Giordano F J; Zioncheck T F
CS Genentech
LO San Francisco, Cal., USA
SO J.Am.Coll.Cardiol. (35, No. 2, Suppl. A, 73A-74A, 2000)
CODEN: JACCDI ISSN: 0735-1097
AV Genentech, S. San Francisco, CA, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 161 OF 549 DRUGU COPYRIGHT 2005 THE THOMSON CORP on STN
AN 1995-00419 DRUGU P
TI Angiogenic therapy of acute myocardial infarction (AMI) by intrapericardial injection of basic fibroblast growth factor (***bFGF***) and heparin sulfate (HS): an experimental study.
AU Uchida Y; Yanagisawa Miwa A; Ikuta M; Makamura F; Tomaru T; Fujimori Y
CS Univ.Tokyo
LO Tokyo, Jap.
SO Circulation (90, No. 4, Pt. 2, I296, 1994) 1 Tab.
CODEN: CIRCAZ ISSN: 0009-7322
AV Second Department of Internal Medicine, University of Tokyo, Tokyo, Japan. (7 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 162 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001350870 EMBASE
TI Fate of latissimus dorsi muscle flap in cardiomyoplasty and availability of omental flap.
AU Okada M.; Tsukube T.; Hariu T.; Ootaki Y.; Okita Y.
CS Dr. M. Okada, 1-1-39-103 Sumiyoshihonmachi, Higashinada-ku, Kobe 658-0051, Japan
SO Journal of Congestive Heart Failure and Circulatory Support, (2000) Vol. 1, No. 4, pp. 285-289.
Refs: 8
ISSN: 1468-3768 CODEN: JCHFAT

DT Journal; Conference Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
029 Clinical Biochemistry
027 Biophysics, Bioengineering and Medical Instrumentation
LA English
SL English
ED Entered STN: 20011018
Last Updated on STN: 20011018

L5 ANSWER 163 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2001018068 EMBASE
TI [Clinical results of the treatment of ***coronary*** ***artery*** ***disease*** with growth factors].
KLINISCHE ERGEBNISSE DER BEHANDLUNG DER KORONAREN HERZKRANKHEIT MIT WACHSTUMSTAKTOREN.
AU Hoppert Th.; Ibing R.; Schneider A.; Popp M.; Stegmann Th.J.
CS Dr. Th. Hoppert, Klin. fur Thorax-, Herz/Gefasschir., Klinikum Fulda, Pacelliallee 4, D-36043 Fulda, Germany. T.Hoppert.THG@klinikum-fulda.de
SO Hamostaseologie, (2000) Vol. 20, No. 4, pp. 167-172.
Refs: 42
ISSN: 0720-9355 CODEN: HAEMD2
CY Germany
DT Journal; Conference Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
LA German
SL English; German
ED Entered STN: 20010201
Last Updated on STN: 20010201

L5 ANSWER 164 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000295090 EMBASE
TI Therapeutic angiogenesis: Potential role of basic fibroblast growth factor in patients with severe ischaemic heart disease.
AU Simons M.; Laham R.J.; Post M.; Sellke F.W.
CS Dr. M. Simons, Angiogenesis Research Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, United States. msimons@caregroup.harvard.edu
SO BioDrugs, (2000) Vol. 14, No. 1, pp. 13-20.
Refs: 61
ISSN: 1173-8804 CODEN: BIDRF4
CY New Zealand
DT Journal; General Review
FS 006 Internal Medicine
018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English
ED Entered STN: 20000914
Last Updated on STN: 20000914

L5 ANSWER 165 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999285095 EMBASE
TI Mechanical endothelial damage results in basic fibroblast growth factor-mediated activation of extracellular signal-regulated kinases.
AU Pintucci G.; Steinberg B.M.; Seghezzi G.; Yun J.; Apazidis A.; Baumann F.G.; Grossi E.A.; Colvin S.B.; Mignatti P.; Galloway A.C.

United States
SO Surgery, (1999) Vol. 126, No. 2, pp. 422-427.
Refs: 21
ISSN: 0039-6060 CODEN: SURGAZ
CY United States
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
026 Immunology, Serology and Transplantation
LA English
SL English
ED Entered STN: 19990826
Last Updated on STN: 19990826

L5 ANSWER 166 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999282282 EMBASE
TI Gene therapy for myocardial angiogenesis.
AU Losordo D.W.; Vale P.R.; Isner J.M.
CS Dr. D.W. Losordo, Department of Medicine, Division of Cardiovascular Research, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135, United States
SO American Heart Journal, (1999) Vol. 138, No. 2 II, pp. S132-S141.
Refs: 47
ISSN: 0002-8703 CODEN: AHJOA2
CY United States
DT Journal; General Review
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 19990826
Last Updated on STN: 19990826

L5 ANSWER 167 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999243631 EMBASE
TI Effects of dehydroepiandrosterone on mitogen-activated protein kinase in human aortic smooth muscle cells.
AU Yoshimata T.; Yoneyama A.; Jin-No Y.; Tamai N.; Kamiya Y.
CS T. Yoshimata, Third Dept. of Internal Medicine, Nagoya City Univ. Medical School, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
SO Life Sciences, (18 Jun 1999) Vol. 65, No. 4, pp. 431-440.
Refs: 43
ISSN: 0024-3205 CODEN: LIFSAK
PUI S 0024-3205(99)00264-7
CY United States
DT Journal; Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 19990802
Last Updated on STN: 19990802

L5 ANSWER 168 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999036557 EMBASE
TI Pharmacokinetics and consistency of pericardial delivery directed to coronary arteries: Direct comparison with endoluminal delivery.
AU Stoll H.-P.; Carlson K.; Keefer L.K.; Hrabie J.A.; March K.L.
CS Dr. K.L. March, Krannert Institute of Cardiology, Indiana University Medical Center, 1111 W 10th Street, Indianapolis, IN 46202-4800, United

SO Clinical Cardiology, (1999) Vol. 22, No. 1 SUPPL., pp. I10-I16.
Refs: 24
ISSN: 0160-9289 CODEN: CLCADC
CY United States
DT Journal; Conference Article
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
039 Pharmacy
LA English
SL English
ED Entered STN: 19990225
Last Updated on STN: 19990225

L5 ANSWER 169 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1998372756 EMBASE
TI Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience.
AU Goncalves L.M.
CS L.M. Goncalves, Cardiology Branch, National Heart, Lung/Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1518, United States. goncalvl@gwgate.nhlbi.nih.gov
SO Revista Portuguesa de Cardiologia, (1998) Vol. 17, No. SUPPL. 2, pp. 11-20.
Refs: 103
ISSN: 0304-4750 CODEN: RPCADZ
CY Portugal
DT Journal; General Review
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
030 Pharmacology
037 Drug Literature Index
052 Toxicology
LA English
SL English; Portuguese
ED Entered STN: 19981130
Last Updated on STN: 19981130

L5 ANSWER 170 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1998363851 EMBASE
TI Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF*** .
AU Metais C.; Li J.; Li J.; Simons M.; Sellke F.W.
CS F.W. Sellke, Division of Cardiothoracic Surgery, Beth Israel-Deaconess Medical Center, East Campus, 330 Brookline Ave., Boston, MA 02215, United States
SO American Journal of Physiology - Heart and Circulatory Physiology, (1998) Vol. 275, No. 4 44-4, pp. H1411-H1418.
Refs: 48
ISSN: 0363-6135 CODEN: AJPPDI
CY United States
DT Journal; Article
FS 002 Physiology
LA English
SL English
ED Entered STN: 19981119
Last Updated on STN: 19981119

L5 ANSWER 171 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 96181927 EMBASE

TI Vascular endothelial growth factor administration in chronic myocardial ischemia.
AU Harada K.; Friedman M.; Lopez J.J.; Wang S.Y.; Li J.; Prasad P.V.; Pearlman J.D.; Edelman E.R.; Sellke F.W.; Simons M.
CS Cardiovascular Division, Beth Israel Hospital, 330 Brookline Ave.,Boston, MA 02215, United States
SO American Journal of Physiology - Heart and Circulatory Physiology, (1996) Vol. 270, No. 5 39-5, pp. H1791-H1802.
ISSN: 0363-6135 CODEN: AJPPDI
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
018 Cardiovascular Diseases and Cardiovascular Surgery
LA English
SL English
ED Entered STN: 960708
Last Updated on STN: 960708

L5 ANSWER 172 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 96035325 EMBASE
DN 1996035325
TI Antithrombin determinants of ***coronary*** ***artery*** ***disease*** in transplanted human hearts.
AU Labarrere C.A.; Faulk W.P.
CS Division of Experimental Pathology, Reprod./Transplant. Immunology Ctr., Methodist Hospital, 1701 N Senate Blvd,Indianapolis, IN 46202, United States
SO Seminars in Hematology, (1995) Vol. 32, No. 4 SUPPL. 2, pp. 61-66.
ISSN: 0037-1963 CODEN: SEHEA3
CY United States
DT Journal; Conference Article
FS 009 Surgery
018 Cardiovascular Diseases and Cardiovascular Surgery
025 Hematology
LA English
SL English
ED Entered STN: 960212
Last Updated on STN: 960212

L5 ANSWER 173 OF 549 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 91230395 EMBASE
DN 1991230395
TI Coronary atherosclerosis: Current therapeutic approaches and future trends.
AU DeFeudis F.V.
CS Institute for BioScience, 3 Spanish River Road, Grafton, MA 01519, United States
SO Life Sciences, (1991) Vol. 49, No. 10, pp. 689-705.
ISSN: 0024-3205 CODEN: LIFSAK
CY United States
DT Journal; (Short Survey)
FS 018 Cardiovascular Diseases and Cardiovascular Surgery
037 Drug Literature Index
LA English
SL English
ED Entered STN: 911216
Last Updated on STN: 911216

L5 ANSWER 174 OF 549 IFIPAT COPYRIGHT 2005 IFI on STN
AN 03175836 IFIPAT;IFIUDB;IFICDB

RESPONSE TO PDGF, EGF, FGF AND ***VEGF*** ; ADMINISTERING COMPOUND THAT INHIBITS SIGNAL TRANSDUCTION THROUGH CELLULAR ACCUMULATION OF NON-ARACHIDONYL PHOSPHATIDIC ACID
IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W
PA Cell Therapeutics Inc (32953)
PI US 5929081 A 19990727 (CITED IN 004 LATER PATENTS)
AI US 1995-485320 19950607
RLI US 1994-181947 19940114 DIVISION
FI US 5929081 19990727
DT Utility
FS CHEMICAL
GRANTED
CLMN 13
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 175 OF 549 IFIPAT COPYRIGHT 2005 IFI on STN
AN 03097071 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF, AND ***VEGF*** ; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERS
IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W
PA Cell Therapeutics Inc (32953)
PI US 5859018 A 19990112 (CITED IN 003 LATER PATENTS)
AI US 1995-485322 19950607
RLI US 1994-181947 19940114 DIVISION ABANDONED
FI US 5859018 19990112
DT Utility
FS CHEMICAL
GRANTED
CLMN 9
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 176 OF 549 IFIPAT COPYRIGHT 2005 IFI on STN
AN 03026608 IFIPAT;IFIUDB;IFICDB
TI METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF,EGF,FGF AND ***VEGF*** ; ANTITUMOR, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS
IN Brown Paul A; Bursten Stuart L; Rice Glenn C; Singer Jack W
PA Cell Therapeutics Inc (32953)
PI US 5795898 A 19980818 (CITED IN 004 LATER PATENTS)
AI US 1995-485325 19950607
RLI US 1994-181947 19940114 DIVISION ABANDONED
FI US 5795898 19980818
DT Utility
FS CHEMICAL
GRANTED
CLMN 9
GI 30 Drawing Sheet(s), 36 Figure(s).

L5 ANSWER 177 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:2695 IMSDRUGNEWS
TITLE: gene therapy, cardiovascular disease GenVec phase change II, USA (peripheral vascular disease)
SOURCE: R&D Focus Drug News (***21 Aug 2000***).
WORD COUNT: 115

L5 ANSWER 178 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:1510 IMSDRUGNEWS
TITLE: gene therapy, cardiovascular disease GenVec begins phase II trial

WORD COUNT: 115

L5 ANSWER 179 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:1070 IMSDRUGNEWS
TITLE: basic fibroblast growth factor Chiron clinical data
SOURCE: R&D Focus Drug News (***27 Mar 2000***).
WORD COUNT: 194

L5 ANSWER 180 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 2000:931 IMSDRUGNEWS
TITLE: gene therapy, ***VEGF*** -2, Vascular Genetics Vascular Genetics trials suspended
SOURCE: R&D Focus Drug News (***13 Mar 2000***).
WORD COUNT: 149

L5 ANSWER 181 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:3459 IMSDRUGNEWS
TITLE: gene therapy, ***VEGF*** -165 Valentis clinical data
SOURCE: R&D Focus Drug News (***22 Nov 1999***).
WORD COUNT: 142

L5 ANSWER 182 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:3354 IMSDRUGNEWS
TITLE: trafermin Scios, Chiron, Orquest, Selective Genetics licensing agreement
SOURCE: R&D Focus Drug News (***15 Nov 1999***).
WORD COUNT: 130

L5 ANSWER 183 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:3161 IMSDRUGNEWS
TITLE: ***VEGF*** 121-based therapy, Scios Scios licensing offer, Worldwide
SOURCE: R&D Focus Drug News (***25 Oct 1999***).
WORD COUNT: 44

L5 ANSWER 184 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:577 IMSDRUGNEWS
TITLE: telbermin Genentech considers product future
SOURCE: R&D Focus Drug News (***1 Mar 1999***).
WORD COUNT: 78

L5 ANSWER 185 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1999:76 IMSDRUGNEWS
TITLE: gene therapy, ***VEGF*** -2, Vascular Genetics Vascular Genetics IND allowed
SOURCE: R&D Focus Drug News (***11 Jan 1999***).
WORD COUNT: 81

L5 ANSWER 186 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:4062 IMSDRUGNEWS
TITLE: basic fibroblast growth factor Chiron phase change II, USA
SOURCE: R&D Focus Drug News (***16 Nov 1998***).
WORD COUNT: 166

ACCESSION NUMBER: 1998:3822 IMSDRUGNEWS
TITLE: angiopoietin 1 Regeneron, Procter & Gamble preclinical data
SOURCE: R&D Focus Drug News (***2 Nov 1998***).
WORD COUNT: 200

L5 ANSWER 188 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:3246 IMSDRUGNEWS
TITLE: gene therapy, vascular endothelial growth factor B Collateral Therapeutics, Ludwig Institute for Cancer Research, AMRAD licensing termination
SOURCE: R&D Focus Drug News (***14 Sep 1998***).
WORD COUNT: 89

L5 ANSWER 189 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:3150 IMSDRUGNEWS
TITLE: telbermin Genentech phase change II, USA (***coronary*** ***artery*** ***disease***)
SOURCE: R&D Focus Drug News (***7 Sep 1998***).
WORD COUNT: 32

L5 ANSWER 190 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:2760 IMSDRUGNEWS
TITLE: trafermin Wyeth Ayerst, Scios Nova terminate trial
SOURCE: R&D Focus Drug News (***10 Aug 1998***).
WORD COUNT: 84

L5 ANSWER 191 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:1108 IMSDRUGNEWS
TITLE: gene therapy, ***VEGF*** -165 GeneMedicine phase change II, Europe
SOURCE: R&D Focus Drug News (***30 Mar 1998***).
WORD COUNT: 96

L5 ANSWER 192 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:2552 IMSDRUGNEWS
TITLE: telbermin Genentech phase change I, USA
SOURCE: R&D Focus Drug News (***18 Aug 1997***).
WORD COUNT: 26

L5 ANSWER 193 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:556 IMSDRUGNEWS
TITLE: trafermin Scios phase change II, USA (***coronary*** ***artery*** ***disease***)
SOURCE: R&D Focus Drug News (***3 Mar 1997***).
WORD COUNT: 43

L5 ANSWER 194 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:3214 IMSDRUGNEWS
TITLE: trafermin Scios, Wyeth Ayerst licensing agreement
SOURCE: R&D Focus Drug News (***4 Nov 1996***).
WORD COUNT: 93

L5 ANSWER 195 OF 549 IMSDRUGNEWS COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 96:1488 IMSDRUGNEWS
TITLE: gene therapy, cardiovascular disease GenVec, Scios licensing agreement
SOURCE: R&D Focus Drug News (***24 Jun 1996***).
WORD COUNT: 59

L5 ANSWER 196 OF 549 IMSRESEARCH COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 1998:1157 IMSRESEARCH
SOURCE: R&D Focus, (***24 Apr 2000***)
GENERIC NAME: angiopoietin 1
STRUCTURE:
STRUCTURE DIAGRAM IS NOT AVAILABLE
CLASSIFICATION: C1D Coronary Therapy; C4A1 Peripheral and Cerebral Vasotherapeutics Excluding Calcium Antagonists
HIGHEST DEV. PHASE: Preclinical (20)

COMPANY INFORMATION:

Type	Company	Nationality
Originator	Procter & Gamble	United States
Co-developer	Regeneron	United States
Assignee	Regeneron	

L5 ANSWER 197 OF 549 IMSRESEARCH COPYRIGHT 2005 IMSWORLD on STN

ACCESSION NUMBER: 97:331 IMSRESEARCH
SOURCE: R&D Focus, (***14 Sep 1998***)
GENERIC NAME: gene therapy, vascular endothelial growth factor B; gene therapy, heart disease
LABORATORY NAME: SH 268
TRADE NAME: GENEVX
STRUCTURE:
STRUCTURE DIAGRAM IS NOT AVAILABLE
CLASSIFICATION: C1D Coronary Therapy; C4A1 Peripheral and Cerebral Vasotherapeutics Excluding Calcium Antagonists
HIGHEST DEV. PHASE: Suspended (3)

COMPANY INFORMATION:

Type	Company	Nationality
Originator	AMRAD	Australia
	Ludwig Institute for Cancer Research	United States

L5 ANSWER 198 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1011012836 JICST-EPlus
TI Gene Therapy Update in Cardiovascular Disease.
AU SYMES J F
CS Tufts Univ. School Of Medicine, Usa
SO Jpn Circ J, (2000) vol. 64, no. Satellite Seminar Abstracts, pp. 104-105.
Journal Code: F0908A
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Preprint
LA English

L5 ANSWER 199 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010449915 JICST-EPlus
TI Therapeutic Angiogenesis Induced by Hepatocyte Growth Factor: Potential Gene Therapy for Ischemic diseases.
AU AOKI M; MORISHITA R; TANIYAMA Y; KANEDA Y; OGIHARA T
CS Osaka Univ. Medical School, Osaka, Jpn
SO J Atheroscler Thromb, (2000) vol. 7, no. 2, pp. 71-76. Journal Code: L2187A (Fig. 5, Ref. 29)
ISSN: 1340-3478
CY Japan
DT Journal; Preprint
LA English
STA New

L5 ANSWER 200 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010355801 JICST-EPlus
TI Myocardial ischemia enhances the expression of acidic fibroblast growth factor in human pericardial fluid.
AU IWAKURA A; FUJITA M; IKEMOTO M; HASEGAWA K; SASAYAMA S; TAMBARA K; KOMEDA M
MIYAMOTO S; YAMAZATO A
CS Kyoto Univ., Kyoto, Jpn
Takeda Hospital, Kyoto, Jpn
SO Heart Vessels, (2000) vol. 15, no. 3, pp. 112-116. Journal Code: X0101A (Fig. 2, Tbl. 1, Ref. 19)
ISSN: 0910-8327
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 201 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010244087 JICST-EPlus
TI The Effects of Administration of Magnesium on the Serum Concentration of Basic Fibroblast Growth Factor, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor.
AU MIYAKE FUMIHIKO; KAMOGAWA ASAHI; TANAKA MARIKO; TANAKA OSAMU; NARITA NOBUYOSHI; SAKAKIBARA MASAYOSHI; MURAYAMA MASAHIRO
CS St. Marianna Univ.
SO Sei Marianna Ika Daigaku Zasshi (St. Marianna Medical Journal), (2000) vol. 28, no. 5, pp. 637-641. Journal Code: Z0605A (Fig. 1, Tbl. 1, Ref. 21)
ISSN: 0387-2289
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 202 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1010164389 JICST-EPlus
TI Molecular mechanism of myocardial injury due to ischemia-reperfusion.
AU YOSHIDA KEN'ICHI
MIZUKAMI YOICHI; AKI TOSHIHIKO
CS Todai Daigakuin'igakukeikenkyuka
Yamaguchi Univ., Sch. of Med.
SO Seibutsu Butsuri Kagaku (Japanese Journal of Electrophoresis), (2000) vol. 44, no. 4, pp. 257-259. Journal Code: G0565A (Ref. 13)
CODEN: SBBKA4; ISSN: 0031-9082
CY Japan
DT Journal; Short Communication
LA Japanese

L5 ANSWER 203 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000916109 JICST-EPlus
TI Transplantation and regenerative medicine - present situation of study and prospect. Heart and blood vessel.
AU KOIKE HIROMI; MORISHITA RYUICHI; KANEDA YASUFUMI
CS Osaka Univ., Grad. Sch.
SO Karento Terapi (Current Therapy), (2000) vol. 18, no. 10, pp. 1847-1851. Journal Code: G0171B (Fig. 1, Tbl. 1, Ref. 14)
ISSN: 0287-8445
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 204 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000846517 JICST-EPlus
TI Remodeling of Coronary Artery Lesions Due to Kawasaki Disease.
AU SUZUKI A
MIYAGAWA-TOMITA S; NAKAZAWA M
YUTANI C
CS Tokyo Teishin Hospital, Jpn
Tokyo Women's Medical Univ., Tokyo, Jpn
National Cardiovascular Center, Osaka, Jpn
SO Jpn Heart J, (2000) vol. 41, no. 3, pp. 245-256. Journal Code: Z0752A (Fig. 4, Ref. 22)
ISSN: 0021-4868
CY Japan
DT Journal; Short Communication
LA English
STA New

L5 ANSWER 205 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000728772 JICST-EPlus
TI Current Topics on Acute Myocardial Infarction. Therapeutic Angiogenesis for Ischemic Heart Disease.
AU NAKAMURA FUMITAKA; NAGAI RYOZO
CS Univ. of Tokyo, Fac. of Med.
SO ICU to CCU (Japanese Journal of Intensive Care Medicine), (2000) vol. 24, no. 7, pp. 491-497. Journal Code: Z0581B (Fig. 3, Ref. 11)
ISSN: 0389-1194
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 206 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000728768 JICST-EPlus
TI Current Topics on Acute Myocardial Infarction. Thrombus Formation Following Plaque Rupture in ***Coronary*** ***Artery*** ***Disease*** .
AU MARUYAMA IKURO
CS Kagoshima Univ.
SO ICU to CCU (Japanese Journal of Intensive Care Medicine), (2000) vol. 24, no. 7, pp. 463-466. Journal Code: Z0581B (Fig. 2, Ref. 8)
ISSN: 0389-1194
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 207 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

TI Gene Therapy for Ischemic Disease.
AU KOIKE HIROMI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Saibo Kogaku (Cell Technology), (2000) vol. 19, no. 8, pp. 1166-1171.
Journal Code: Y0229A (Fig. 3, Ref. 8)
ISSN: 0287-3796
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 208 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000627035 JICST-EPlus
TI Pericardial Fluid From Patients With Ischemic Heart Disease Accelerates the Growth of Human Vascular Smooth Muscle Cells.
AU YONEDA T; FUJITA M; KIHARA Y; HASEGAWA K; INANAMI M; NOHARA R; SASAYAMA S
SAWAMURA T
TANAKA T
CS Kyoto Univ., Kyoto, Jpn
National Cardiovasular Center Res. Inst., Osaka, Jpn
Takeda Hospital, Kyoto, Jpn
SO Jpn Circ J, (2000) vol. 64, no. 7, pp. 495-498. Journal Code: F0908A (Fig. 3, Ref. 13)
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 209 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000456471 JICST-EPlus
TI Basic Fibroblast Growth Factor Inhibits Lipopolysaccharide-induced Apoptosis in Cardiac Myocytes.
AU IWAI-KANAI E; HASEGAWA K; ARAKI M; FUJITA M; KAKITA T; MORIMOTO T; SASAYAMA S
CS Kyoto Univ., Kyoto, Jpn
SO Jpn Circ J, (2000) vol. 64, no. Supplement 1, pp. 141. Journal Code: F0908A
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Preprint
LA English
STA New

L5 ANSWER 210 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000456433 JICST-EPlus
TI Gene Therapy for Cardiovascular Disease.
AU ROSENGART T K
CS Evanston Northwestern Healthcare, Usa
SO Jpn Circ J, (2000) vol. 64, no. Supplement 1, pp. 129. Journal Code: F0908A
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Preprint
LA English
STA New

L5 ANSWER 211 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000302675 JICST-EPlus
TI Therapeutic angiogenesis.
AU ASAHARA TAKAYUKI; HAYASHI SHIN'ICHIRO
CS Tufts Univ.

Journal Code: Y0568A (Fig. 4, Ref. 19)
ISSN: 0288-5514
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 212 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000297206 JICST-EPlus
TI Gene Therapy for ASO: Toward the clinical trial.
AU AOKI MOTOKUNI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Idenshi Igaku, (2000) vol. 4, no. 1, pp. 151-155. Journal Code: L3408A (Fig. 6, Ref. 7)
ISSN: 1343-0971
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 213 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000256799 JICST-EPlus
TI ***VEGF*** and vasculoangiogenesis/vascular remodeling.
AU ITO HIROSHI; NAKAO KAZUWA
CS Kyoto Univ., Grad. Sch.
SO Nippon Rinsho (Japanese Journal of Clinical Medicine), (2000) vol. 58, pp. 200-205. Journal Code: Z0679A (Fig. 7, Ref. 20)
ISSN: 0047-1852
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 214 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189138 JICST-EPlus
TI Cytokines in pericardial fluid collected at open heart surgery.
AU TOMIZAWA YASUKO; ENDO MASAHIRO; NISHIDA HIROSHI; IMAI YASUHARU; ISHIZUKA TSUTOMU; HAYASHI TETSUO; KOYANAGI HITOSHI
CS Tokyo Women's Medical College, Heart Inst. of Japan
SO Coronary, (1999) vol. 16, no. 4, pp. 288-292. Journal Code: Y0812A (Fig. 3, Ref. 13)
ISSN: 0910-3031
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 215 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189137 JICST-EPlus
TI Angiogenic therapy.
AU TOMARU TAKANOBU
UCHIDA YUKO
UCHIDA HARUKO; KIMURA KENJIRO
KANAI MASAHITO; UCHIDA YASUMI
CS Red Cross Med. Center
Chiba Univ., Sch. of Med.
Univ. of Tokyo, Fac. of Med.
Toho Univ. School of Medicine., Sakura Hospital
SO Coronary, (1999) vol. 16, no. 4, pp. 281-287. Journal Code: Y0812A (Fig. 3, Ref. 15)
ISSN: 0910-3031
CY Japan

LA Japanese
STA New

L5 ANSWER 216 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189089 JICST-EPlus
TI Gene therapy for coronary arterial diseases.
AU MASAKI ICHIRO; YONEMITSU YOSHIKAZU
CS Kyushu Univ., Grad. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000) vol. 192, no. 3, pp. 213-217. Journal Code: Z0649A (Fig. 2, Ref. 25)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 217 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189087 JICST-EPlus
TI Gene therapy for cardiovascular diseases.
AU AOKI MOTOKUNI
MORISHITA RYUICHI
CS Osaka Univ., Med. Sch.
Osaka Univ., Grad. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000) vol. 192, no. 3, pp. 205-208. Journal Code: Z0649A (Fig. 4, Ref. 3)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 218 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189066 JICST-EPlus
TI History and prospect of angiogenic therapy.
AU UCHIDA YASUMI; KANAI MASAHITO
UCHIDA HARUKO
UCHIDA YUKO
OGAWA MUNEYUKI
CS Toho Univ. School of Medicine., Sakura Hospital
Univ. of Tokyo, Fac. of Med.
Chiba Univ., Sch. of Med.
Jikei Univ. School of Medicine
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000) vol. 192, no. 1, pp. 128-133. Journal Code: Z0649A (Fig. 3, Ref. 16)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 219 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189064 JICST-EPlus
TI Gene therapy for restenosis.
AU AOKI MOTOKUNI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000) vol. 192, no. 1, pp. 116-120. Journal Code: Z0649A (Fig. 3, Tbl. 1, Ref. 22)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese

L5 ANSWER 220 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000189048 JICST-EPlus
TI New role of adenosine for the treatment of ischemic heart disease.
AU KITAKAZE MASAFUMI; HORI MASATSUGU
CS Osaka Univ., Grad. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (2000) vol. 192, no. 1, pp. 35-39. Journal Code: Z0649A (Fig. 2, Tbl. 2, Ref. 16)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 221 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000122825 JICST-EPlus
TI HGF-treated Gene Therapy for Cardiovascular Diseases.
AU AOKI MOTOKUNI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Nippon Kessen Shiketsu Gakkaishi (Japanese Journal of Thrombosis and Hemostasis), (1999) vol. 10, no. 6, pp. 435-443. Journal Code: L2757A (Fig. 9, Ref. 8)
ISSN: 0915-7441
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 222 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000122237 JICST-EPlus
TI New Development of Genetic Medicine. Gene Therapy for Cardiovascular Diseases.
AU AOKI MOTOKUNI; MORISHITA RYUICHI; KANEDA YASUFUMI
CS Osaka Univ.
SO Saishin Igaku, (2000) vol. 55, no. 1, pp. 38-43. Journal Code: Z0358A (Fig. 4, Ref. 7)
CODEN: SAIGAK; ISSN: 0370-8241
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 223 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000055956 JICST-EPlus
TI The Angiogenesis Therapy using ***VEGF*** .
AU TAKESHITA SATOSHI
CS Teikyo Univ., Sch. of Med.
SO Ther Res, (1999) vol. 20, no. 11, pp. 3035-3040. Journal Code: Y0681A (Fig. 2, Ref. 22)
ISSN: 0289-8020
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 224 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000050410 JICST-EPlus
TI Vascular Medicine. Therapeutic angiogenesis.
AU ASAHARA TAKAYUKI; IWAGURO HIDEKI
CS St. Elizabeth's Medical Center Cardiovascular Res. And Medicine
SO Bio Clin, (1999) vol. 14, no. 14, pp. 1254-1260. Journal Code: L0059A (Fig. 3, Ref. 19)

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 225 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000044430 JICST-EPlus
TI Gene therapy strategies for therapeutic angiogenesis.
AU FUJITA HIDEO; NAKAMURA FUMITAKA; NAGAI RYOZO
CS Univ. of Tokyo
SO Pharma Med, (1999) vol. 17, no. 11, pp. 107-111. Journal Code: F0652B (Tbl. 3, Ref. 16)
ISSN: 0289-5803
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 226 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 1000044428 JICST-EPlus
TI Angiogenesis; Drug therapy.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Pharma Med, (1999) vol. 17, no. 11, pp. 97-100. Journal Code: F0652B (Fig. 1, Ref. 15)
ISSN: 0289-5803
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 227 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 991025845 JICST-EPlus
TI Molecular mechanism of plaque formation, progression, and rupture in human coronary arteries.
AU OGAMI MASAYUKI; UEDA MAKIKO
CS Osaka City Univ., Med. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1999) vol. 191, no. 5, pp. 505-508. Journal Code: Z0649A (Fig. 3, Ref. 34)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 228 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990991097 JICST-EPlus
TI Elucidation of intracellular information transfer mechanism in the myocardial ischemia reperfusion injury and the establishment of the anti-adhesion molecule therapy.
AU SEKO YOSHINORI
CS Univ. of Tokyo, Fac. of Med.
SO Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu, (1999) vol. 14, pp. 99-109. Journal Code: L2409A (Fig. 7, Ref. 8)
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 229 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990985611 JICST-EPlus
TI Combination of Physiology and Molecular Biology in Cardiology. Ischemic

AU KITAKAZE MASAFUMI; KUZUYA TSUNEHIKO; HORI MASATSUGU
CS Osaka Univ., Grad. Sch.
SO Junkanki Senmon'i, (1999) vol. 7, no. 2, pp. 215-223. Journal Code: L1766A (Fig. 6, Tbl. 3, Ref. 19)
ISSN: 0918-9599
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 230 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990954127 JICST-EPlus
TI Disease state and treatment of acute coronary syndrome. 3 Molecular cellular mechanism of coronary artery thrombus.
AU MARUYAMA IKURO
CS Kagoshima Univ.
SO Nippon Naika Gakkai Zasshi (Journal of the Japanese Society of Internal Medicine), (1999) vol. 88, no. 9, pp. 1727-1730. Journal Code: F0916A (Fig. 4, Tbl. 1, Ref. 10)
CODEN: NNGAAS; ISSN: 0021-5384
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 231 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990950419 JICST-EPlus
TI Blood vessel wall cells. Vascularization and etiology. Mechanism of vascularization necessary for clinicians.
AU SATO YASUFUMI
CS Res. Inst. Tuberculosis and Cancer, Tohoku Univ.
SO Rinsho Kensa (Journal of Medical Technology), (1999) vol. 43, no. 10, pp. 1075-1083. Journal Code: Z0290B (Fig. 6, Tbl. 1, Ref. 33)
ISSN: 0485-1420
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 232 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990918875 JICST-EPlus
TI Basic and Clinical Science of gene therapy. Gene therapy for cardiovascular diseases.
AU AOKI MOTOKUNI; MORISHITA RYUICHI; KANEDA YASUFUMI
CS Osaka Univ.
SO Gekkan Soshiki Baiyo Kogaku (Tissue Culture Engineering), (1999) vol. 25, no. 11, pp. 447-451. Journal Code: F0781B (Fig. 5, Ref. 9)
ISSN: 0386-1791
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 233 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990880725 JICST-EPlus
TI Ischemic heart disease handbooks. Angina pectoris and asymptomatic myocardial ischemia. Present of gene therapy for the angina pectoris.
AU AOKI MOTOKUNI; MORISHITA RYUICHI
CS Osaka Univ., Grad. Sch.
SO Shindan to Chiryo (Diagnosis and Treatment), (1999) vol. 87, no. 9, pp. 1604-1609. Journal Code: Z0941A (Fig. 3, Tbl. 2, Ref. 6)
ISSN: 0370-999X

DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 234 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990874402 JICST-EPlus
TI Co-localized expression of vascular endothelial growth factor(***VEGF***) and its receptor in atherectomy specimens mediates restenosis after coronary angioplasty.
AU SAKOMURA YASUNARI; YAMAGUCHI JUN'ICHI; TSURUMI YUKIO; KAWANA MASATOSHI; KASANUKI HIROSHI
CS Tokyo Women's Medical College, Heart Inst. of Japan
SO Tokyo Joshi Ika Daigaku Sogo Kenkyujo Kiyo, (1998) vol. 19, pp. 72-73. Journal Code: L0631A (Ref. 3)
ISSN: 0911-4491
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L5 ANSWER 235 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990820576 JICST-EPlus
TI Gene therapy for resterosis: From the view point of remodeling.
AU MORISHITA RYUICHI; OGIHARA TOSHIO; KANEDA YASUSHI
CS Osaka Univ., Grad. Sch.
SO Kekkan (Japanese Journal of Circulation Research), (1999) vol. 22, no. 2, pp. 33-41. Journal Code: Y0849A (Fig. 6, Tbl. 2, Ref. 58)
ISSN: 0911-4637
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 236 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990752702 JICST-EPlus
TI Kawasaki disease : The 23rd Kinki area Kawasaki disease workshop. Blood vessel remodeling of Kawasaki disease coronary artery failure :Immunohistologic examination on from convalescence early stage to remote stage.
AU SUZUKI ATSUKO
TOMITA SACHIKO; BOKU JINZO; KOMATSU KEIKO; NAKAZAWA MAKOTO
YUTANI CHIKAO
CS Tokyo Posts. and Telecommun. Hosp.
Tokyo Women's Medical Coll.
National Cardiovascular Center
SO Prog Med, (1999) vol. 19, no. 7, pp. 1664-1669. Journal Code: F0664B (Fig. 6, Ref. 10)
ISSN: 0287-3648
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 237 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990719527 JICST-EPlus
TI Rehabilitation of heart failure. Cure. 8-b. Exercise therapy for ischemic heart disease with complication. Exercise therapy for angina pectoris.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Heart View, (1999) vol. 3, no. 8, pp. 867-870. Journal Code: L3359A (Fig. 3, Ref. 18)

CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 238 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990709417 JICST-EPlus
TI Recent topics on common diseases. Circulatory organ. Ischemic heart disease.
AU OGAWA HISAO
CS Kumamoto Univ., Med. Sch.
SO Gendai Iryo, (1999) vol. 31, no. 7, pp. 1637-1642. Journal Code: Z0273B (Fig. 2, Tbl. 1, Ref. 12)
ISSN: 0533-7259
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 239 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990705297 JICST-EPlus
TI Heart failure carried over from childhood. 11. Blood vessel remodeling in distal stage of kawasaki disease coronary artery failure.
AU SUZUKI JUNKO
TOMITA SACHIKO; BOKU JINSAN; NAKAZAWA MAKOTO
CS Tokyo Posts. and Telecommun. Hosp.
Tokyo Women's Medical College, Heart Inst. of Japan
SO Heart View, (1999) vol. 3, no. 7, pp. 756-762. Journal Code: L3359A (Fig. 6, Ref. 12)
ISSN: 1342-6591
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 240 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990655890 JICST-EPlus
TI Gene Therapy for Carediovascular Diseases.
AU AOKI MOTOKUNI; MORISHITA RYUICHI; OGIHARA TOSHIO
CS Osaka Univ., Med. Sch.
SO Shinpo suru Shinzo Kenkyu (Tokyo Heart Journal), (1999) vol. 19, no. 1, pp. 10-18. Journal Code: Z0890B (Fig. 8, Tbl. 1, Ref. 32)
ISSN: 0285-6581
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 241 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990608051 JICST-EPlus
TI Function of Vascular Adventitia. A Role of Neovascularization in the Vascular Adventitia on Arteriosclerosis.
AU SUEISHI KATSUO; CHEN Y-X; TANAKA KEN'ICHIRO
CS Kyushu Univ., Fac. of Med.
SO Kekkan to Naihi (Blood Vessel & Endothelium), (1999) vol. 9, no. 3, pp. 262-267. Journal Code: L1975A (Fig. 5, Tbl. 2, Ref. 18)
ISSN: 0917-5318
CY Japan
DT Journal; Commentary
LA Japanese
STA New

AN 990550807 JICST-EPlus
TI Gene therapy for atherosclerosis.
AU MORISHITA RYUICHI; OGIHARA TOSHIO; KANEDA YASUFUMI
CS Osaka Univ., Grad. Sch.
SO Idenshi Igaku, (1999) vol. 3, no. 2, pp. 326-331. Journal Code: L3408A (Fig. 3, Tbl. 1, Ref. 25)
ISSN: 1343-0971
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 243 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990509421 JICST-EPlus
TI A Study to Determine if Basic Fibroblast Growth Factor(***bFGF***) Reduces Myocardial Infarct Size in Acute Coronary Arterial Occlusion.
AU SASAME A; NAKAJIMA H; TAMURA K; MIYAGI M; RAKUE H; USUI M; KATOH T; NAITOH Y; IBUKIYAMA C
CS Tokyo Medical Univ., Tokyo, Jpn
SO Jpn Heart J, (1999) vol. 40, no. 2, pp. 165-178. Journal Code: Z0752A (Fig. 6, Ref. 35)
ISSN: 0021-4868
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 244 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990509187 JICST-EPlus
TI Therapeutic Angiogenesis for Ischemic Heart Disease.
AU TAKESHITA SATOSHI
CS Teikyo Univ., Sch. of Med.
SO Kokyu to Junkan (Respiration and Circulation), (1999) vol. 47, no. 5, pp. 449-453. Journal Code: Z0660A (Ref. 18)
ISSN: 0452-3458
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 245 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990509186 JICST-EPlus
TI ***VEGF*** Gene Transfer for Therapeutic Angiogenesis.
AU ASAHARA TAKAYUKI
CS St. Elizabeth's Medical Center Boston, Massachusetts, Usa
SO Kokyu to Junkan (Respiration and Circulation), (1999) vol. 47, no. 5, pp. 441-447. Journal Code: Z0660A (Fig. 6, Tbl. 3, Ref. 12)
ISSN: 0452-3458
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 246 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990430625 JICST-EPlus
TI A Series in Vascular Morphology. 4 Arteriosclerosis and Vascularization.
AU ISEKI KATSUO; CHIN EISHO; TANAKA KEN'ICHIRO; NAKAJIMA YUTAKA; NAKAGAWA KAZUNORI
CS Kyushu Univ., Fac. of Med.
SO Kekkan to Naihi (Blood Vessel & Endothelium), (1999) vol. 9, no. 2, pp. 220-223. Journal Code: L1975A (Fig. 5, Ref. 4)
ISSN: 0917-5318

DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 247 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990415308 JICST-EPlus
TI Progression of human coronary sclerosis. Vasoactive substances and ***VEGF*** .
AU UEDA MAKIKO
CS Osaka City Univ., Med. Sch.
SO Ther Res, (1999) vol. 20, no. 3, pp. 587-595. Journal Code: Y0681A (Fig. 6, Ref. 19)
ISSN: 0289-8020
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 248 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990399674 JICST-EPlus
TI Elevated Circulating Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Patients With Acute Myocardial Infarction.
AU TAMURA K; NAKAJIMA H; RAKUE H; SASAME A; NAITO Y; NAGAI Y; IBUKIYAMA C
CS Tokyo Medical Univ., Tokyo, Jpn
SO Jpn Circ J, (1999) vol. 63, no. 5, pp. 357-361. Journal Code: F0908A (Fig. 2, Ref. 40)
CODEN: NJUGAK; ISSN: 0047-1828
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 249 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 990371647 JICST-EPlus
TI Effect of Angiogenic Therapy with Vascular Endothelial Growth Factor for Acute Myocardial Infarction.
AU HARA TAKESHI; NAITO YUICHI; NAKAJIMA HITOSHI; TAMURA KEN; IBUKIYAMA CHIHARU
CS Tokyo Medical College
SO Nippon Rinsho Seiri Gakkai Zasshi (Japanese Journal of Applied Physiology), (1999) vol. 29, no. 1, pp. 5-13. Journal Code: Y0689A (Fig. 7, Ref. 23)
ISSN: 0286-7052
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 250 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980985741 JICST-EPlus
TI Molecular biology of the vital phenomenon in the blood vessel. Part3. Cytokine in the blood vessel. Natriuretic peptide family-The significance of angiogenesis factor ***VEGF*** .
AU INOUE MAYUMI; ITO HIROSHI; NAKAO KAZUWA
CS Kyoto Univ., Grad. Sch.
SO Kekkan to Naihi (Blood Vessel & Endothelium), (1998) vol. 8, no. 5, pp. 511-518. Journal Code: L1975A (Fig. 9, Tbl. 1, Ref. 18)
ISSN: 0917-5318
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 251 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980891597 JICST-EPlus
TI Regeneration medicine. V.Blood vessel. 2.Angiogenesis therapy in ischemic heart disease.
AU UENO HIKARU
CS Kyushu Univ., Fac. of Med.
SO Rinsho Kagaku (Journal of Clinical Science), (1998) vol. 34, no. 9, pp. 1208-1216. Journal Code: Z0350B (Fig. 3, Ref. 35)
ISSN: 0385-0323
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 252 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980738187 JICST-EPlus
TI kawasaki disease. The 22nd Kinki area kawasaki disease workshop. Immunohistochemical examination of coronary artery failure remodeling in the kawasaki disease remoteness stage. The second report.
AU SUZUKI ATSUKO
TOMITA SACHIKO; NAKAZAWA MAKOTO; KOMATSU KEIKO
CS Tokyo Posts. and Telecommun. Hosp.
Tokyo Women's Medical Coll.
SO Prog Med, (1998) vol. 18, no. 7, pp. 1594-1599. Journal Code: F0664B (Fig. 5, Ref. 11)
ISSN: 0287-3648
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L5 ANSWER 253 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980640272 JICST-EPlus
TI Approach to the elucidation of disease state.By what reason multiple risk factor syndrome causes the arteriosclerosis. 3.Mechanism of crisis of arteriosclerosis in hyperlipidemia. Significance of arterialization factor ***VEGF*** .
AU ITO YUTAKA; NAKAO KAZUYASU
CS Kyoto Univ., Graduate School
SO Mebio, (1998) vol. 15, pp. 104-110. Journal Code: X0106A (Fig. 9, Tbl. 2, Ref. 7)
ISSN: 0910-0474
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 254 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980612724 JICST-EPlus
TI Molecular-biological approach of cardiovascular disease.From the basic to the clinic.The control using the gene of the restenosis after the PTCA.
AU MATSUSHITA HIDETSUGU; MORISHITA RYUICHI; OGIWARA TOSHIO
CS Osaka Univ., Med. Sch.
SO Junkan Kagaku (Circulation Science), (1998) vol. 18, no. 6, pp. 536-539. Journal Code: Y0815A (Fig. 3, Tbl. 1, Ref. 10)
ISSN: 0389-2336
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 255 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

TI Thrombus and vascular medicine. Fundanentals and clinics. Clinics. Directions of new treatment for thrombosis. Gene therapy.
AU MORISHITA RYUICHI; OGIWARA TOSHIO
KANEDA YASUSHI
CS Osaka Univ., Med. Sch.
Osakadaigaku Saiboseitaikogakusenta
SO Gendai Iryo, (1998) vol. 30, no. 6, pp. 1681-1686. Journal Code: Z0273B (Fig. 3, Tbl. 1, Ref. 14)
ISSN: 0533-7259
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 256 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980377215 JICST-EPlus
TI Diagnostic imaging of coronary sclerosis. Histopathologic image.
AU UEDA MAKIKO; KOMATSU RYUJI
CS Osaka City Univ., Med. Sch.
SO Heart View, (1997) vol. 1, no. 11, pp. 1332-1338. Journal Code: L3359A (Fig. 12, Ref. 23)
ISSN: 1342-6591
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 257 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980325579 JICST-EPlus
TI Effects of Transient Coronary Occlusion on the Capillary Network in the Left Ventricle of Rat.
AU XIE Z; GAO M; KOYAMA T
CS Hokkaido Univ., Sapporo, JPN
SO Jpn J Physiol, (1997) vol. 47, no. 6, pp. 537-543. Journal Code: Z0753A (Fig. 5, Tbl. 1, Ref. 17)
CODEN: JJPHAM; ISSN: 0021-521X
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 258 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 980264305 JICST-EPlus
TI Regulation and failure of coronary circulation. Coronary collateral circulation.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1998) pp. 89-93. Journal Code: Z0649A (Fig. 4, Ref. 18)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 259 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970989373 JICST-EPlus
TI Experimental study of effects of adenosine on angiogenesis in rat myocardial infarction.
AU KOBAYASHI MASAO; ABE GEN; SHIMIZU HIROSHI; OGAWA YASUHIKO; OMOTO NAOKI; MATSUOKA KAZUSHI; KAWAMURA KOICHI; MASUDA HIROTAKE; MIURA MAMORU
CS Akita Univ., Sch. of Med.

19(1996), pp. 147-152. Journal Code: X0646A (Fig. 4, Ref. 10)
CY Japan
DT Conference; Article
LA Japanese
STA New

L5 ANSWER 260 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970760085 JICST-EPlus
TI The gene therapy. The gene therapy for blood vessel restenosis.
AU MORISHITA RYUICHI; HIGAKI JITSUO; OGIHARA TOSHIO
CS Osaka Univ., Med. Sch.
SO Gendai Iryo, (1997) vol. 29, no. 8, pp. 1997-2001. Journal Code: Z0273B (Fig. 2, Tbl. 1, Ref. 19)
ISSN: 0533-7259
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 261 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970720745 JICST-EPlus
TI Revascularization in Ischemic Heart with Autologous Bone Marrow Transplantation.
AU MARAT; DOULET
CS Yokohama City Univ.
SO Nippon Shinzo Kekkan Geka Gakkai Zasshi (Japanese Journal of Cardiovascular Surgery), (1997) vol. 26, no. 4, pp. 248-253. Journal Code: Y0192A (Fig. 3, Ref. 21)
ISSN: 0285-1474
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 262 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970062760 JICST-EPlus
TI Coronary collateral circulation.
AU FUJITA MASATOSHI
CS Kyoto Univ., Coll. of Med. Technol.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996) vol. 179, no. 10, pp. 835-839. Journal Code: Z0649A (Fig. 4, Ref. 18)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 263 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 970062755 JICST-EPlus
TI Vascular remodeling.
AU FUJIKAWA HIDEYUKI; SHIMADA KAZUYUKI
CS Jichi Med. Sch.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1996) vol. 179, no. 10, pp. 809-814. Journal Code: Z0649A (Fig. 3, Tbl. 1, Ref. 24)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 264 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN

TI Ischemic heart disease. New development of treatment and prevention. Gene therapy for post PTCA restenosis.
AU MORISHITA RYUICHI; HIGAKI TSUNEO; OGIWARA TOSHIO
CS Osaka Univ., Med. Sch.
SO Rinsho Kagaku (Journal of Clinical Science), (1996) vol. 32, no. 11, pp. 1419-1425. Journal Code: Z0350B (Fig. 5, Tbl. 3, Ref. 23)
ISSN: 0385-0323
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 265 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 961020647 JICST-EPlus
TI Ischemic heart disease. New development of treatment and prevention. ***VEGF*** and angiogenesis.
AU SHIBUYA MASABUMI
CS Inst. of Med. Sci., Univ. of Tokyo
SO Rinsho Kagaku (Journal of Clinical Science), (1996) vol. 32, no. 11, pp. 1456-1462. Journal Code: Z0350B (Fig. 4, Ref. 26)
ISSN: 0385-0323
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 266 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 961020639 JICST-EPlus
TI Ischemic heart disease. New development of treatment and prevention. Treatment based on the promotion of crown collateral circulation.
AU FUJITA MASATOSHI
SASAYAMA SHIGETAKE
CS Kyoto Univ., Coll. of Med. Technol.
Kyoto Univ., Graduate School
SO Rinsho Kagaku (Journal of Clinical Science), (1996) vol. 32, no. 11, pp. 1385-1392. Journal Code: Z0350B (Fig. 7, Tbl. 2, Ref. 23)
ISSN: 0385-0323
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 267 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960846902 JICST-EPlus
TI Expression of vascular endothelial growth factor in human myocardial infarction.
AU SHINOHARA K; SHINOHARA T; MOCHIZUKI N; MOCHIZUKI Y; SAWA H; KOHYA T; FUJITA M; FUJIOKA Y; NAGASHIMA K
CS Hokkaido Univ. School of Medicine, Sapporo, JPN
SO Heart Vessels, (1996) vol. 11, no. 3, pp. 113-122. Journal Code: X0101A (Fig. 7, Tbl. 2, Ref. 33)
ISSN: 0910-8327
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 268 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960813551 JICST-EPlus
TI Roles of inflammatory cytokine/growth factor in coronary sclerosis and crown twitch.
AU ITO AKIRA; SHIMOKAWA HIROAKI; FUKUMOTO YOSHIHIRO; KADOKAMI TOSHIAKI;

AU TAKESHITA AKIRA
CS Kyushu Univ., Fac. of Med.
SO Ther Res, (1996) vol. 17, no. 8, pp. 3239-3247. Journal Code: Y0681A (Fig. 10, Ref. 4)
ISSN: 0289-8020
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 269 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960765728 JICST-EPlus
TI Therapeutic angiogenesis and its clinical applications.
AU TAKESHITA SATORU
CS Teikyo Univ., Sch. of Med.
SO Jikken Igaku (Experimental Medicine), (1996) vol. 14, no. 15, pp. 2160-2162. Journal Code: Y0568A (Fig. 2, Ref. 8)
ISSN: 0288-5514
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L5 ANSWER 270 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960716751 JICST-EPlus
TI Approach to atheroma lesions. Diabrosis of atheroma and the intraintimal newborn blood vessel.
AU SUEISHI KATSUO; KUMAMOTO MASATO; YONEMITSU YOSHIKAZU; NAKAGAWA KAZUNORI
CS Kyushu Univ., Fac. of Med.
SO Bio Clin, (1996) vol. 11, no. 10, pp. 737-743. Journal Code: L0059A (Fig. 6, Tbl. 1, Ref. 21)
ISSN: 0919-8237
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 271 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960590281 JICST-EPlus
TI Regional blood flow in infarcted myocardium of basic fibroblast growth factor-treated rats.
AU INAGAKI M; ISHIKAWA K; OGAWA I; KOKA H; NAKAI S; KINO H; KIMURA A; MIYATAKA M; KATORI R
CS Kinki Univ. School of Medicine, Osaka, JPN
SO Acta Med Kinki Univ, (1996) vol. 21, no. 1, pp. 59-63. Journal Code: S0990A (Tbl. 2, Ref. 16)
ISSN: 0386-6092
CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 272 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960590280 JICST-EPlus
TI Contralateral arterial bolus injection of 30 micrograms of basic fibroblast growth factor failed to augment myocardial blood flow in infarcted myocardium in dogs.
AU MIYATAKA M; ISHIKAWA K; OGAWA I; KOKA H; NAKAI S; KINO H; INAGAKI M; KIMURA A; KATORI R
CS Kinki Univ. School of Medicine, Osaka, JPN
SO Acta Med Kinki Univ, (1996) vol. 21, no. 1, pp. 53-58. Journal Code: S0990A (Tbl. 3, Ref. 22)

CY Japan
DT Journal; Article
LA English
STA New

L5 ANSWER 273 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960220340 JICST-EPlus
TI ***Coronary*** ***artery*** ***disease*** of dialysis patient. Coronary circulation adjustment and disease state. (2). The control of vascular endothelial cell proliferation.
AU KUZUYA TSUNEHIKO; NISHIDA MASASHI; TADA MICHIHIKO
CS Osaka Univ., Med. Sch.
SO Rinsho Toseki (Japanese Journal of Clinical Dialysis), (1996) vol. 12, no. 2, pp. 171-174. Journal Code: X0146A (Fig. 1, Ref. 7)
ISSN: 0910-5808
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 274 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 960101131 JICST-EPlus
TI Elastase and cell matrix interactions in the pathobiology of vascular disease.
AU RABINOVITCH M
CS Univ. Toronto, Ontario, CAN
SO Acta Paediatr Jpn, (1995) vol. 37, no. 6, pp. 657-666. Journal Code: Z0373B (Fig. 9, Ref. 45)
ISSN: 0374-5600
CY Japan
DT Journal; General Review
LA English
STA New

L5 ANSWER 275 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 951007500 JICST-EPlus
TI New development of circulatory adjusting peptide research. Trial of elucidation of cardiac and vascular disease state by gene transfer and application to therapy.
AU UENO HIKARU; TAKESHITA AKIRA
CS Kyushu Univ., Fac. of Med.
SO Gendai Iryo, (1995) vol. 27, no. 11, pp. 3259-3265. Journal Code: Z0273B (Fig. 3, Ref. 18)
ISSN: 0533-7259
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 276 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950916066 JICST-EPlus
TI Immunohistochemical localization of acid fibroblast growth factor in the ischemia heart.
AU O RAKUMIN; FU SEEI; YO RIN
RI SOCHU
CS Harbin Medical Sci., Inst., Harbin, CHN
Harbin Medical Univ., Harbin, CHN
SO Soshiki Baiyo Kenkyu (Tissue Culture Research Communications), (1995) vol. 14, no. 3, pp. 195-198. Journal Code: Z0362B (Fig. 5, Ref. 6)
ISSN: 0912-3636
CY Japan
DT Journal; Article

STA New

L5 ANSWER 277 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950854178 JICST-EPlus
TI Effect of Basie Fibroblast Growth Factor(b-FGF) in Expansion and Remodeling after Acute Myocardial Infarction.
AU WANG D Y; NAGAO KEN; WATANABE IKUYOSHI; KANMATSUSE KATSUO
CS Nihon Univ., Sch. of Med.
SO Nichidai Igaku Zasshi (Journal of Nihon University Medical Association), (1995) vol. 54, no. 5, pp. 304-309. Journal Code: F0911A (Fig. 4, Tbl. 2, Ref. 17)
CODEN: NICHAS; ISSN: 0029-0424
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 278 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950758711 JICST-EPlus
TI Recent view on coronal collateral circulation.
AU SHINOYAMA SHIGETAKE
CS Kyoto Univ., Fac. of Med.
SO Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine), (1995) vol. 72, no. 8, pp. 2025-2035. Journal Code: Z0376B (Fig. 10, Ref. 35)
ISSN: 0021-4965
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 279 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950751806 JICST-EPlus
TI Q&A for acute myocardial infarction Therapeutic angiogenesis.
AU TAKESHITA SATOSHI; SATO TOMOHIDE
CS Teikyo Univ., Sch. of Med.
SO Medicina, (1995) vol. 32, no. 8, pp. 1599-1601. Journal Code: Z0074B (Fig. 1, Ref. 4)
ISSN: 0025-7699
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 280 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950661377 JICST-EPlus
TI Localization and Function of Basic Fibroblast Growth Factor(***bFGF***) in Porcine Coronary and Aortic Smooth Muscle Cells in Culture.
AU OGAWA HIKOICHIRO; YOSHITAKE YOSHINO
CS Kanazawa Med. Univ.
SO Kanazawa Ika Daigaku Zasshi (Journal of Kanazawa Medical University), (1995) vol. 20, no. 1, pp. 110-120. Journal Code: Z0020B (Fig. 7, Tbl. 1, Ref. 29)
ISSN: 0385-5759
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 281 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950545304 JICST-EPlus
TI Physiology and Pathophysiology of Vascular Remodeling. Pathophysiological

Angiogenesis.
AU ITO HIDEKI
CS Tokyo Metrop, Geriatr. Hosp.
SO Saishin Igaku, (1995) vol. 50, no. 6, pp. 1121-1125. Journal Code: Z0358A (Fig. 3, Ref. 17)
CODEN: SAIGAK; ISSN: 0370-8241
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 282 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950365635 JICST-EPlus
TI Angiogenesis by ***bFGF*** .
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Coronary, (1995) vol. 12, no. 1, pp. 33-40. Journal Code: Y0812A (Fig. 9, Ref. 26)
ISSN: 0910-3031
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 283 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950262206 JICST-EPlus
TI Coronary collateral vessels and fibroblast growth factor.
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Igaku no Ayumi (Journal of Clinical and Experimental Medicine), (1995) vol. 172, no. 9, pp. 594-598. Journal Code: Z0649A (Fig. 4, Ref. 26)
CODEN: IGAYAY; ISSN: 0039-2359
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 284 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 950196851 JICST-EPlus
TI Current Perspectives on the Problem of Ischemic Heart Disease. Angiogenesis and Cornary Collateral Development.
AU UCHIDA YASUMI; MIWA ATSUKO
CS Univ. of Tokyo, Fac. of Med.
SO Saishin Igaku, (1995) vol. 50, no. 2, pp. 218-226. Journal Code: Z0358A (Fig. 9, Ref. 26)
CODEN: SAIGAK; ISSN: 0370-8241
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 285 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940896709 JICST-EPlus
TI Special issue : New treatment of ischemic heart diseases.New approach to the treatment.
AU KURODA RYOHEI; HIRATA KEN'ICHI; KAWASHIMA SEINOSUKE; YOKOYAMA MITSUHIRO
CS Kobe Univ., Sch. of Med.
SO Rinsho to Kenkyu (Japanese Journal of Clinical and Experimental Medicine), (1994) vol. 71, no. 10, pp. 2613-2618. Journal Code: Z0376B (Fig. 4, Tbl. 1, Ref. 20)
ISSN: 0021-4965
CY Japan

LA Japanese
STA New

L5 ANSWER 286 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940842962 JICST-EPlus
TI Gene therapy with replication-deficient recombinant adenovirus vectors which carry the cDNA for angiogenic polypeptides: a new potential approach to the treatment of ischemic diseases.
AU MUEHLHAUSER J; PILI R; MERRILL M J; CHANG J; MAEDA H; PASSANITI A
BEWIG B; CRYSTAL R G
CAPOGROSSI M C
CS National Inst. Health, MD
Cornell Univ. Medical Center, NY
Inst. Dermopatico dell'Immacolata, Roma, ITA
SO Kiso Roka Kenkyu (Biomedical Gerontology), (1994) vol. 18, no. 2, pp. 134-137. Journal Code: Y0748A (Ref. 13)
ISSN: 0912-8921
CY Japan
DT Journal; Commentary
LA English
STA New

L5 ANSWER 287 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940756922 JICST-EPlus
TI The Expression and the Role of Vascular Endothelial Growth Factor(***VEGF***) in Human Normal and Myocardial Infarcted Heart.
AU SHINOHARA KAHORU
CS Hokkaido Univ., Sch. of Med.
SO Hokkaido Igaku Zasshi (Hokkaido Journal of Medical Science), (1994) vol. 69, no. 4, pp. 978-989,991,993. Journal Code: Z0749A (Fig. 7, Tbl. 2, Ref. 20)
ISSN: 0367-6102
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 288 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 940112450 JICST-EPlus
TI Angiogenic therapy by basic fibroblast growth factor for myocardial infarction.
AU MIWAvYANAGISAWA ATSUKO; UCHIDA YASUMI
ITO HIDEKI
CS Univ. of Tokyo, Faculty of Medicine
Tokyotorojin'iryosenta
SO Rinsho Men'eki (Clinical Immunology), (1994) vol. 26, no. 1, pp. 99-106. Journal Code: Z0528B (Fig. 5, Tbl. 2, Ref. 23)
ISSN: 0386-9695
CY Japan
DT Journal; General Review
LA Japanese
STA New

L5 ANSWER 289 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930952681 JICST-EPlus
TI Repair action for ischemia heart of acid fibroblast growth factor (ACIDIC FIBROBLAST GROWTH FACTOR).
AU RI SOCHU
YA SHIN; O SHINMIN; WANG L M
CS Harbin Medical Science Inst., Harbin, CHN
Harbin Medical Univ., Harbin, CHN
SO Soshiki Baiyo Kenkyu (Tissue Culture Research Communications), (1993) vol.

ISSN: 0912-3636
CY Japan
DT Journal; Short Communication
LA Japanese
STA New

L5 ANSWER 290 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930670615 JICST-EPlus
TI Effects of FGF on myocardial infarction. Coronary angiogenic action of FGF.
AU MIWA ATSUKO; UCHIDA YASUMI
ITO HIDEKI
CS Univ. of Tokyo, Faculty of Medicine
Tokyotorojin'iryosenta
SO Mol Med, (1993) vol. 30, no. 8, pp. 1038-1046. Journal Code: Z0625A (Fig. 6, Tbl. 2, Ref. 24)
CODEN: MOLMEL; ISSN: 0918-6557
CY Japan
DT Journal; Commentary
LA Japanese
STA New

L5 ANSWER 291 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930074737 JICST-EPlus
TI Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor.
AU MIWA ATSUKO; UCHIDA YASUMI; TOMARU TAKANOBU; NAKAMURA FUMITAKA; KIDO HIDEAKI; SUGIMOTO TSUNEAKI
YOSHITAKE YOSHINO
ITO HIDEKI
KAJI KAZUHIKO
CS Univ. of Tokyo, Faculty of Medicine
Tokyotorojin'iryosenta
Tokyo Metrop. Inst. of Gerontology
Kanazawa Medical Univ.
SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32, no. 11, pp. 1229-1234. Journal Code: Z0216B (Fig. 8, Ref. 11)
ISSN: 0387-1126
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 292 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930074736 JICST-EPlus
TI Hypoxia Induces the Alterations in Endothelial Cell Growth.
AU OGAWA SATOSHI; MATSUMOTO MASAYASU; MAEDA YUSUKE; KAMADA TAKENOBU
KUWABARA KEISUKE; KOGA SHIN; KOGA YUKI; STERN D
CS Osaka Univ., Medical School
Koronbiadai
SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32, no. 11, pp. 1225-1228. Journal Code: Z0216B (Fig. 4, Ref. 8)
ISSN: 0387-1126
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 293 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 930074735 JICST-EPlus
TI The Role of Basic Fibroblast Growth Factor in the Developemtn of Collateral Circulation.

KAZUNORI; NAKATA MASASHI; IKEDA HISAO; TOSHIMA HIRONORI
CS Kurume Univ., Faculty of Medicine
SO Myakkangaku (Journal of Japanese College of Angiology), (1992) vol. 32, no. 11, pp. 1219-1223. Journal Code: Z0216B (Fig. 9, Ref. 10)
ISSN: 0387-1126
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 294 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 920702834 JICST-EPlus
TI The effect of hypoxia in basic fibroblast factor synthesis of cultured myocardial cells.
AU CHIBA MICHIO; SUMIDA EMIKO; OKA NAOKI; SUMIDA EIJI; NAKATA MASASHI; TOSHIMA HIRONORI
CS Kurume Univ., Faculty of Medicine
SO Shinkin no Kozo to Taisha (Cardiac Structure and Metabolism), (1991) vol. 1990, pp. 185-191. Journal Code: X0646A (Fig. 7, Ref. 9)
CY Japan
DT Conference; Article
LA Japanese
STA New

L5 ANSWER 295 OF 549 JICST-EPlus COPYRIGHT 2005 JST on STN
AN 920446249 JICST-EPlus
TI Presence of Human Epidermal Growth Factor(hEGF), Basic Fibroblast Growth Factor(***bFGF***) in Human Aqueous.
AU NAMIKI MARI; TAGAMI YUSAKU
YAMAMOTO MISAO; ITO MIKI
YAMANAKA AKIO; KANO MASAFUMI
CS Kobe Social Insurance Central Hospital
Kobe Univ., School of Medicine
Kobe Kaisei Hospital
SO Nippon Ganka Gakkai Zasshi (Journal of Japanese Ophthalmological Society), (1992) vol. 96, no. 5, pp. 652-656. Journal Code: Z0666A (Fig. 6, Ref. 11)
ISSN: 0029-0203
CY Japan
DT Journal; Article
LA Japanese
STA New

L5 ANSWER 296 OF 549 MEDLINE on STN
AN 2003455187 MEDLINE
DN PubMed ID: 14517380
TI Marked elevation of vascular endothelial growth factor and basic fibroblast growth factor in pericardial fluid of patients with angina pectoris.
AU Fujita M; Ikemoto M; Tanaka T; Tamaki S; Yamazato A; Sawamura T; Hasegawa K; Kihara Y; Nohara R; Sasayama S
CS College of Medical Technology, Kyoto University, Kyoto 606-01, Japan.
SO Angiogenesis, ***(1998)*** 2 (1) 105-8.
Journal code: 9814575. ISSN: 0969-6970.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS NONMEDLINE; PUBMED-NOT-MEDLINE
EM 200310
ED Entered STN: 20031001
Last Updated on STN: 20031011
Entered Medline: 20031010

RESERVED. on STN
AN 2000-0358764 PASCAL
CP Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.
TIEN Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
AU UNGER E. F.; GONCALVES L.; EPSTEIN S. E.; CHEW E. Y.; TRAPNELL C. B.; CANNON R. O. III; QUYYUMI A. A.; STINE A.; LOSCALZO F.; STIBER J. A.
CS Cardiology Branch, National Heart, Lung, and Blood Institute, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; Pharmacology/Toxicology Branch, Division of Clinical Trial Design and Analysis, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, United States
SO The American journal of cardiology, ***(2000)*** , 85(12), 1414-1419, 15 refs.
ISSN: 0002-9149 CODEN: AJCDAG
DT Journal
BL Analytic
CY United States
LA English
AV INIST-8674, 354000090122960040

L5 ANSWER 298 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1999-0466955 PASCAL
CP Copyright .COPYRGT. 1999 INIST-CNRS. All rights reserved.
TIEN Gene therapy for myocardial angiogenesis
The dawn of a new era in the treatment of acute myocardial infarction
AU LOSORDO D. W.; VALE P. R.; ISNER J. M.
ANTONIUCCI David (ed.); BOLOGNESE Leonardo (ed.); SANTORO Giovanni M. (ed.)
CS St Elizabeth's Medical Center, Tufts University School of Medicine, United States
Division of Cardiology, Careggi Hospital, Florence, Italy
European Society of Cardiology. Working Group on Coronary Circulation, EUR (patr.)
SO The American heart journal, ***(1999)*** , 138(2, PART2), S132-S141, 41 refs.
Conference: The Dawn of a New Era in the Treatment of Acute Myocardial Infarction. Meeting, Florence (Italy), Jan 1999
ISSN: 0002-8703 CODEN: AHJOA2
DT Journal; Conference
BL Analytic
CY United States
LA English
AV INIST-2057, 354000089385660140

L5 ANSWER 299 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1998-0489871 PASCAL
CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.
TIEN Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF***
AU METAIS C.; JIANYI LI; JIAN LI; SIMONS M.; SELLKE F. W.
CS Division of Cardiothoracic Surgery, Department of Surgery, of the Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, United States; Cardiovascular Division, Department of Medicine of Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, United States
SO American journal of physiology. Heart and circulatory physiology, ***(1998)*** , 44(4), H1411-H1418, 48 refs.
ISSN: 0363-6135 CODEN: AJPPDI
DT Journal

CY United States
LA English
AV INIST-670D, 354000070093100360

L5 ANSWER 300 OF 549 PASCAL COPYRIGHT 2005 INIST-CNRS. ALL RIGHTS RESERVED. on STN
AN 1998-0161236 PASCAL
CP Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.
TIEN Growth factors as a potential new treatment for ischemic heart disease Endothelial dysfunction, the renin-angiotensin system, and nitric oxide: impact on ***coronary*** ***artery*** ***disease*** and therapeutic interventions
AU BAUTERS C.
PEPINE Carl J. (ed.)
CS Service de Cardiologie B et Hemodynamique, Hopital Cardiologique, Universite de Lille, Lille, France
Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida, United States
SO Clinical cardiology. Supplement:(Mahwah, NJ), ***(1997)*** , 20(11, p.2), II.52-II.57, 34 refs.
DT Journal
BL Analytic
CY United States
LA English
AV INIST-19682S, 354000077887720080

L5 ANSWER 301 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1654317 PHARMAML
TI Genentech's ***VEGF*** safe, but efficacy data are inconclusive
SO Marketletter November 14, 2000
DT Newsletter
WC 335

L5 ANSWER 302 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1650915 PHARMAML
TI Chiron ***FGF*** - ***2*** study in CAD disappoints
SO Marketletter March 15, 2000
DT Newsletter
WC 373

L5 ANSWER 303 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1650847 PHARMAML
TI FDA calls a halt to "biological bypass" study
SO Marketletter March 9, 2000
DT Newsletter
WC 269

L5 ANSWER 304 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1647453 PHARMAML
TI ***VEGF*** -2 gene therapy tested in coronary patients
SO Marketletter June 24, 1999
DT Newsletter
WC 40

L5 ANSWER 305 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1645746 PHARMAML
TI Genentech disappointed by Phase II rhVEGF165 data
SO Marketletter February 22, 1999
DT Newsletter
WC 503

L5 ANSWER 306 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN

TI Genentech Starts Trials Of Recombinant ***VEGF***
SO Marketletter April 3, 1998
DT Newsletter
WC 750

L5 ANSWER 307 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1640985 PHARMAML
TI ***VEGF*** Gene Therapy For CAD/PAD
SO Marketletter March 25, 1998
DT Newsletter
WC 61

L5 ANSWER 308 OF 549 PHARMAML COPYRIGHT 2005 MARKETLETTER on STN
AN 1639829 PHARMAML
TI First Patient Gets Gene Therapy For CAD
SO Marketletter January 8, 1998
DT Newsletter
WC 296

L5 ANSWER 309 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2001:138 PHIN
DN B00689884
DED 1 Dec 2000
TI Twisted Genes A passing fashion? By Tim Searle
SO Bioventure-View (***2000***) No. 1512 p5
DT Newsletter
FS FULL

L5 ANSWER 310 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:19902 PHIN
DN B00684880
DED 1 Nov 2000
TI New Therapies for Cardiovascular Disease: Getting to the heart of the matter By Tim Searle
SO Bioventure-View (***2000***) No. 1511 p8
DT Newsletter
FS FULL

L5 ANSWER 311 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:14943 PHIN
DN S00676634
DED 25 Aug 2000
TI Clinical trials update
SO Scrip (***2000***) No. 2569 p25
DT Newsletter
FS FULL

L5 ANSWER 312 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:9109 PHIN
DN S00664290
DED 19 May 2000
TI Phase II trials for GenVec's Biobypass angiogen
SO Scrip (***2000***) No. 2541 p22
DT Newsletter
FS BRIEF

L5 ANSWER 313 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

DN C00663242
DED 8 May 2000
TI Phase II CAD (***coronary*** ***artery*** ***disease***) gene therapy trials begin
SO Clinica (***2000***) No. 907 p16
DT Newsletter
FS BRIEF

L5 ANSWER 314 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:7020 PHIN
DN B00659202
DED 1 Apr 2000
TI COMPANY SNAPSHOT - Human Genome Sciences Inc. Rockville, MD * Nasdaq: HGSI
SO Bioventure-View (***2000***) No. 1504 p12
DT Newsletter
FS FULL

L5 ANSWER 315 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 2000:5904 PHIN
DN C00658114
DED 20 Mar 2000
TI Researches say gene therapy trials for heart disease show promising results, despite FDA "caution"
SO Clinica (***2000***) No. 900 p15
DT Newsletter
FS FULL

L5 ANSWER 316 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:17149 PHIN
DN S00638962
DED 1 Oct 1999
TI Chiron poised for new growth opportunities
SO Scrip (***1999***) No. 2477 p9
DT Newsletter
FS FULL

L5 ANSWER 317 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:6817 PHIN
DN S00617066
DED 24 Mar 1999
TI Megabios/GeneMedicine become Valentis
SO Scrip (***1999***) No. 2422 p11
DT Newsletter
FS BRIEF

L5 ANSWER 318 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:4532 PHIN
DN C00613514
DED 1 Mar 1999
TI Genentech has poor results from growth factor trials
SO Clinica (***1999***) No. 848 p14
DT Newsletter
FS FULL

L5 ANSWER 319 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1999:3227 PHIN

DED 27 Jan 1999
TI Rituxan and Herceptin drive Genentech
SO Scrip (***1999***) No. 2406 p15
DT Newsletter
FS FULL

L5 ANSWER 320 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 1998:19416 PHIN
DN S00600330
DED 30 Oct 1998
TI Preclinical research update
SO Scrip (***1998***) No. 2383 p23
DT Newsletter
FS FULL

L5 ANSWER 321 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:16345 PHIN
DN S00551440
DED 10 Sep 1997
TI Parke-Davis and GenVec partnership
SO Scrip (***1997***) No. 2267 p9
DT Newsletter
FS FULL

L5 ANSWER 322 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 97:13715 PHIN
DN S00546366
DED 3 Jul 1997
TI Genentech earnings down, sales flat
SO Scrip (***1997***) No. 2253 p12
DT Newsletter
FS FULL

L5 ANSWER 323 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 96:21681 PHIN
DN S00517376
DED 29 Nov 1996
TI Scios' Natrecor moves into Phase III
SO Scrip (***1996***) No. 2185 p13
DT Newsletter
FS FULL

L5 ANSWER 324 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 96:20093 PHIN
DN S00513988
DED 1 Nov 1996
TI Scios and Wyeth-Ayerst to develop Fiblast
SO Scrip (***1996***) No. 2177 p7
DT Newsletter
FS FULL

L5 ANSWER 325 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 95:15445 PHIN
DN S00456629
DED 21 Aug 1995
TI Scios Nova granted US patent for basic fibroblast growth factor (

SO Scrip-Online-plus (***1995***)
DT Newsletter
FS BRIEF

L5 ANSWER 326 OF 549 PHIN COPYRIGHT 2005 T&F Informa UK Ltd on STN

AN 95:11703 PHIN
DN S00450122
DED 29 Jun 1995
TI Bristol-Myers Squibb Company Profile (1995)
SO Scrip-Online-plus (***1995***)
DT Newsletter
FS FULL

L5 ANSWER 327 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2001:4835 PROMT
TITLE: ***VEGF*** -138 Stimulates Endothelial Cells.
SOURCE: Applied Genetics News, (***Dec 2000***) Vol. 21, No. 5.
ISSN: 0271-7107.
PUBLISHER: Business Communications Company, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 214
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 328 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1116652 PROMT
TITLE: Human Genome Sciences Forms Biotech Deals.(Brief Article)
AUTHOR(S): PAPANIKOLAW, JIM
SOURCE: Chemical Market Reporter, (***6 Mar 2000***) Vol. 257, No. 10, pp. 22.
ISSN: ISSN: 1092-0110.
PUBLISHER: Schnell Publishing Company, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 525
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 329 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1077662 PROMT
TITLE: GENVEC RAISES $38M IN IPO FOR ADENOVECTOR TECHNOLOGY.(Brief Article)
AUTHOR(S): Osborne, Randall
SOURCE: BIOWORLD Today, (***13 Dec 2000***) Vol. 11, No. 240.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 371
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 330 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1073568 PROMT
TITLE: GENVEC INC.(initial public offering)(Brief Article)
SOURCE: The IPO Reporter, (***11 Dec 2000***) pp. ITEM00346006.
PUBLISHER: Securities Data Publishing, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 235

L5 ANSWER 331 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1043295 PROMT
TITLE: Collateral Therapeutics Announces Research on New Angiogenic Growth Factor Gene ***VEGF*** -138.
SOURCE: PR Newswire, (***30 Nov 2000***) pp. 7931.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 704
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 332 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:1008528 PROMT
TITLE: Genentech's ***VEGF*** safe, but efficacy data are inconclusive.
SOURCE: Marketletter, (***20 Nov 2000***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 341
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 333 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:939684 PROMT
TITLE: Newly Published Preclinical Study Demonstrates Relaxin Selectively Stimulates ***VEGF*** and ***bFGF*** at Ischemic Sites.
SOURCE: PR Newswire, (***31 Oct 2000***) pp. 6454.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 604
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 334 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:869511 PROMT
TITLE: GENVEC TRIES AGAIN FOR IPO, SEEKS $50M FOR GENE PRODUCTS.
AUTHOR(S): Huggett, Brady
SOURCE: BIOWORLD Today, (***9 Oct 2000***) Vol. 11, No. 195.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 517
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 335 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:851873 PROMT
TITLE: Genzyme Surgical Products Initiates Second Cardiovascular Gene Therapy Clinical Trial.
SOURCE: PR Newswire, (***2 Oct 2000***) pp. 7025.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1439
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 336 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:759976 PROMT
TITLE: Collateral announces issuance of United States patent for angiogenic gene therapy for the treatment of heart disease.(Brief Article)
SOURCE: BIOTECH Patent News, (***August 2000***) Vol. 14, No. 8
.
ISSN: 0898-2813.
PUBLISHER: Biotech Patent News
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 559
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 337 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:696893 PROMT
TITLE: Collateral Announces Issuance of U.S. Patent for Angiogenic Gene Therapy For the Treatment of Heart Disease.
SOURCE: PR Newswire, (***8 Aug 2000***) pp. 8216.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 827
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 338 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:670655 PROMT
TITLE: HUMAN GENOME SCIENCES SEEKS ANOTHER $300M IN NOTES OFFERING.
AUTHOR(S): Welch, Mary
SOURCE: BIOWORLD Today, (***7 Mar 2000***) Vol. 11, No. 44.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 656
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 339 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:665667 PROMT
TITLE: Collateral Announces Expanded Angiogenic Gene Research Collaboration With New York University.
SOURCE: PR Newswire, (***2 Aug 2000***) .
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 703
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 340 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:588546 PROMT
TITLE: Transgene Selects Two Novel Cardiovascular Genes From Human Genome Sciences for Gene Therapy Development.
SOURCE: PR Newswire, (***12 Jul 2000***) pp. 6625.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2145

L5 ANSWER 341 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:527148 PROMT
TITLE: REPAIR INC. PURSUING ANGIOGENIC THERAPIES BASED ON ***FGF*** - ***1*** , FIBRIN.(Brief Article)
AUTHOR(S): Welch, Mary
SOURCE: BIOWORLD Today, (***21 Jun 2000***) Vol. 11, No. 120.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 782
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 342 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:493718 PROMT
TITLE: Vasomedical Expands EECP Education To Clinicians Specializing In Diabetes; EECP Therapy Is Being Presented For The First Time At Two International Scientific Sessions This Summer.
SOURCE: Business Wire, (***12 Jun 2000***) pp. 2617.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 682
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 343 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:457030 PROMT
TITLE: Protein goes to the heart of ***coronary*** ***artery*** ***disease*** .
AUTHOR(S): Conchas, Edmundo
SOURCE: San Antonio Business Journal, (***16 Jul 1999***) Vol. 13, No. 23, pp. 21.
ISSN: 0895-1551.
PUBLISHER: American City Business Journals, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 923
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 344 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:390881 PROMT
TITLE: gene therapy, cardiovascular disease GenVec begins phase II trial.(Brief Article)
SOURCE: R & D Focus Drug News, (***8 May 2000***) .
ISSN: 1350-1135.
PUBLISHER: IMS World Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 142
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 345 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:369841 PROMT
TITLE: Collateral Therapeutics Appoints John F. Warner Ph.D. Vice President Of Technology.
SOURCE: PR Newswire, (***9 May 2000***) .

DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 787
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 346 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:316730 PROMT
TITLE: Human Genome Sciences Inc. Rockville, MD * Nasdaq: HGSI.(Brief Article)(Statistical Data Included)
SOURCE: BioVenture View, (***April 2000***) Vol. 15, No. 4, pp. 12.
ISSN: 0892-1903.
PUBLISHER: BioVenture Publishing
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 660
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 347 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:284447 PROMT
TITLE: HUMAN GENOME SCIENCES SEEKS ANOTHER $300M IN NOTES OFFERING.(Brief Article)
AUTHOR(S): Welch, Mary
SOURCE: BIOWORLD Today, (***7 Mar 2000***) Vol. 11, No. 44.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 656
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 348 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:261161 PROMT
TITLE: Vascular Genetics Reports on Initial Phase I/II Trials of ***VEGF*** -2.
SOURCE: PR Newswire, (***7 Apr 2000***) pp. 8825.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 269
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 349 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:257315 PROMT
TITLE: Human Genome Sciences, Vical and Vascular Genetics Enter Strategic Collaboration.
SOURCE: PR Newswire, (***7 Apr 2000***) pp. 5526.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 709
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 350 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:230890 PROMT
TITLE: GENE THERAPY: Naked Gene Delivery Service.(Brief Article)
SOURCE: Applied Genetics News, (***March 2000***) Vol. 20, No. 8.

PUBLISHER: Business Communications Company, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 269
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 351 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:193460 PROMT
TITLE: Chiron ***FGF*** - ***2*** study in CAD disappoints.(Brief Article)
SOURCE: Marketletter, (***20 Mar 2000***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 375
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 352 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:187473 PROMT
TITLE: AMERICAN COLLEGE OF CARDIOLOGY'S SCIENTIFIC SESSION CHIRON'S ***FGF*** - ***2*** REDUCES ANGINA, BUT FAILS WITH PRIMARY ENDPOINT.
AUTHOR(S): Pihl; Carey, Karen
SOURCE: BIOWORLD Today, (***14 Mar 2000***) Vol. 11, No. 49.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1104
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 353 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:181365 PROMT
TITLE: FDA calls a halt to "biological bypass" study.(Brief Article)
SOURCE: Marketletter, (***13 Mar 2000***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 268
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 354 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:169609 PROMT
TITLE: Gene genies.
AUTHOR(S): Truelove, Christiane
SOURCE: Med Ad News, (***Sept 1999***) Vol. 18, No. 9, pp. 122.
ISSN: 1067-733X.
PUBLISHER: Engel Publishing Partners
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2599
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 355 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:141883 PROMT

PHARMA.
AUTHOR(S): Pihl; Carey, Karen
SOURCE: BIOWORLD Today, (***28 Feb 2000***) Vol. 11, No. 37.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 662
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 356 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:133836 PROMT
TITLE: Vical, Human Genome Sciences and Vascular Genetics Enter Strategic Collaboration.
SOURCE: Business Wire, (***25 Feb 2000***) pp. 43.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 765
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 357 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:111745 PROMT
TITLE: Collateral Therapeutics announces issuance of United States patent for angiogenic growth factor gene ***Vegf*** -145.(Brief Article)
SOURCE: BIOTECH Patent News, (***Jan 2000***) Vol. 14, No. 1. ISSN: 0898-2813.
PUBLISHER: Biotech Patent News
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 511
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 358 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 2000:23408 PROMT
TITLE: Collateral Therapeutics Announces Issuance of U.S. Patent for Angiogenic Growth Factor Gene ***VEGF*** -145.
SOURCE: PR Newswire, (***11 Jan 2000***) pp. 8712.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 791
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 359 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:736191 PROMT
TITLE: AMERICAN HEART ASSOCIATION MEETING.
AUTHOR(S): Welch, Mary
SOURCE: BIOWORLD Today, (***11 Nov 1999***) Vol. 10, No. 216.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 718
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 360 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:733152 PROMT

for Gene Medicine For Angiogenesis.
SOURCE: PR Newswire, (***10 Nov 1999***) pp. 1428.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 684
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 361 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:727610 PROMT
TITLE: Collateral Therapeutics Creates First Combination FGF/ ***VEGF*** Gene For Non-Surgical Cardiovascular Angiogenesis.
SOURCE: PR Newswire, (***8 Nov 1999***) pp. 8563.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 695
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 362 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:654487 PROMT
TITLE: Scios Announces 1999 Third Quarter Financial Results.
SOURCE: PR Newswire, (***8 Oct 1999***) pp. 2565.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1696
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 363 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:527351 PROMT
TITLE: COLLATERAL THERAPEUTICS RAISES $33.9M IN PRIVATE PLACEMENT.
AUTHOR(S): Seachrist, Lisa
SOURCE: BIOWORLD Today, (***13 Aug 1999***) Vol. 10, No. 156.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 562
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 364 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:481316 PROMT
TITLE: Scios Announces 1999 Second Quarter Financial Results.
SOURCE: PR Newswire, (***29 Jul 1999***) pp. 1389.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1805
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 365 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:412014 PROMT
TITLE: ***VEGF*** -2 gene therapy tested in coronary patients.(Vascular Genetics)(Brief Article)
SOURCE: Marketletter, (***28 Jun 1999***) .
ISSN: 0951-3175.

DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 42
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 366 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:391940 PROMT
TITLE: Human Genome Sciences Collaborates in Second Gene Therapy Clinical Trials; Two Protocols Target ***Coronary*** ***Artery*** ***Disease*** .
SOURCE: PR Newswire, (***17 Jun 1999***) pp. 1113.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 808
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 367 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:376201 PROMT
TITLE: Biosense Webster Announces Collaboration with Vascular Genetics Inc. on Catheter Delivery of Gene Therapy to Treat Cardiac Disease.
SOURCE: PR Newswire, (***10 Jun 1999***) pp. 6525.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 448
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 368 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:329291 PROMT
TITLE: Trimedyne Subsidiary Enters Gene Therapy Collaboration With Endovasc Ltd. Inc.
SOURCE: Business Wire, (***20 May 1999***) pp. 1125.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 452
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 369 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:273148 PROMT
TITLE: Megabios Acquires Angiogenesis Gene.
SOURCE: PR Newswire, (***27 Apr 1999***) pp. 3938.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 764
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 370 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:247722 PROMT
TITLE: Regeneron Scientists Report That Angiopoietin-1 Increases Blood Vessel Formation.
SOURCE: Business Wire, (***16 Oct 1998***) pp. 1068.
PUBLISHER: Business Wire
DOCUMENT TYPE: Newsletter

WORD COUNT: 802
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 371 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:178765 PROMT
TITLE: Vascular Genetics Inc. Announces First External Investment.
SOURCE: PR Newswire, (***29 Mar 1999***) pp. 9614.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 562
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 372 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:178763 PROMT
TITLE: Human Genome Sciences Announces Completion of Private Financing For Vascular Genetics Inc.
SOURCE: PR Newswire, (***29 Mar 1999***) pp. 9611.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 660
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 373 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:175526 PROMT
TITLE: Genentech disappointed by Phase II rhVEGF165 data.
SOURCE: Marketletter, (***1 Mar 1999***) .
ISSN: 0951-3175.
PUBLISHER: Marketletter Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 504
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 374 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:162782 PROMT
TITLE: Megabios and GeneMedicine Complete Merger.
SOURCE: PR Newswire, (***19 Mar 1999***) pp. 8437.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 636
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 375 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:145715 PROMT
TITLE: vascular endothelial growth factor Genentech considers product future.
SOURCE: R & D Focus Drug News, (***3 Mar 1999***) .
ISSN: 1350-1135.
PUBLISHER: IMSWorld Publications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 90
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

ACCESSION NUMBER: 1999:107590 PROMT
TITLE: LITTLE SHORT-TERM IMPACT ON COMPANY, ANALYST SAYS GENENTECH'S ***VEGF*** DRUG FAILS TO MEET PHASE II ENDPOINTS.
SOURCE: BIOWORLD Today, (***19 Feb 1999***) Vol. 10, No. 33.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 531
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 377 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:62246 PROMT
TITLE: LUDWIG INSTITUTE ALSO PART OF DEAL RPR GENCELL PAYING AMRAD UP TO $50M FOR ***VEGF*** -B RIGHTS.
SOURCE: BIOWORLD Today, (***3 Feb 1999***) Vol. 10, No. 22.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 498
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 378 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:58098 PROMT
TITLE: AMRAD and Ludwig Institute License Gene Patents and Technology to RPR Gencell.
SOURCE: PR Newswire, (***1 Feb 1999***) pp. 5882.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 674
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 379 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:40475 PROMT
TITLE: Genzyme General Forms Collaboration to Develop Cell Therapies for Cardiovascular Disease.
SOURCE: PR Newswire, (***21 Jan 1999***) pp. 8640.
PUBLISHER: PR Newswire Association, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2579
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 380 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1999:21785 PROMT
TITLE: Gene therapy, ***VEGF*** -2, Vascular Genetics Vascular Genetics IND allowed.
SOURCE: R & D Focus Drug News, (***11 Jan 1999***) pp. NA(1). ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 106
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 381 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:687886 PROMT

SOURCE: M2 Presswire, (***26 Jan 1998***) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1687
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 382 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:670405 PROMT
TITLE: Vascular Genetics Initiates Gene Therapy Clinical Studies To Stimulate Growth Of Blood Vessels.
SOURCE: PR Newswire, (***23 Dec 1998***) pp. 8890.
LANGUAGE: English
WORD COUNT: 469
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 383 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:670403 PROMT
TITLE: Human Genome Sciences Announces Collaboration in Gene Therapy Clinical Studies.
SOURCE: PR Newswire, (***23 Dec 1998***) pp. 8892.
LANGUAGE: English
WORD COUNT: 805
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 384 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:670402 PROMT
TITLE: Vascular Genetics Initiates Gene Therapy Clinical Studies To Stimulate Growth of Blood Vessels.
SOURCE: PR Newswire, (***23 Dec 1998***) pp. 8891.
LANGUAGE: English
WORD COUNT: 468
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 385 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:611763 PROMT
TITLE: More data reported for HDL's role in heart disease.(high-density lipoprotein cholesterol)(includes related article on gene therapy for peripheral artery disease)
AUTHOR(S): Husten, Larry
SOURCE: The Lancet, (***14 Nov 1998***) pp. 1603(1).
ISSN: 0099-5355.
LANGUAGE: English
WORD COUNT: 794
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 386 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:567527 PROMT
TITLE: Angiogenesis May Be Stimulated by EECP(R) Therapy.
SOURCE: PR Newswire, (***4 Nov 1998***) pp. 5638.
LANGUAGE: English
WORD COUNT: 221
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 387 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

TITLE: angiopoietin 1 Regeneron, Procter & Gamble preclinical data.
SOURCE: R & D Focus Drug News, (***2 Nov 1998***) pp. NA(1). ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 233
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 388 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:469943 PROMT
TITLE: Gene therapy, vascular endothelial growth factor B Collateral Therapeutics, Ludwig Institute for Cancer Research, AMRAD licensing termination
SOURCE: R & D Focus Drug News, (***14 Sep 1998***) pp. N/A. ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 171
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 389 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:460361 PROMT
TITLE: Collateral Therapeutics Announces Termination of Agreement With AMRAD Development and Ludwig Institute
SOURCE: PR Newswire, (***4 Sep 1998***) pp. 904SFF004.
LANGUAGE: English
WORD COUNT: 544
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 390 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:456293 PROMT
TITLE: Clinicians Report Evidence of Added Patient Benefits From Vasomedical's EECP Cardiovascular Disease Therapy; Could Positively Affect Blood Flow, Renal Function.
SOURCE: Business Wire, (***3 Sep 1998***) pp. 9030023.
LANGUAGE: English
WORD COUNT: 535
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 391 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:416334 PROMT
TITLE: trafermin Scios Nova, Wyeth Ayerst terminate trial
SOURCE: R & D Focus Drug News, (***10 Aug 1998***) pp. NA. ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 159
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 392 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:413454 PROMT
TITLE: COLLATERAL THERAPEUTICS WINS ANGIOGENESIS GENES PATENT By Randall Osborne Staff Writer
SOURCE: BIOWORLD Today, (***12 Aug 1998***) pp. N/A.
LANGUAGE: English
WORD COUNT: 401
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 393 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:398071 PROMT
TITLE: GENVEC WITHDRAWS IPO; BLAMES UNSTABLE MARKET CONDITIONS
SOURCE: BIOWORLD Today, (***4 Aug 1998***) pp. N/A.
LANGUAGE: English
WORD COUNT: 463
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 394 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:232468 PROMT
TITLE: Research Study Indicates That TMR Using The Heart Laser System Enhances The Effectiveness Of Gene Therapy For Heart Disease
SOURCE: PR Newswire, (***8 May 1998***) pp. 508NEF003.
LANGUAGE: English
WORD COUNT: 574
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 395 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:175708 PROMT
TITLE: DEVELOPMENTS IN BIOTECHNOLOGY :GeneMedicine-Cationic Lipid Gene Delivery System In Two Phase II Gene Therapy Angioplasty Clinical Trials
SOURCE: BioAccess, (***1 Apr 1998***) pp. N/A.
ISSN: 1356-3432.
LANGUAGE: English
WORD COUNT: 712
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 396 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:173353 PROMT
TITLE: Genentech Starts Trials Of Recombinant ***VEGF***
SOURCE: Marketletter, (***13 Apr 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 756
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 397 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:150551 PROMT
TITLE: ***VEGF*** Gene Therapy For CAD/PAD
SOURCE: Marketletter, (***30 Mar 1998***) pp. N/A.
ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 61
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 398 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:143219 PROMT
TITLE: GENEMEDICINE Proprietary Cationic Lipid Gene Delivery System Is Employed in Two Phase II Gene Therapy Angioplasty Clinical Trials.
SOURCE: Business Wire, (***19 Mar 1998***) pp. 3190068.
LANGUAGE: English
WORD COUNT: 900
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 399 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:64791 PROMT
TITLE: gene therapy, FGF-4, gene therapy, heart disease, Collateral Therapeutics Collateral Therapeutics IND submission Schering AG IND submission Schering AG Collateral Therapeutics
SOURCE: R & D Focus Drug News, (***19 Jan 1998***) pp. N/A. ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 209
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 400 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:41293 PROMT
TITLE: Genentech's Year-End Results Show Growth Plan on Track: Earnings Increase Nine Percent on Revenues Exceeding $1 Billion.
SOURCE: Business Wire, (***22 Jan 1998***) pp. 01220134.
LANGUAGE: English
WORD COUNT: 2029
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 401 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:32445 PROMT
TITLE: First Patient Gets Gene Therapy For CAD
SOURCE: Marketletter, (***19 Jan 1998***) pp. N/A. ISSN: 0951-3175.
LANGUAGE: English
WORD COUNT: 297
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 402 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:17434 PROMT
TITLE: Collateral Therapeutics Announces Details of First Commercial IND Filing for Revolutionary, New, Non-Surgical Gene Therapy Treatment for ***Coronary*** ***Artery*** ***Disease***
SOURCE: PR Newswire, (***5 Jan 1998***) pp. 0105SFM044.
LANGUAGE: English
WORD COUNT: 719
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 403 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 1998:15172 PROMT
TITLE: Revolutionary New Development in Treatment of Heart Disease; First Gene Therapy Administered to the Heart
SOURCE: PR Newswire, (***5 Jan 1998***) pp. 0105NYM004.
LANGUAGE: English
WORD COUNT: 656
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 404 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:731773 PROMT
TITLE: GENENTECH: Genentech reports 1997 second quarter results
SOURCE: M2 Presswire, (***16 Jul 1997***) .
PUBLISHER: M2 Communications Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 405 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:594655 PROMT
TITLE: Medco Research Announces Adenosine And Heparin May Be Beneficial In Chronic Stable Angina
SOURCE: PR Newswire, (***11 Nov 1997***) pp. 1111CHTU009.
LANGUAGE: English
WORD COUNT: 675
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 406 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:445891 PROMT
TITLE: vascular endothelial growth factor Genentech phase change I, USA
Vascular endothelial growth factor for ***coronary*** ***artery*** ***disease*** enters Phase II trials
SOURCE: R & D Focus Drug News, (***18 Aug 1997***) pp. N/A.
ISSN: 1350-1135.
LANGUAGE: English
WORD COUNT: 40
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 407 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:283114 PROMT
TITLE: Companies aim novel therapeutic strategies at dual nature of angiogenesis.
Novel therapeutic strategies are being developed by several biotechnology companies, based on dual nature of angiogenesis
AUTHOR(S): Liszewski, Kathy
SOURCE: Genetic Engineering News, (***1 May 1997***) pp. 6.
ISSN: 0270-6377.
LANGUAGE: English

L5 ANSWER 408 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 97:77299 PROMT
TITLE: The Long and the Short of Business Development
SOURCE: Genesis Report-Rx, (***1 Dec 1996***) pp. N/A.
ISSN: 1061-2270.
LANGUAGE: English
WORD COUNT: 864
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 409 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:653056 PROMT
TITLE: Scios/Wyeth-Ayerst sign Fiblast deal
SOURCE: Biotechnology Business News, (***13 Nov 1996***) pp. N/A.
ISSN: 0965-9595.
LANGUAGE: English
WORD COUNT: 232
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 410 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:625107 PROMT

FIBLAST FOR NEUROLOGICAL AND CARDIOVASCULAR DISORDERS
SOURCE: News Release, (***23 Oct 1996***) pp. N/A.
LANGUAGE: English
WORD COUNT: 892
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 411 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:587597 PROMT
TITLE: GenVec Inc. licenses the human iNOS gene from University of Pittsburgh for all gene transfer pharmaceutical applications
SOURCE: BIOTECH Patent News, (***1 Oct 1996***) pp. N/A.
ISSN: 0898-2813.
LANGUAGE: English
WORD COUNT: 684
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 412 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:557916 PROMT
TITLE: Scios and Wyeth-Ayerst Announce Agreement to Develop FIBLAST for Neurological and Cardiovascular Disorders
SOURCE: PR Newswire, (***23 Oct 1996***) pp. 1023SFW050.
LANGUAGE: English
WORD COUNT: 952
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 413 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:554482 PROMT
TITLE: Industry News (Licensing) Human iNOS Gene Licensed for Gene Transfer Pharmaceutical Applications
SOURCE: Blood Weekly, (***21 Oct 1996***) pp. N/A.
ISSN: 1065-6073.
LANGUAGE: English
WORD COUNT: 562
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 414 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:521824 PROMT
TITLE: GenVec, Inc. Licenses The Human iNOS Gene From The University of Pittsburgh For All Gene Transfer Pharmaceutical Applications
SOURCE: PR Newswire, (***9 Oct 1996***) pp. 1009NYW003.
LANGUAGE: English
WORD COUNT: 777
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 415 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:388705 PROMT
TITLE: EUROPEAN PATENT OFFICE RULES IN FAVOR OF SCIOS FOR FIBLAST TRAFERMIN (***bFGF***)
SOURCE: News Release, (***21 Jun 1996***) pp. N/A.
LANGUAGE: English
WORD COUNT: 499
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 416 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

TITLE: Can Gene Therapy Replace Heart Bypass?
SOURCE: Applied Genetics News, (***1 Jul 1996***) pp. N/A.
ISSN: 0271-7107.
LANGUAGE: English
WORD COUNT: 242
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 417 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:370403 PROMT
TITLE: European Patent Office rules in favor of Scios in patent opposition related to human basic fibroblast growth factor
SOURCE: BIOTECH Patent News, (***1 Jul 1996***) pp. N/A.
ISSN: 0898-2813.
LANGUAGE: English
WORD COUNT: 501
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 418 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:351262 PROMT
TITLE: SCIOS RECEIVES U.S. PATENT FOR THE RECOMBINANT PRODUCTION OF FIBLAST TRAFERMIN (***bFGF***)
SOURCE: News Release, (***8 May 1996***) pp. N/A.
LANGUAGE: English
WORD COUNT: 474
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 419 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:285146 PROMT
TITLE: GENVEC INC. LICENSES GENE FROM SCIOS INC. FOR BIOBYPASS PRODUCT IN HEART AND VASCULAR DISEASE
SOURCE: PR Newswire, (***4 Jun 1996***) pp. 0604NYTU010.
LANGUAGE: English
WORD COUNT: 535
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 420 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:282152 PROMT
TITLE: COMPANY DEVELOPMENTS-Product Developments: SCIOS INC
SOURCE: Bioventure View, (***Jun 1996***) pp. N/A.
ISSN: 0892-1903.
LANGUAGE: English
WORD COUNT: 36
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 421 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:270947 PROMT
TITLE: Scios to patent method of producing recombinant human basic fibroblast growth factor
SOURCE: BIOTECH Patent News, (***1 May 1996***) pp. N/A.
ISSN: 0898-2813.
LANGUAGE: English
WORD COUNT: 454
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 422 OF 549 PROMT COPYRIGHT 2005 Gale Group on STN

ACCESSION NUMBER: 96:240262 PROMT

OF FIBLAST(R) TRAFERMIN (***bFGF***)
SOURCE: PR Newswire, (***8 May 1996***) pp. 0508SJW003.
LANGUAGE: English
WORD COUNT: 506
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 423 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:831659 SCISEARCH
GA The Genuine Article (R) Number: 481WB
TI Focal angiogenic therapy for myocardial ischemia
AU Symes J F (Reprint)
CS 11 Nevins St, Suite 306, Boston, MA 02135 USA (Reprint); Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Div Cardiothorac Surg, Boston, MA 02111 USA
CYA USA
SO JOURNAL OF CARDIAC SURGERY, (***JUL-AUG 2000***) Vol. 15, No. 4, pp. 283-290.
Publisher: FUTURA PUBL CO, 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418 USA.
ISSN: 0886-0440.
DT Article; Journal
LA English
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 424 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2001:86909 SCISEARCH
GA The Genuine Article (R) Number: 390VG
TI Angiogenesis as an antiischemic mechanism
AU Busiashvili Y I (Reprint); Picano E; Ambatyello S G; Matskeplishvili S T
CS AN Bakulev Cardiovasc Surg Res Ctr, Rublevskoe Sh 135, Moscow 121552, Russia (Reprint); AN Bakulev Cardiovasc Surg Res Ctr, Moscow 121552, Russia
CYA Russia
SO KARDIOLOGIYA, (***OCT-DEC 2000***) Vol. 40, No. 12, pp. 82-86.
Publisher: IZD VO MEDITSINA, PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA.
ISSN: 0022-9040.
DT General Review; Journal
LA Russian
REC Reference Count: 43

L5 ANSWER 425 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:779094 SCISEARCH
GA The Genuine Article (R) Number: 361YH
TI Angiogenesis and vasculogenesis. Therapeutic approaches for stimulation of post-natal neovascularization
AU Kalka C (Reprint); Asahara T; Krone W; Isner J M
CS TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOVASC RES, 736 CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); UNIV COLOGNE, KLIN & POLIKLIN INNERE MED 2, D-5000 COLOGNE 41, GERMANY
CYA USA; GERMANY
SO HERZ, (***SEP 2000***) Vol. 25, No. 6, pp. 611-622.
Publisher: URBAN & VOGEL, C/O SPRINGER GMBH & CO AUSLIEFERUNGSGESELLSCHAFT KUNDENSERVICE ZEITSCHRIFTEN, D-69126 HABERSTRASBE 7, GERMANY.
ISSN: 0340-9937.
DT Article; Journal
FS CLIN
LA German
REC Reference Count: 90

L5 ANSWER 426 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:598823 SCISEARCH
GA The Genuine Article (R) Number: 339PB
TI Adenovirus-mediated ***VEGF*** (121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia
AU Gowdak L H W; Poliakova L; Wang X T; Kovesdi I; Fishbein K W; Zacheo A; Palumbo R; Straino S; Emanueli C; MarroccoTrischitta M; Lakatta E G; Anversa P; Spencer R G S; Talan M (Reprint); Capogrossi M C
CS NIA, GERONTOL RES CTR, CARDIOVASC SCI LAB, NIH, 5600 NATHAN SHOCK DR, BALTIMORE, MD 21224 (Reprint); NIA, GERONTOL RES CTR, CARDIOVASC SCI LAB, NIH, BALTIMORE, MD 21224; NIA, GENE THERAPY UNIT, CARDIOVASC SCI LAB, NIH, BALTIMORE, MD 21224; NIA, NUCL MAGNET RESONANCE UNIT, CELLULAR & MOL BIOL LAB, NIH, BALTIMORE, MD 21224; GENVEC INC, ROCKVILLE, MD; IRCCS, IST DERMOPAT IMMACOLATA, LAB PATOL VASCOLARE, ROME, ITALY; NEW YORK MED COLL, DEPT MED, VALHALLA, NY 10595
CYA USA; ITALY
SO CIRCULATION, (***1 AUG 2000***) Vol. 102, No. 5, pp. 565-571.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621.
ISSN: 0009-7322.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 427 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 2000:287589 SCISEARCH
GA The Genuine Article (R) Number: 302MA
TI Biomedical developments
AU ANON
SO BIOTECHNOLOGY LAW REPORT, (***FEB 2000***) Vol. 19, No. 1, pp. 55-56.
Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY 10538.
ISSN: 0730-031X.
DT Article; Journal
LA English
REC Reference Count: 0

L5 ANSWER 428 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:982252 SCISEARCH
GA The Genuine Article (R) Number: 265KJ
TI Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia
AU Sumino H; Nakamura T (Reprint); Ichikawa S; Kanda T; Sakamaki T; Sato K; Kobayashi I; Nagai R
CS GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, 3-39-22 SHOWA, MAEBASHI, GUMMA 3718511, JAPAN (Reprint); GUNMA UNIV, SCH MED, DEPT INTERNAL MED 2, MAEBASHI, GUMMA 3718511, JAPAN; CARDIOVASC HOSP CENT JAPAN, GUNMA 3770061, JAPAN; GUNMA UNIV, SCH MED, DEPT LAB MED, MAEBASHI, GUMMA 371, JAPAN; GUNMA UNIV, SCH MED, DEPT MED INFORMAT & DESIC SCI, MAEBASHI, GUMMA 371, JAPAN
CYA JAPAN
SO ATHEROSCLEROSIS, (***JAN 2000***) Vol. 148, No. 1, pp. 189-195.
Publisher: ELSEVIER SCI IRELAND LTD, CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND.
ISSN: 0021-9150.

FS LIFE; CLIN
LA English
REC Reference Count: 25
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 429 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:654157 SCISEARCH
GA The Genuine Article (R) Number: 227QN
TI Increased production of cytokines and growth factors by aortic allografts: A possible explanation for myointimal hyperplasia formation
AU Sterpetti A V (Reprint); Cucina A; Randone B; Guglielmi M B; Fragale A; Cavallaro A
CS UNIV ROMA LA SAPIENZA, IST CLIN CHIRURG 1, LAB CASTRO LAURENZIANO, VIA A SCARPA 14, I-00161 ROME, ITALY (Reprint); UNIV ROMA LA SAPIENZA, IST ISTOL & EMBRIOL, I-00161 ROME, ITALY
CYA ITALY
SO EUROPEAN SURGICAL RESEARCH, (***JUL-AUG 1999***) Vol. 31, No. 4, pp. 297-304.
Publisher: KARGER, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND.
ISSN: 0014-312X.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 27
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 430 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1999:360111 SCISEARCH
GA The Genuine Article (R) Number: 185GH
TI Direct intramyocardial gene therapy with ***VEGF*** for inoperable ***coronary*** ***artery*** ***disease*** : Preliminary clinical results
AU Lathi K G (Reprint); Cespedes R M; Losordo D W; Vale P R; Symes J F; Isner J M
CS TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT ANESTHESIOL, BOSTON, MA 02135; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED CARDIOL, BOSTON, MA 02135; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT CARDIOTHORAC SURG, BOSTON, MA 02135
CYA USA
SO ANESTHESIA AND ANALGESIA, (***APR 1999***) Vol. 88, No. 4, Supp. [S], pp. U78-U78.
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106.
ISSN: 0003-2999.
DT Conference; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 1

L5 ANSWER 431 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1998:758407 SCISEARCH
GA The Genuine Article (R) Number: 124DT
TI Effects of ***coronary*** ***artery*** ***disease*** on expression and microvascular response to ***VEGF***
AU Metais C; Li J Y; Li J; Simons M; Sellke F W (Reprint)
CS BETH ISRAEL DEACONESS MED CTR, DEPT SURG, DIV CARDIOTHORAC SURG, EAST CAMPUS, DANA 905, BOSTON, MA 02215 (Reprint); BETH ISRAEL DEACONESS MED CTR, DEPT SURG, DIV CARDIOTHORAC SURG, BOSTON, MA 02215; BETH ISRAEL

UNIV, SCH MED, BOSTON, MA 02215
CYA USA
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, (***OCT*** 1998***) Vol. 44, No. 4, pp. H1411-H1418.
Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0363-6135.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 48
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 432 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 1998:300195 SCISEARCH
GA The Genuine Article (R) Number: ZG762
TI Gene therapy for restenosis
AU Steg P G (Reprint); Feldman L
CS HOP BICHAT, SERV CARDIOL, INSERM U460, 46 RUE HENRI HUCHARD, F-75877 PARIS 18, FRANCE (Reprint)
CYA FRANCE
SO PATHOLOGIE BIOLOGIE, (***MAR 1998***) Vol. 46, No. 3, pp. 201-204.
Publisher: EXPANSION SCI FRANCAISE, 31 BLVD LATOUR MAUBOURG, 75007 PARIS, FRANCE.
ISSN: 0369-8114.
DT Article; Journal
FS LIFE
LA French
REC Reference Count: 10
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 433 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 97:84096 SCISEARCH
GA The Genuine Article (R) Number: WC725
TI Stent endothelialization - Time course, impact of local catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition
AU VanBelle E; Tio F O; Couffinhal T; Maillard L; Passeri J; Isner J M (Reprint)
CS TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED CARDIOL, 736 CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT MED CARDIOL, BOSTON, MA 02135; TUFTS UNIV, SCH MED, ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02135; UNIV TEXAS, DEPT PATHOL, SAN ANTONIO, TX 78285
CYA USA
SO CIRCULATION, (***21 JAN 1997***) Vol. 95, No. 2, pp. 438-448.
Publisher: AMER HEART ASSOC, 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596.
ISSN: 0009-7322.
DT Article; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 56
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 434 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 96:381304 SCISEARCH
GA The Genuine Article (R) Number: UK351
TI VASCULAR ENDOTHELIAL GROWTH-FACTOR ADMINISTRATION IN CHRONIC

AU HARADA K; FRIEDMAN M; LOPEZ J J; WANG S Y; LI J; PRASAD P V; PEARLMAN J D; EDELMAN E R; SELLKE F W; SIMONS M (Reprint)
CS HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD THORNDIKE LAB, BOSTON, MA, 02215 (Reprint); HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, CARDIOVASC DIV, HARVARD THORNDIKE LAB, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT SURG, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIOL, BOSTON, MA, 02215; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, CHARLES A DANA RES INST, VASC BIOL UNIT, BOSTON, MA, 02215; MIT, PROGRAM HLTH SCI & TECHNOL, CAMBRIDGE, MA, 02139
CYA USA
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, (***MAY*** 1996***) Vol. 39, No. 5, pp. H1791-H1802.
ISSN: 0363-6135.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 435 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 95:835524 SCISEARCH
GA The Genuine Article (R) Number: TG800
TI EFFECTS OF CYTOMEGALOVIRUS-INFECTION ON GROWTH-FACTOR PRODUCTION IN ENDOTHELIAL-CELLS AND FIBROBLASTS
AU GARRETT J S; NARUS J C; BOHNSACK J F; CARLING D E; GRIEVES K G; WALDMAN W J; SHADDY R E (Reprint)
CS PRIMARY CHILDRENS MED CTR, DIV CARDIOL, 100 N MED DR, SALT LAKE CITY, UT, 84113 (Reprint); UNIV UTAH, SCH MED, DEPT PEDIAT, SALT LAKE CITY, UT, 84132; OHIO STATE UNIV, DEPT PATHOL, COLUMBUS, OH, 43210
CYA USA
SO PEDIATRIC RESEARCH, (***DEC 1995***) Vol. 38, No. 6, pp. 1003-1008.
ISSN: 0031-3998.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 43
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 436 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 95:283893 SCISEARCH
GA The Genuine Article (R) Number: QT280
TI ASSOCIATION OF ACIDIC FIBROBLAST GROWTH-FACTOR AND UNTREATED LOW-GRADE REJECTION WITH CARDIAC ALLOGRAFT VASCULOPATHY
AU ZHAO X M; CITRIN B S; MILLER G G (Reprint); FRIST W H; MERRILL W H; FISCHELL T A; ATKINSON J B; YEOH T K
CS VANDERBILT UNIV, SCH MED, DEPT MED, A3310 MED CTR N, NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT THORAC SURG, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT PATHOL, NASHVILLE, TN, 37232
CYA USA
SO TRANSPLANTATION, (***15 APR 1995***) Vol. 59, No. 7, pp. 1005-1010.
ISSN: 0041-1337.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 37
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

on STN
AN 95:189426 SCISEARCH
GA The Genuine Article (R) Number: QK225
TI CONFIRMATION OF ALTERNATIVELY SPLICED PLATELET-DERIVED GROWTH FACTOR-A CHAIN AND CORRELATION WITH EXPRESSION OF PDGF RECEPTOR-ALPHA IN HUMAN CARDIAC ALLOGRAFTS
AU ZHAO X M; FRIST W H; YEOH T K; MILLER G G (Reprint)
CS VANDERBILT UNIV, SCH MED, CTR VANDERBILT TRANSPLANT, DEPT MED, A3310 MED CTR N, NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, CTR VANDERBILT TRANSPLANT, DEPT MED, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT CARDIOTHORAC SURG, NASHVILLE, TN, 37232
CYA USA
SO TRANSPLANTATION, (***27 FEB 1995***) Vol. 59, No. 4, pp. 605-611.
ISSN: 0041-1337.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 48
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 438 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 94:580349 SCISEARCH
GA The Genuine Article (R) Number: PF354
TI MODIFICATION OF ALTERNATIVE MESSENGER-RNA SPLICING OF FIBROBLAST GROWTH-FACTOR RECEPTORS IN HUMAN CARDIAC ALLOGRAFTS DURING REJECTION
AU ZHAO X M; FRIST W H; YEOH T K; MILLER G G (Reprint)
CS VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, A3310 MED CTR N, NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT THORAC SURG, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN, 37232
CYA USA
SO JOURNAL OF CLINICAL INVESTIGATION, (***SEP 1994***) Vol. 94, No. 3, pp. 992-1003.
ISSN: 0021-9738.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 42
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 439 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 94:491287 SCISEARCH
GA The Genuine Article (R) Number: PA963
TI INDUCTION OF ACIDIC FIBROBLAST GROWTH-FACTOR AND FULL-LENGTH PLATELET-DERIVED GROWTH-FACTOR EXPRESSION IN HUMAN CARDIAC ALLOGRAFTS - ANALYSIS BY PCR, IN-SITU HYBRIDIZATION, AND IMMUNOHISTOCHEMISTRY
AU ZHAO X M; YEOH T K; FRIST W H; PORTERFIELD D L; MILLER G G (Reprint)
CS VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, A3310 MED CTR N, NASHVILLE, TN, 37232 (Reprint); VANDERBILT UNIV, SCH MED, VANDERBILT TRANSPLANT CTR, NASHVILLE, TN, 37232; VANDERBILT UNIV, SCH MED, DEPT THORAC SURG, NASHVILLE, TN, 37212; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN, 37212
CYA USA
SO CIRCULATION, (***AUG 1994***) Vol. 90, No. 2, pp. 677-685.
ISSN: 0009-7322.
DT Article; Journal
FS LIFE; CLIN
LA ENGLISH
REC Reference Count: 52

L5 ANSWER 440 OF 549 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation on STN
AN 93:718786 SCISEARCH
GA The Genuine Article (R) Number: MH951
TI THE EXPRESSION OF ACIDIC FIBROBLAST GROWTH-FACTOR (HEPARIN-BINDING GROWTH FACTOR-I) AND CYTOKINE GENES IN HUMAN CARDIAC ALLOGRAFTS AND T-CELLS
AU ZHAO X M; YEOH T K; HIEBERT M; FRIST W H; MILLER G G (Reprint)
CS VANDERBILT UNIV, SCH MED, DEPT MED, DIV INFECT DIS, NASHVILLE, TN, 37232; VANDERBILT TRANSPLANT CTR, DEPT THORAC SURG, NASHVILLE, TN, 37232
CYA USA
SO TRANSPLANTATION, (***NOV 1993***) Vol. 56, No. 5, pp. 1177-1182. ISSN: 0041-1337.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 43
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 441 OF 549 USPATFULL on STN
AN 2004:301964 USPATFULL
TI Compositions and methods for modulating expression within smooth muscle cells
IN Owens, Gary K., Earlysville, VA, United States
Mack, Christopher, Chapel Hill, NC, United States
Blank, Randall, Charlottesville, VA, United States
PA Setagon, Inc., Charlottesville, VA, United States (U.S. corporation)
PI US 6825035 B1 20041130
WO 2000024254 20000504 <--
AI US 2001-807757 20010417 (9)
WO 1999-US24972 19991022
20010417 PCT 371 date
PRAI US 1998-105330P 19981023 (60)
DT Utility
FS GRANTED
LN.CNT 3217
INCL INCLM: 435/325.000
INCLS: 536/024.100; 435/320.100; 800/013.000
NCL NCLM: 435/325.000
NCLS: 435/320.100; 536/024.100; 800/013.000
IC [7]
ICM: C12N005-10
ICS: C12N015-63; C07H021-04; A01K067-00
EXF 536/24.1; 435/320.1; 435/325; 800/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 442 OF 549 USPATFULL on STN
AN 2004:78898 USPATFULL
TI Detecting genetic predisposition to sight-threatening diabetic retinopathy
IN Duff, Gordon W., South Yorkshire, UNITED KINGDOM
Richardson, Patrick R. S., Litton Nr. Buxton, UNITED KINGDOM
Rennie, Ian G., Newbold, UNITED KINGDOM
PA Interleukin Genetics, Inc., Waltham, MA, United States (U.S. corporation)
PI US 6713253 B1 20040330
WO 9815653 19980416 <--
AI US 1998-37472 19980310 (9)
WO 1997-GB2790 19971009
PRAI GB 1996-21129 19961010
DT Utility
FS GRANTED

INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/023.500; 536/024.310; 536/024.330
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.500; 536/024.310; 536/024.330
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-04; C07H021-02
EXF 435/6; 435/91.2; 435/810; 536/23.5; 536/24.31; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 443 OF 549 USPATFULL on STN
AN 2003:190552 USPATFULL
TI Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
IN Schaper, Wolfgang, Bad Nauheim/Rodgen, GERMANY, FEDERAL REPUBLIC OF
Ito, Wulf D., Luneburg, GERMANY, FEDERAL REPUBLIC OF
PA Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Berlin, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6592862 B1 20030715
WO 9844953 19981015 <--
AI US 1999-402358 19991210 (9)
WO 1998-EP1891 19980401
PRAI EP 1997-105647 19970404
DT Utility
FS GRANTED
LN.CNT 1379
INCL INCLM: 424/085.100
INCLS: 514/002.000; 514/008.000; 514/012.000
NCL NCLM: 424/085.100
NCLS: 514/002.000; 514/008.000; 514/012.000
IC [7]
ICM: A61K038-19
EXF 424/85.1; 435/724; 514/12; 514/44; 514/2; 514/8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 444 OF 549 USPATFULL on STN
AN 2002:340044 USPATFULL
TI Expandable space frame
IN Stevens, Walter J., Mountain View, CA, United States
Springer, George S., Stanford, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA, United States (U.S. corporation)
PI US 6497724 B1 20021224
WO 9955257 19991104 <--
AI US 2000-674185 20001027 (9)
WO 1999-US9383 19990430
20001027 PCT 371 date
RLI Continuation-in-part of Ser. No. US 70476, now abandoned
DT Utility
FS GRANTED
LN.CNT 859
INCL INCLM: 623/001.150
INCLS: 623/001.160; 623/001.220
NCL NCLM: 623/001.150
NCLS: 623/001.160; 623/001.220
IC [7]
ICM: A61F002-06
EXF 623/1.15; 623/1.16; 623/1.2; 623/1.22; 606/213

L5 ANSWER 445 OF 549 USPATFULL on STN
AN 2002:263279 USPATFULL
TI Electrically mediated angiogenesis

Pertile, Terence, Blaine, MN, United States
Shapland, J. Edward, Shoreview, MN, United States
Hoek, John Vanden, Elk River, MN, United States
Walsh, Robert, Lakeville, MN, United States
PA EM Vascular, Inc., Shoreview, MN, United States (U.S. corporation)
PI US 6463323 B1 20021008
WO 2000027466 20000518 <--
AI US 2001-743836 20010521 (9)
WO 1999-US26834 19991112
20010521 PCT 371 date
PRAI US 1998-108080P 19981112 (60)
DT Utility
FS GRANTED
LN.CNT 1015
INCL INCLM: 607/002.000
NCL NCLM: 607/002.000
IC [7]
ICM: A61N001-00
EXF 600/9-15; 607/1; 607/2

L5 ANSWER 446 OF 549 USPATFULL on STN
AN 2002:129260 USPATFULL
TI Gene therapeutic treatment of blood vessel associated disorders
IN Varenne, Olivier Henry, Brussels, BELGIUM
Collen, Desire Jose, Winksele, BELGIUM
Janssens, Stefan Pierre, Heverlee, BELGIUM
PA Leuven Research & Development VZW, Leuven, BELGIUM (non-U.S. corporation)
Vlaams Interuniversitair Instituut voor Biotechnologie, Zwijnaarde, BELGIUM (non-U.S. corporation)
PI US 6398757 B1 20020604
WO 9834667 19980813 <--
AI US 1999-367014 19991026 (9)
WO 1998-EP723 19980209
19991026 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 773
INCL INCLM: 604/103.020
NCL NCLM: 604/103.020
IC [7]
ICM: A61M029-00
EXF 606/108; 606/194; 606/192; 604/103.01; 604/103.02; 604/183; 604/191

L5 ANSWER 447 OF 549 USPATFULL on STN
AN 2001:33286 USPATFULL
TI Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6197789 B1 20010306
WO 9640098 19961219 <--
AI US 1997-973570 19971205 (8)
WO 1996-US10211 19960607
19980908 PCT 371 date
19980908 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-478936, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1995-476735, filed on 7 Jun 1995, now patented, Pat. No. US 5595722 Continuation-in-part of

Ser. No. US 1995-486334, filed on 7 Jun 1995, now patented, Pat. No. US 5770609
DT Utility
FS Granted
LN.CNT 4577
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000; 514/866.000
IC [7]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/319; 514/324; 514/422; 514/428; 514/444; 514/448; 514/651; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 448 OF 549 USPATFULL on STN
AN 2000:174716 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6166090 20001226 <--
AI US 1997-965589 19971106 (8)
RLI Continuation of Ser. No. US 1994-242161, filed on 12 May 1994, now patented, Pat. No. US 5847007 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2490
INCL INCLM: 514/651.000
INCLS: 514/824.000
NCL NCLM: 514/651.000
NCLS: 514/824.000
IC [7]
ICM: A61K031-135
EXF 514/651; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 449 OF 549 USPATFULL on STN
AN 2000:167536 USPATFULL
TI Intracoronary stents containing quinazolinone derivatives
IN Nagler, Arnon, Jerusalam, Israel
Hazum, Eli, Rehovot, Israel
Geller, Ehud, Herzelia, Israel
Slavin, Shimon, Jerusalem, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Pines, Mark, Rehovot, Israel
PA Agricultural Research Org. Ministry of Agriculture (Gov.), Israel (non-U.S. government)
HadasitMedical Research Serv. & Devel. Ltd., Israel (non-U.S. government)
PI US 6159488 20001212 <--
AI US 1999-325198 19990603 (9)
RLI Continuation-in-part of Ser. No. US 1999-180498, filed on 29 Mar 1999 which is a continuation of Ser. No. WO 1997-US15254, filed on 14 Aug 1997
DT Utility
FS Granted

INCL INCLM: 424/423.000
INCLS: 424/422.000; 424/424.000; 424/473.000; 514/259.000
NCL NCLM: 424/423.000
NCLS: 424/422.000; 424/424.000; 424/473.000; 514/266.220
IC [7]
ICM: A61K031-505
EXF 424/422; 424/473; 424/423; 424/424; 514/259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 450 OF 549 USPATFULL on STN
AN 2000:167245 USPATFULL
TI Methods and apparatus for transvascular muscular revascularization and drug delivery
IN Ruiz, Carlos, 1747 N. Country La., Pasadena, CA, United States 91107
PI US 6159196 20001212 <--
AI US 1998-37590 19980309 (9)
DT Utility
FS Granted
LN.CNT 978
INCL INCLM: 604/500.000
INCLS: 604/046.000; 604/264.000
NCL NCLM: 604/500.000
NCLS: 604/046.000; 604/264.000
IC [7]
ICM: A61M031-00
EXF 604/20; 604/21; 604/22; 604/46; 604/48; 604/117; 604/264; 604/523; 604/528; 606/167; 606/170; 606/172; 606/181-186; 600/433-435; 600/585; 607/48

L5 ANSWER 451 OF 549 USPATFULL on STN
AN 2000:158570 USPATFULL
TI Method and system for myocardial identifier repair
IN Soykan, Orhan, New Brighton, MN, United States
Donovan, Maura G., St. Paul, MN, United States
PA Medtronic, Inc., Minneapolis, MN, United States (U.S. corporation)
PI US 6151525 20001121 <--
AI US 1998-145743 19980902 (9)
DT Utility
FS Granted
LN.CNT 1401
INCL INCLM: 607/050.000
INCLS: 607/003.000
NCL NCLM: 607/050.000
NCLS: 607/003.000
IC [7]
ICM: A61N001-08
EXF 607/50; 607/3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 452 OF 549 USPATFULL on STN
AN 2000:156701 USPATFULL
TI Local delivery of estrogen for angiogenesis
IN Ungs, Mark T., St. Paul, MN, United States
PA SciMed Life Systems, Inc., Maple Grove, MN, United States (U.S. corporation)
PI US 6149641 20001121 <--
AI US 1998-220985 19981223 (9)
RLI Continuation of Ser. No. US 1997-916430, filed on 21 Aug 1997, now patented, Pat. No. US 5866561
DT Utility
FS Granted
LN.CNT 250

INCLS: 604/507.000; 604/103.010; 604/103.020; 623/001.000
NCL NCLM: 604/501.000
NCLS: 604/103.010; 604/103.020; 604/507.000
IC [7]
ICM: A61N001-30
EXF 623/1; 604/21; 604/506-510; 604/501; 604/103.01-103.02

L5 ANSWER 453 OF 549 USPATFULL on STN
AN 2000:145865 USPATFULL
TI Targeted contrast agents for diagnostic and therapeutic use
IN Unger, Evan C., Tucson, AZ, United States
Fritz, Thomas A., Tucson, AZ, United States
Gertz, Edward W., Paradise Valley, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 6139819 20001031 <--
AI US 1997-932273 19970917 (8)
RLI Continuation-in-part of Ser. No. US 1996-660032, filed on 6 Jun 1996, now abandoned which is a continuation-in-part of Ser. No. US 1996-640464, filed on 1 May 1996, now abandoned which is a continuation-in-part of Ser. No. US 1995-497684, filed on 7 Jun 1995, now abandoned And a continuation-in-part of Ser. No. US 1996-666129, filed on 19 Jun 1996, now patented, Pat. No. US 6033645
DT Utility
FS Granted
LN.CNT 7523
INCL INCLM: 424/009.520
INCLS: 424/009.510; 424/450.000
NCL NCLM: 424/009.520
NCLS: 424/009.510; 424/450.000
IC [7]
ICM: A61B008-00
ICS: A61K009-127
EXF 424/9.52; 424/9.51; 424/9.5; 424/450; 424/812; 600/441; 600/458; 264/4.1; 427/2.14; 427/213.3; 428/402.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 454 OF 549 USPATFULL on STN
AN 2000:138360 USPATFULL
TI Hydroxyl-containing bicyclic compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6133274 20001017 <--
AI US 1996-756703 19961126 (8)
RLI Continuation of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1646
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
NCLS: 544/267.000
IC [7]
ICM: C07D473-04
ICS: A61K031-52
EXF 544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:138055 USPATFULL
TI Methods and compositions for diagnosis of hyperhomocysteinemia
IN Austin, Richard C., Ancaster, Canada
Hirsh, Jack, Hamilton, Canada
Weitz, Jeffrey I., Hamilton, Canada
PA Hamilton Civic Hospitals Research Development Inc., Canada (non-U.S. corporation)
PI US 6132965 20001017 <--
AI US 1998-16540 19980130 (9)
RLI Continuation of Ser. No. US 1996-582261, filed on 3 Jan 1996
DT Utility
FS Granted
LN.CNT 2529
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330
IC [7]
ICM: C07H021-04
ICS: C12Q001-68
EXF 435/6; 435/91.2; 536/23.1; 536/24.3; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 456 OF 549 USPATFULL on STN
AN 2000:131591 USPATFULL
TI Nucleic acid ligands of tissue target
IN Stephens, Andrew, Boulder, CO, United States
Gold, Larry, Boulder, CO, United States
Speck, Ulrich, Berlin, Germany, Federal Republic of
PA NeXstar Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)
PI US 6127119 20001003 <--
AI US 1997-976413 19971121 (8)
RLI Continuation-in-part of Ser. No. US 1995-433124, filed on 3 May 1995, now patented, Pat. No. US 5750342 which is a continuation-in-part of Ser. No. US 1991-714131, filed on 10 Jun 1991, now patented, Pat. No. US 5475096 which is a continuation-in-part of Ser. No. US 1990-536428, filed on 11 Jun 1990, now abandoned And a continuation-in-part of Ser. No. US 1992-964624, filed on 21 Oct 1992, now patented, Pat. No. US 5496938
DT Utility
FS Granted
LN.CNT 8538
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/024.300; 536/024.310; 536/025.400
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/024.300; 536/024.310; 536/025.400
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-02; C07H021-04
EXF 435/6; 435/91.2; 536/24.3; 536/24.31; 536/25.4; 514/44; 424/1.73; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 457 OF 549 USPATFULL on STN
AN 2000:128465 USPATFULL
TI Compositions and methods for treatment and diagnosis of cardiovascular disease
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

corporation)
PI US 6124433 20000926 <--
AI US 1997-944496 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5924
INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
IC [7]
ICM: C07K016-00
ICS: C12N015-00
EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 935/32; 935/52; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 458 OF 549 USPATFULL on STN
AN 2000:125551 USPATFULL
TI MRI imaging method and apparatus
IN Pearlman, Justin D., Brookline, MA, United States
PA Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States (U.S. corporation)
PI US 6121775 20000919 <--
AI US 1998-98175 19980616 (9)
DT Utility
FS Granted
LN.CNT 857
INCL INCLM: 324/309.000
INCLS: 324/318.000; 324/300.000; 128/653.000
NCL NCLM: 324/309.000
NCLS: 324/300.000; 324/318.000; 600/419.000
IC [7]
ICM: G01V003-00
EXF 324/309; 324/318; 324/300; 128/653; 600/410

L5 ANSWER 459 OF 549 USPATFULL on STN
AN 2000:125047 USPATFULL
TI Epoxide-containing compounds
IN Underiner, Gail, Brier, WA, United States
Klein, J. Peter, Vashon, WA, United States
Michnick, John, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
Kumar, Anil, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6121270 20000919 <--
AI US 1998-98473 19980617 (9)
RLI Division of Ser. No. US 1997-778563, filed on 3 Jan 1997 which is a continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-991655, filed on 16 Dec 1992, now abandoned
DT Utility
FS Granted
LN.CNT 3145
INCL INCLM: 514/263.000
INCLS: 544/263.000

NCLS: 544/263.000
IC [7]
ICM: A61K031-52
ICS: C07D473-04
EXF 544/267; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 460 OF 549 USPATFULL on STN
AN 2000:124300 USPATFULL
TI Apparatus and methods for stimulating revascularization and/or tissue growth
IN Saadat, Vahid, Redwood Shores, CA, United States
Ream, John H., San Jose, CA, United States
PA Angiotrax, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6120520 20000919 <--
AI US 1999-271094 19990317 (9)
RLI Continuation-in-part of Ser. No. US 1997-863791, filed on 27 May 1997, now patented, Pat. No. US 5931848 And a continuation-in-part of Ser. No. US 1997-863877, filed on 27 May 1997, now patented, Pat. No. US 5910150 And a continuation-in-part of Ser. No. US 1997-863925, filed on 27 May 1997, now patented, Pat. No. US 5941839
DT Utility
FS Granted
LN.CNT 682
INCL INCLM: 606/170.000
INCLS: 606/159.000; 606/046.000
NCL NCLM: 606/170.000
NCLS: 606/046.000; 606/159.000
IC [7]
ICM: A61B017-00
EXF 606/1; 606/7; 606/14; 606/46; 606/159; 606/170

L5 ANSWER 461 OF 549 USPATFULL on STN
AN 2000:121539 USPATFULL
TI Methods for regulating transcription factors
IN Qabar, Maher N., Redmond, WA, United States
McMillan, Michael K., Bellevue, WA, United States
Kahn, Michael S., Kirkland, WA, United States
Tulinsky, John E., Seattle, WA, United States
Ogbu, Cyprian O., Bellevue, WA, United States
Mathew, Jessymol, Bellevue, WA, United States
PA Molecumetics Ltd., Bellevue, WA, United States (U.S. corporation)
PI US 6117896 20000912 <--
AI US 1998-22934 19980212 (9)
RLI Continuation-in-part of Ser. No. US 1997-797915, filed on 10 Feb 1997, now abandoned And a continuation-in-part of Ser. No. US 692420
PRAI US 1997-47067P 19970519 (60)
DT Utility
FS Granted
LN.CNT 4501
INCL INCLM: 514/384.000
INCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
NCL NCLM: 514/384.000
NCLS: 514/248.000; 530/323.000; 530/332.000; 548/263.400
IC [7]
ICM: A61K031-41
ICS: C07K005-00; C07K007-00; C07K016-00; C07D249-12
EXF 514/248; 514/384; 530/332; 530/323; 548/263.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 462 OF 549 USPATFULL on STN
AN 2000:105913 USPATFULL

IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6103730 20000815 <--
AI US 1995-486264 19950607 (8)
RLI Continuation of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1702
INCL INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/270.000; 544/271.000; 544/272.000
NCL NCLM: 514/263.200
NCLS: 514/151.000; 514/210.210; 514/263.210; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/270.000; 544/271.000; 544/272.000
IC [7]
ICM: A61K031-522
ICS: C07D473-10
EXF 544/268; 544/269; 544/220; 544/271; 544/272; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 463 OF 549 USPATFULL on STN
AN 2000:102304 USPATFULL
TI Therapeutic compounds containing xanthinyl
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6100271 20000808 <--
AI US 1995-483871 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1986
INCL INCLM: 514/263.000
INCLS: 514/265.000; 544/268.000; 544/269.000; 544/271.000
NCL NCLM: 514/263.200
NCLS: 514/210.210; 514/234.200; 514/263.220; 514/263.230; 514/263.240; 514/263.350; 544/268.000; 544/269.000; 544/271.000
IC [7]
ICM: A61K031-522
ICS: C07D473-10
EXF 544/271; 544/268; 544/269; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 464 OF 549 USPATFULL on STN
AN 2000:102275 USPATFULL
TI Gene therapies for enhancing cardiac function
IN Hammond, H. Kirk, La Jolla, CA, United States
Giordano, Frank J., Del Mar, CA, United States
Dillmann, Wolfgang H., Solana Beach, CA, United States4)
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6100242 20000808 <--
WO 9626742 19960906 <--
AI US 1997-722271 19971229 (8)

19971229 PCT 371 date
19971229 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1995-485472, filed on 7 Jun 1995, now patented, Pat. No. US 5792453, issued on 11 Aug 1998 which is a continuation-in-part of Ser. No. US 1995-396207, filed on 28 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1586
INCL INCLM: 514/044.000
INCLS: 424/093.210; 435/320.100
NCL NCLM: 514/044.000
NCLS: 424/093.210; 435/320.100
IC [7]
ICM: A61K048-00
EXF 424/93.21; 435/320.1; 435/455; 435/366; 536/23.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 465 OF 549 USPATFULL on STN
AN 2000:95042 USPATFULL
TI Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
IN Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PA Medinox Inc., San Diego, CA, United States (U.S. corporation)
PI US 6093743 20000725 <--
AI US 1998-103639 19980623 (9)
DT Utility
FS Granted
LN.CNT 2691
INCL INCLM: 514/599.000
INCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
NCL NCLM: 514/599.000
NCLS: 514/706.000; 514/707.000; 514/851.000; 514/861.000; 514/863.000; 514/866.000; 514/909.000; 514/912.000
IC [7]
ICM: A61K031-16
ICS: A61K031-095; A61K031-105
EXF 514/599; 514/706; 514/707; 514/851; 514/861; 514/863; 514/866; 514/909; 514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 466 OF 549 USPATFULL on STN
AN 2000:91735 USPATFULL
TI Interferon responsive transcript (IRT-1)
IN Autieri, Michael V., Blue Bell, PA, United States
PA Temple University of the Commonwealth System of Higher Education, Philadelphia, PA, United States (U.S. corporation)
PI US 6090580 20000718 <--
AI US 1998-4171 19980102 (9)
DT Utility
FS Granted
LN.CNT 1142
INCL INCLM: 435/069.100
INCLS: 435/252.330; 435/325.000; 435/320.100; 530/350.000; 536/023.100; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/252.330; 435/320.100; 435/325.000; 530/350.000; 536/023.100; 536/023.500
IC [7]
ICM: C12P021-06

EXF 530/350; 536/23.5; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 467 OF 549 USPATFULL on STN
AN 2000:37806 USPATFULL
TI Methods for using therapeutic compounds containing xanthinyl
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6043250 20000328 <--
AI US 1995-472296 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
DT Utility
FS Granted
LN.CNT 2052
INCL INCLM: 514/263.000
NCL NCLM: 514/234.200
NCLS: 514/210.210; 514/263.200; 514/263.220; 514/263.230; 514/263.350
IC [7]
ICM: A61K003-52
EXF 514/263

L5 ANSWER 468 OF 549 USPATFULL on STN
AN 2000:34403 USPATFULL
TI Vascular endothelial growth factor 2
IN Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
Cao, Liang, South Horizons, Hong Kong
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6040157 20000321 <--
AI US 1998-42105 19980313 (9)
RLI Continuation-in-part of Ser. No. US 1997-999811, filed on 24 Dec 1997, now patented, Pat. No. US 5932540 which is a continuation-in-part of Ser. No. US 1997-824996, filed on 27 Mar 1997 And a continuation-in-part of Ser. No. US 1995-465968, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994
DT Utility
FS Granted
LN.CNT 5292
INCL INCLM: 435/069.400
INCLS: 435/007.100; 435/325.000; 435/243.000; 435/320.100; 536/023.510; 530/399.000
NCL NCLM: 435/069.400
NCLS: 435/007.100; 435/243.000; 435/320.100; 435/325.000; 530/399.000; 536/023.510
IC [7]
ICM: C12N015-18
ICS: C12N015-63; C12N001-21; C12N005-00
EXF 435/69.4; 435/320.1; 435/325; 435/243; 536/23.51; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 469 OF 549 USPATFULL on STN
AN 2000:12926 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States

corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6020463 20000201 <--
AI US 1997-944423 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995, now patented, Pat. No. US 5968770 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5972
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.100
IC [6]
ICM: C07K016-00
ICS: C12N015-00
EXF 435/320.1; 435/325; 435/69.1; 435/6; 536/23.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 470 OF 549 USPATFULL on STN
AN 2000:12925 USPATFULL
TI Nucleic acids encoding the hypoxia inducible factor-1
IN Semenza, Gregg L., Towson, MD, United States
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)
PI US 6020462 20000201 <--
AI US 1997-915213 19970820 (8)
RLI Division of Ser. No. US 1995-480473, filed on 6 Jun 1995, now patented, Pat. No. US 5882914
DT Utility
FS Granted
LN.CNT 2956
INCL INCLM: 530/350.000
INCLS: 536/023.500
NCL NCLM: 530/350.000
NCLS: 536/023.500
IC [6]
ICM: C07K014-435
ICS: C12N015-12
EXF 530/350; 514/2; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 471 OF 549 USPATFULL on STN
AN 2000:12800 USPATFULL
TI Electronegative-substituted long chain xanthine compounds
IN Leigh, Alistair J., Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil M., Seattle, WA, United States
Klein, J. Peter, Vashon, WA, United States
Underiner, Gail, Malvern, PA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6020337 20000201 <--
AI US 1997-950810 19970916 (8)
RLI Continuation-in-part of Ser. No. US 1993-42946, filed on 5 Apr 1993, now patented, Pat. No. US 5670506 And a continuation-in-part of Ser. No. US 1997-910579, filed on 26 Jul 1997
DT Utility
FS Granted

INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/263.340
NCLS: 514/210.210; 514/263.360; 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 514/258; 544/267; 544/272; 544/277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 472 OF 549 USPATFULL on STN
AN 2000:10014 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target
IN Falb, Dean A., Wellesley, MA, United States
Gimbrone, Jr., Michael A., Jamaica Plain, MA, United States
PA Millenium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 6018025 20000125 <--
AI US 1997-944868 19971006 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996, now patented, Pat. No. US 5882925 which is a continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 6133
INCL INCLM: 530/350.000
INCLS: 530/324.000; 530/326.000; 536/023.100; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/324.000; 530/326.000; 536/023.100; 536/023.500
IC [6]
ICM: C07K016-00
ICS: C12N015-00
EXF 536/23.1; 536/24.1; 536/24.3; 536/23.5; 435/6; 435/810; 435/69.1; 435/7.1; 435/172.3; 435/320.1; 435/325; 436/501; 436/63; 935/32; 935/52; 935/77; 530/350; 530/325; 530/326
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 473 OF 549 USPATFULL on STN
AN 2000:4941 USPATFULL
TI ***VEGF*** .sub.145 expression vectors
IN Neufeld, Gera, Haifa, Israel
Keshet, Eli, Kiryat Yam, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Poltorak, Zoya, Jerusalem, Israel
PA Technion Research & Development Co. Ltd., Haifa, Israel (non-U.S. corporation)
PI US 6013780 20000111 <--
AI US 1997-784551 19970121 (8)
PRAI US 1996-25537P 19960906 (60)
DT Utility
FS Granted
LN.CNT 2158
INCL INCLM: 536/023.100
INCLS: 435/320.100
NCL NCLM: 536/023.100
NCLS: 435/320.100

ICM: C07H021-04
ICS: C12N015-11; C12N015-63
EXF 514/44; 435/172.3; 435/320.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 474 OF 549 USPATFULL on STN
AN 1999:159127 USPATFULL
TI Minimally invasive gene therapy delivery device and method
IN Rosengart, Todd K., Tenafly, NJ, United States
Crystal, Ronald G., Potomac, MD, United States
Hartman, Raymond A., Carlsbad, CA, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 5997509 19991207 <--
AI US 1998-35892 19980306 (9)
DT Utility
FS Granted
LN.CNT 543
INCL INCLM: 604/164.000
INCLS: 604/116.000; 604/181.000; 604/187.000
NCL NCLM: 604/164.010
NCLS: 604/116.000; 604/181.000; 604/187.000
IC [6]
ICM: A61M005-178
ICS: A61M005-00
EXF 604/1; 604/95; 604/115; 604/116; 604/117; 604/181; 604/188; 604/187; 604/164; 604/207; 604/208; 604/211; 604/218; 604/246; 604/264; 604/272

L5 ANSWER 475 OF 549 USPATFULL on STN
AN 1999:151195 USPATFULL
TI GATA-6 transcription factor: compositions and methods
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5990092 19991123 <--
AI US 1997-927394 19970827 (8)
DT Utility
FS Granted
LN.CNT 2449
INCL INCLM: 514/044.000
INCLS: 435/320.100; 536/023.500
NCL NCLM: 514/044.000
NCLS: 435/320.100; 536/023.500
IC [6]
ICM: A61K048-00
ICS: C12N015-12; C12N015-85
EXF 435/320.1; 435/375; 435/377; 514/44; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 476 OF 549 USPATFULL on STN
AN 1999:150350 USPATFULL
TI Method and apparatus for therapeutic laser treatment
IN Prescott, Marvin A., 833 Moraga Dr, Suite 15, Los Angeles, CA, United States 90049
PI US 5989245 19991123 <--
AI US 1997-829247 19970331 (8)
RLI Continuation-in-part of Ser. No. US 1994-215263, filed on 21 Mar 1994, now patented, Pat. No. US 5616140 which is a continuation-in-part of Ser. No. US 1996-703488, filed on 26 Aug 1996, now patented, Pat. No. US 5814039
DT Utility
FS Granted

INCL INCLM: 606/014.000
INCLS: 607/089.000
NCL NCLM: 606/014.000
NCLS: 607/089.000
IC [6]
ICM: A61B017-36
EXF 606/2; 606/3; 606/7; 606/10-14; 606/27; 606/28; 607/88; 607/89; 607/92; 604/20; 604/21

L5 ANSWER 477 OF 549 USPATFULL on STN
AN 1999:132529 USPATFULL
TI Fluorescence-based assays for measuring cell proliferation
IN Parandoosh, Zahra, San Diego, CA, United States
PA Irori, La Jolla, CA, United States (U.S. corporation)
PI US 5972639 19991026 <--
AI US 1997-901229 19970724 (8)
DT Utility
FS Granted
LN.CNT 1358
INCL INCLM: 435/029.000
NCL NCLM: 435/029.000
IC [6]
ICM: C12Q001-02
EXF 435/6; 435/7.1; 435/7.4; 435/7.72; 435/21; 435/29; 435/195; 435/196; 435/375; 935/66; 935/76
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 478 OF 549 USPATFULL on STN
AN 1999:124900 USPATFULL
TI Enantiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5965564 19991012 <--
AI US 1998-44976 19980320 (9)
RLI Continuation of Ser. No. US 1995-457703, filed on 1 Jun 1995, now patented, Pat. No. US 5739138 which is a division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1770
INCL INCLM: 514/263.000
INCLS: 514/267.000; 514/270.000; 514/271.000
NCL NCLM: 514/263.360
NCLS: 514/265.100; 514/267.000; 514/270.000; 514/271.000
IC [6]
ICM: A61K031-52
EXF 514/263; 514/262; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 479 OF 549 USPATFULL on STN
AN 1999:120365 USPATFULL
TI Use of hollow microcapsules in diagnosis and therapy
IN Kaul, Sanjiv, Charlottesville, VA, United States

PA Andaris Limited, United Kingdom (non-U.S. corporation)
PI US 5961459 19991005 <--
AI US 1997-953513 19971017 (8)
PRAI GB 1996-21826 19961019
GB 1996-21833 19961019
DT Utility
FS Granted
LN.CNT 565
INCL INCLM: 600/439.000
NCL NCLM: 600/439.000
IC [6]
ICM: A61B008-00
EXF 600/439; 600/458; 600/462; 600/463; 600/466; 600/467; 600/469; 607/105; 607/120; 424/9.5; 424/9.51; 424/9.52

L5 ANSWER 480 OF 549 USPATFULL on STN
AN 1999:99016 USPATFULL
TI Localized intravascular delivery of growth factors for promotion of angiogenesis
IN Kaplan, Aaron V., Los Altos, CA, United States
Simons, Michael, Chestnut Hill, MA, United States
PA Localmed, Inc., Palo Alto, CA, United States (U.S. corporation)
Beth Israel Deaconess Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5941868 19990824 <--
AI US 1996-753224 19961122 (8)
PRAI US 1995-9086P 19951222 (60)
DT Utility
FS Granted
LN.CNT 544
INCL INCLM: 604/500.000
NCL NCLM: 604/500.000
IC [6]
ICM: A61M031-00
EXF 604/96; 604/101; 604/99; 604/265; 604/266; 604/890.1; 604/892.1; 604/52; 604/53; 606/192; 606/194

L5 ANSWER 481 OF 549 USPATFULL on STN
AN 1999:92656 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Weisz, Paul B., State College, PA, United States
PA Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5935940 19990810 <--
AI US 1997-906500 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1497
INCL INCLM: 514/058.000
INCLS: 514/021.000; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/812.000; 530/813.000
IC [6]

ICS: A61K038-00
EXF 514/58; 514/21; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 482 OF 549 USPATFULL on STN
AN 1999:89116 USPATFULL
TI Vascular endothelial growth factor 2
IN Hu, Jing-Shan, Sunnyvale, CA, United States
Rosen, Craig A., Laytonsville, MD, United States
Cao, Liang, Hong Kong, Hong Kong
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 5932540 19990803 <--
AI US 1997-999811 19971224 (8)
RLI Continuation-in-part of Ser. No. US 1994-207550, filed on 8 Mar 1994, now abandoned And Ser. No. US 1995-465968, filed on 6 Jun 1995
DT Utility
FS Granted
LN.CNT 2605
INCL INCLM: 514/002.000
INCLS: 530/326.000; 530/399.000; 530/402.000
NCL NCLM: 514/002.000
NCLS: 530/326.000; 530/399.000; 530/402.000
IC [6]
ICM: A61K038-14
ICS: C07K014-475
EXF 514/2; 514/12; 530/399; 530/326; 530/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 483 OF 549 USPATFULL on STN
AN 1999:56471 USPATFULL
TI Methods of modulating tissue growth and regeneration
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5902799 19990511 <--
AI US 1997-906501 19970805 (8)
RLI Division of Ser. No. US 1994-345011, filed on 23 Nov 1994, now patented, Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809
DT Utility
FS Granted
LN.CNT 1703
INCL INCLM: 514/058.000
INCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 530/810.000; 530/813.000; 530/817.000
IC [6]
ICM: A61K031-715
ICS: A61K031-735
EXF 514/58; 514/21; 514/56; 530/810; 530/812; 530/813; 530/817
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 484 OF 549 USPATFULL on STN

TI Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
IN Nagler, Arnon, Jerusalem, Israel
Slavin, Shimon, Jerusalem, Israel
Vlodavsky, Israel, Mevaseret Zion, Israel
Pines, Mark, Rehovot, Israel
PA Hadasit Medical Research Services & Development Co., Inc., Jerusalem, Israel (non-U.S. corporation)
Agricultural Organization Ministry of Agriculture State of Israel, Bet Dagan, Israel (non-U.S. corporation)
PI US 5891879 19990406 <--
WO 9606616 19960307 <--
AI US 1996-722046 19961209 (8)
WO 1995-US11186 19950829
19961209 PCT 371 date
19961209 PCT 102(e) date
PRAI IL 1994-110831 19940831
DT Utility
FS Granted
LN.CNT 436
INCL INCLM: 514/259.000
NCL NCLM: 514/266.220
IC [6]
ICM: A61K031-505
EXF 514/259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 485 OF 549 USPATFULL on STN
AN 1999:40428 USPATFULL
TI Substituted amino alkyl compounds
IN Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5889011 19990330 <--
AI US 1997-884037 19970627 (8)
RLI Continuation of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813
DT Utility
FS Granted
LN.CNT 1351
INCL INCLM: 514/263.000
INCLS: 514/261.000; 544/267.000; 544/264.000; 544/265.000
NCL NCLM: 514/263.350
NCLS: 544/264.000; 544/265.000; 544/267.000
IC [6]
ICM: C07D473-00
ICS: A61K031-52
EXF 544/257; 544/267; 544/263; 544/285; 544/287; 514/263; 514/261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 486 OF 549 USPATFULL on STN
AN 1999:40187 USPATFULL
TI Endothelial-cell specific promoter
IN Patterson, Winston Campbell, Brighton, MA, United States
Lee, Mu-En, Newton, MA, United States
Haber, Edgar, Salisbury, NH, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 5888765 19990330 <--
AI US 1995-494282 19950623 (8)

FS Granted
LN.CNT 1003
INCL INCLM: 435/069.100
INCLS: 435/172.300; 435/320.100; 435/325.000; 536/024.100; 536/023.100
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 435/455.000; 536/023.100; 536/024.100
IC [6]
ICM: C12N015-09
ICS: C12N015-11; C12N015-79; C12N015-85
EXF 435/69.1; 435/325; 435/320.1; 435/172.3; 536/24.1; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 487 OF 549 USPATFULL on STN
AN 1999:33831 USPATFULL
TI Compositions and method for the treatment and diagnosis of cardiovascular disease using rchd502 as a target
IN Falb, Dean A., Wellesley, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5882925 19990316 <--
AI US 1996-599654 19960209 (8)
RLI Continuation-in-part of Ser. No. US 1995-485573, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5758
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000
NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300
IC [6]
ICM: C12N015-12
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/325; 435/320.1; 435/455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 488 OF 549 USPATFULL on STN
AN 1999:33821 USPATFULL
TI Nucleic acids encoding the hypoxia inducible factor-1
IN Semenza, Gregg L., Towson, MD, United States
PA The Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)
PI US 5882914 19990316 <--
AI US 1995-480473 19950606 (8)
DT Utility
FS Granted
LN.CNT 2493
INCL INCLM: 435/252.300
INCLS: 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 435/252.300
NCLS: 435/320.100; 435/325.000; 536/023.500
IC [6]
ICM: C12N001-20
ICS: C12N015-63; C12N005-00; C07H021-04
EXF 435/325; 435/252.3; 435/320.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 489 OF 549 USPATFULL on STN
AN 1999:27739 USPATFULL

IN Quertermous, Thomas, Nashville, TN, United States
Hogan, Brigid, Brentwood, TN, United States
Snodgrass, H. Ralph, Powell, OH, United States
Zupancic, Thomas Joel, Worthington, OH, United States
PA Progenitor, Inc., Menlo Park, CA, United States (U.S. corporation)
Vanderbilt University, Nashville, TN, United States (U.S. corporation)
PI US 5877281 19990302 <--
AI US 1996-659235 19960605 (8)
RLI Continuation-in-part of Ser. No. US 1995-480229, filed on 7 Jun 1995
DT Utility
FS Granted
LN.CNT 2861
INCL INCLM: 530/350.000
INCLS: 530/402.000; 530/300.000; 530/383.000; 435/069.700; 536/023.100; 536/023.400; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.700; 530/300.000; 530/383.000; 530/402.000; 536/023.100; 536/023.400; 536/023.500
IC [6]
ICM: C07K014-435
ICS: C07K014-485; C07K014-755; C12N015-11
EXF 530/350; 530/402; 530/300; 530/383; 435/69.7; 536/23.1; 536/23.4; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 490 OF 549 USPATFULL on STN
AN 1999:24778 USPATFULL
TI Nucleic acid encoding developmentally-regulated endothelial cell locus-1
IN Quertermous, Thomas, Nashville, TN, United States
Hogan, Bridgid, Brentwood, TN, United States
Snodgrass, H. Ralph, Powell, OH, United States
Zupancic, Thomas Joel, Worthington, OH, United States
PA Progenitor, Inc., Menlo Park, CA, United States (U.S. corporation)
Vanderbilt University, Nashville, TN, United States (U.S. corporation)
PI US 5874562 19990223 <--
AI US 1995-480229 19950607 (8)
DT Utility
FS Granted
LN.CNT 2266
INCL INCLM: 536/023.500
INCLS: 536/023.400; 435/069.100; 435/320.100; 435/325.000; 435/252.300; 435/254.110; 530/350.000
NCL NCLM: 536/023.500
NCLS: 435/069.100; 435/252.300; 435/254.110; 435/320.100; 435/325.000; 530/350.000; 536/023.400
IC [6]
ICM: C12N015-12
ICS: C12N005-10; C12N015-63
EXF 435/69.1; 435/325; 435/410; 435/25.3; 435/254.11; 435/320.1; 536/23.4; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 491 OF 549 USPATFULL on STN
AN 1999:24638 USPATFULL
TI Compositions and methods for modulating growth of a tissue in a mammal
IN Herrmann, Howard C., Bryn Mawr, PA, United States
Barnathan, Elliot, Havertown, PA, United States
Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)
PI US 5874419 19990223 <--
AI US 1997-905612 19970804 (8)

Pat. No. US 5658894 which is a continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US 20 -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1482
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000; 424/652.000; 424/682.000; 424/617.000; 536/103.000
NCL NCLM: 514/058.000
NCLS: 424/617.000; 424/652.000; 424/682.000; 514/021.000; 514/023.000; 514/054.000; 514/060.000; 514/769.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: A61K047-02; C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 514/769; 536/103; 424/652; 424/682; 424/617
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 492 OF 549 USPATFULL on STN
AN 1999:15930 USPATFULL
TI Epoxide-containing compounds
IN Underiner, Gail, Brier, WA, United States
Klein, J. Peter, Vashon, WA, United States
Michnick, John, Seattle, WA, United States
Leigh, Alistair, Brier, WA, United States
Kumar, Anil, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5866576 19990202 <--
AI US 1997-778563 19970103 (8)
RLI Continuation of Ser. No. US 1993-167600, filed on 13 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-991655, filed on 16 Dec 1992, now abandoned
DT Utility
FS Granted
LN.CNT 3141
INCL INCLM: 514/256.000
INCLS: 514/396.000; 514/263.000; 544/242.000; 548/300.100; 548/311.100
NCL NCLM: 514/256.000
NCLS: 514/262.100; 514/263.230; 514/396.000; 544/242.000; 548/300.100; 548/311.100
IC [6]
ICM: A61K031-505
ICS: C07D239-02
EXF 544/269; 544/266; 544/267; 544/268; 544/270; 544/272; 544/273; 544/271; 544/242; 514/263; 514/256; 548/300.1; 548/311.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 493 OF 549 USPATFULL on STN
AN 1999:15915 USPATFULL
TI Local delivery of estrogen for angiogenesis
IN Ungs, Mark T., St. Paul, MN, United States
PA SciMed Life Systems, Inc., Maple Grove, MN, United States (U.S. corporation)
PI US 5866561 19990202 <--
AI US 1997-916430 19970821 (8)
DT Utility

LN.CNT 229
INCL INCLM: 514/182.000
INCLS: 604/096.000
NCL NCLM: 514/182.000
NCLS: 604/096.010
IC [6]
ICM: A61K031-56
EXF 514/182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 494 OF 549 USPATFULL on STN
AN 1999:4647 USPATFULL
TI Fas ligand compositions for treatment of proliferative disorders
IN Walsh, Kenneth, Carlisle, MA, United States
PA St. Elizabeth's Medical Center, Boston, MA, United States (U.S. corporation)
PI US 5858990 19990112 <--
AI US 1997-810453 19970304 (8)
DT Utility
FS Granted
LN.CNT 3038
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/172.100; 435/320.100; 435/069.100; 435/375.000; 435/377.000
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/375.000; 435/377.000
IC [6]
ICM: A61K048-00
ICS: C12N015-11
EXF 435/6; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/69.1; 435/31.1; 435/375; 435/377; 536/23.1; 536/23.5; 514/2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 495 OF 549 USPATFULL on STN
AN 1998:157185 USPATFULL
TI Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target
IN Falb, Dean A., Massachusetts, MA, United States
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 5849578 19981215 <--
AI US 1996-616844 19960315 (8)
RLI Division of Ser. No. US 1996-599654, filed on 9 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-458873, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1995-386844, filed on 10 Feb 1995
DT Utility
FS Granted
LN.CNT 5753
INCL INCLM: 435/325.000
INCLS: 536/023.100; 536/024.100; 536/024.300; 435/006.000; 435/069.100; 435/320.100; 435/455.000
NCL NCLM: 435/325.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/455.000; 536/023.100; 536/024.100; 536/024.300
IC [6]
ICM: C12N015-12
EXF 536/23.1; 536/24.1; 536/24.3; 435/6; 435/69.1; 435/7.1; 435/325; 435/320.1; 435/455; 436/201; 436/63; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 496 OF 549 USPATFULL on STN

TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
Weissberg, Peter L., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5847007 19981208 <--
AI US 1994-242161 19940512 (8)
RLI Continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2429
INCL INCLM: 514/651.000
INCLS: 514/824.000
NCL NCLM: 514/651.000
NCLS: 514/824.000
IC [6]
ICM: A61K031-135
EXF 514/56; 514/651; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 497 OF 549 USPATFULL on STN
AN 1998:154038 USPATFULL
TI Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease
IN Foulkes, J. Gordon, Huntington Station, NY, United States
Liechtfried, Franz E., Vienna, Austria
Pieler, Christian, Vienna, Austria
Stephenson, John R., Santa Cruz, CA, United States
Case, Casey C., Lynbrook, NY, United States
PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)
PI US 5846720 19981208 <--
AI US 1996-700757 19960815 (8)
RLI Continuation of Ser. No. US 1992-832905, filed on 7 Feb 1992, now patented, Pat. No. US 5580722 which is a continuation-in-part of Ser. No. US 1990-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-382712, filed on 18 Jul 1989, now abandoned
DT Utility
FS Granted
LN.CNT 3998
INCL INCLM: 435/006.000
INCLS: 435/069.800; 435/091.500; 435/320.100; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/069.800; 435/091.500; 435/320.100
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; C12N015-85; C07H021-04
EXF 435/6; 435/91.5; 435/69.8; 435/320.1; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 498 OF 549 USPATFULL on STN
AN 1998:153557 USPATFULL
TI Gene transfer therapy delivery device and method
IN Rosengart, Todd K., Tenafly, NJ, United States
Hartman, Raymond A., Carlsbad, CA, United States
Mack, III, Charles A., New York, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 5846225 19981208 <--
AI US 1997-801352 19970219 (8)

FS Granted
LN.CNT 571
INCL INCLM: 604/115.000
INCLS: 604/191.000
NCL NCLM: 604/115.000
NCLS: 604/191.000
IC [6]
ICM: A61M005-00
EXF 604/131; 604/115; 604/134; 604/135; 604/136; 604/137; 604/191; 222/330; 222/548
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 499 OF 549 USPATFULL on STN
AN 1998:144102 USPATFULL
TI Amino-alcohol substituted cyclic compounds
IN Kumar, Anil M., Seattle, WA, United States
Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5837703 19981117 <--
AI US 1993-152650 19931112 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000; 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000; 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
NCL NCLM: 514/183.000
NCLS: 514/211.150; 514/228.800; 514/241.000; 514/242.000; 514/249.000; 514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000; 514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000; 514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000; 540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000; 544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000; 546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000; 548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000
IC [6]
ICM: A61K031-55
ICS: A61K031-515; A61K031-445; A61K031-52
EXF 544/276; 544/272; 544/216; 544/257; 544/285; 544/286; 544/301; 544/311; 544/335; 514/263; 514/183; 514/211; 514/228.8; 514/241; 514/242; 514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315; 514/348; 514/357; 514/374; 514/400; 514/418; 514/425; 514/427; 540/467; 540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334; 548/215; 548/340.1; 548/485; 548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 500 OF 549 USPATFULL on STN
AN 1998:143321 USPATFULL
TI Apparatus and methods for gene therapy
IN Lemelson, Jerome H., Suite 286, Unit 802, 930 Tahoe Blvd., Incline Village, NV, United States 89451

60035
PI US 5836905 19981117 <--
AI US 1996-775047 19961227 (8)
RLI Continuation of Ser. No. US 1994-262581, filed on 20 Jun 1994, now abandoned
DT Utility
FS Granted
LN.CNT 562
INCL INCLM: 604/021.000
INCLS: 604/102.000; 606/015.000; 607/116.000
NCL NCLM: 604/021.000
NCLS: 604/101.050; 606/015.000; 607/116.000
IC [6]
ICM: A61N001-30
EXF 604/15; 604/16; 604/20; 604/21; 604/41; 604/51-53; 604/102; 604/104; 604/163; 604/171; 604/264; 607/116; 607/89; 935/52-54; 935/85; 600/115; 600/373; 606/15; 606/16

L5 ANSWER 501 OF 549 USPATFULL on STN
AN 1998:128265 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5824677 19981020 <--
AI US 1995-474816 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 , said Ser. No. US -152650 And Ser. No. US -164081 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3136
INCL INCLM: 514/222.500
INCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000; 514/249.000; 514/255.000; 514/258.000; 514/274.000; 514/301.000; 514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000; 514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/433.000; 514/452.000; 514/432.000; 514/438.000; 346/113.000; 346/114.000; 346/164.000; 346/300.000; 549/014.000; 549/050.000; 549/075.000; 549/367.000; 549/368.000; 544/002.000; 544/003.000; 544/005.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/127.000; 544/128.000; 544/162.000; 544/215.000; 544/219.000; 544/229.000; 544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000; 544/353.000; 544/385.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000; 548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000; 548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000; 548/486.000; 548/543.000; 548/546.000
NCL NCLM: 514/222.500
NCLS: 514/223.500; 514/224.500; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/248.000;

514/303.000; 514/311.000; 514/351.000; 514/360.000; 514/361.000;
514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000;
514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000;
514/378.000; 514/379.000; 514/380.000; 514/387.000; 514/395.000;
514/415.000; 514/418.000; 514/424.000; 514/425.000; 514/432.000;
514/433.000; 514/438.000; 514/452.000; 544/002.000; 544/003.000;
544/005.000; 544/008.000; 544/053.000; 544/063.000; 544/065.000;
544/066.000; 544/067.000; 544/090.000; 544/091.000; 544/127.000;
544/128.000; 544/162.000; 544/215.000; 544/219.000; 544/229.000;
544/235.000; 544/237.000; 544/255.000; 544/278.000; 544/311.000;
544/353.000; 544/385.000; 546/113.000; 546/114.000; 546/164.000;
546/300.000; 548/123.000; 548/125.000; 548/131.000; 548/134.000;
548/143.000; 548/146.000; 548/153.000; 548/174.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/228.000;
548/229.000; 548/237.000; 548/240.000; 548/241.000; 548/243.000;
548/247.000; 548/267.200; 548/303.700; 548/307.100; 548/453.000;
548/486.000; 548/543.000; 548/546.000; 549/014.000; 549/050.000;
549/075.000; 549/367.000; 549/368.000

IC [6]
ICM: A61K031-385
ICS: A61K031-445; A61K031-47; A61K031-505

EXF 549/75; 549/50; 549/14; 549/367; 549/368; 514/432; 514/438; 514/222.5;
514/223.5; 514/224.5; 514/226.8; 514/227.5; 514/228.8; 514/229.2;
514/230.5; 514/230.8; 514/237.8; 514/248; 514/249; 514/255; 514/258;
514/274; 514/301; 514/303; 514/311; 514/351; 514/360; 514/361; 514/362;
514/363; 514/364; 514/365; 514/367; 514/372; 514/373; 514/374; 514/375;
514/376; 514/378; 514/379; 514/380; 514/387; 514/395; 514/415; 514/418;
514/424; 514/425; 514/433; 514/452; 544/2; 544/3; 544/5; 544/8; 544/53;
544/63; 544/65; 544/66; 544/67; 544/90; 544/91; 544/127; 544/128;
544/162; 544/215; 544/219; 544/229; 544/235; 544/237; 544/255; 544/278;
544/311; 544/353; 544/385; 546/113; 546/114; 546/164; 546/300; 548/123;
548/125; 548/131; 548/134; 548/145; 548/146; 548/153; 548/174; 548/207;
548/214; 548/215; 548/217; 548/221; 548/228; 548/229; 548/237; 548/240;
548/241; 548/243; 548/247; 548/267.2; 548/303.7; 548/307.1; 548/453;
548/486; 548/543; 548/546

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 502 OF 549 USPATFULL on STN
AN 1998:128232 USPATFULL
TI Method of attenuating arterial stenosis
IN Abendschein, Dana R., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5824644 19981020 <--
AI US 1996-675122 19960703 (8)
RLI Continuation-in-part of Ser. No. US 1996-648777, filed on 16 May 1996,
now abandoned which is a continuation-in-part of Ser. No. US
1994-271930, filed on 7 Jul 1994, now abandoned
DT Utility
FS Granted
LN.CNT 679
INCL INCLM: 514/012.000
INCLS: 514/002.000; 514/021.000; 530/324.000; 530/350.000; 530/380.000;
424/422.000
NCL NCLM: 514/012.000
NCLS: 424/422.000; 514/002.000; 514/021.000; 530/324.000; 530/350.000;
530/380.000
IC [6]
ICM: A61K038-00
ICS: C07K014-00; A61F013-00
EXF 514/12; 514/2; 514/21; 530/350; 530/324; 530/380; 424/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:122413 USPATFULL
TI Substituted amino alkyl compounds
IN Klein, J. Peter, Vashon Island, WA, United States
Underiner, Gail E., Brier, WA, United States
Leigh, Alistair J., Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5817662 19981006 <--
AI US 1995-468656 19950606 (8)
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9 Nov 1992, now patented, Pat. No. US 5340813
DT Utility
FS Granted
LN.CNT 1358
INCL INCLM: 514/263.000
INCLS: 424/824.000; 424/825.000; 424/885.000; 424/921.000
NCL NCLM: 514/263.350
NCLS: 424/824.000; 424/825.000
IC [6]
ICM: A61K031-52
EXF 514/397; 514/263; 424/824; 424/825; 424/885; 424/921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 504 OF 549 USPATFULL on STN
AN 1998:122217 USPATFULL
TI Methods and compositions for diagnosis of hyperhomocysteinemia
IN Austin, Richard C., Ancaster, Canada
Hirsh, Jack, Hamilton, Canada
Weitz, Jeffrey I., Hamilton, Canada
PA Hamilton Civic Hospitals Research Development Inc., Hamilton, Canada (non-U.S. corporation)
PI US 5817461 19981006 <--
AI US 1996-582261 19960103 (8)
DT Utility
FS Granted
LN.CNT 2624
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330; 935/006.000; 935/017.000; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.100; 536/024.300; 536/024.330
IC [6]
ICM: C12Q001-68
ICS: C12P019-34; C07H021-04
EXF 435/6; 435/91.2; 435/7.1; 536/23.1; 536/24.3; 536/24.31; 536/24.33; 935/6; 935/8; 935/17; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 505 OF 549 USPATFULL on STN
AN 1998:111942 USPATFULL
TI Therapeutic compounds containing pyrimidinyl moieties
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair J., Brier, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807862 19980915 <--
AI US 1995-478112 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994, now abandoned
DT Utility
FS Granted

INCL INCLM: 514/269.000
INCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 544/309.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-54
EXF 514/269; 514/274; 544/309; 544/310; 544/311; 544/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 506 OF 549 USPATFULL on STN
AN 1998:111941 USPATFULL
TI Amine substituted xanthinyl compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
Rice, Glenn C., Seattle, WA, United States
Leung, David W., Mercer Island, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5807861 19980915 <--
AI US 1995-476911 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1713
INCL INCLM: 514/263.000
NCL NCLM: 514/263.350
NCLS: 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220; 514/263.230
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 507 OF 549 USPATFULL on STN
AN 1998:111649 USPATFULL
TI Methods of preventing degeneration of myoplasties
IN Mannion, John D., Mt. Laurel, NJ, United States
Magno, Michael G., Oxford, PA, United States
PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
PI US 5807556 19980915 <--
AI US 1996-683228 19960718 (8)
PRAI US 1995-1213P 19950718 (60)
DT Utility
FS Granted
LN.CNT 618
INCL INCLM: 424/198.100
INCLS: 514/056.000; 530/399.000; 536/021.000; 607/003.000; 607/050.000
NCL NCLM: 424/198.100
NCLS: 514/056.000; 530/399.000; 536/021.000; 607/003.000; 607/050.000
IC [6]
ICM: A61K038-18
ICS: C07K014-50; A61N001-18
EXF 514/12; 514/56; 424/548; 424/198.1; 530/399; 536/21; 607/3; 607/50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 508 OF 549 USPATFULL on STN
AN 1998:108415 USPATFULL
TI Therapeutic compounds containing a monocyclic five- to six- membered

IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5804584 19980908 <--
AI US 1995-468659 19950606 (8)
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1554
INCL INCLM: 514/269.000
INCLS: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000
NCL NCLM: 514/269.000
NCLS: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000
IC [6]
ICM: C07D239-54
ICS: A61K031-52
EXF 514/242; 514/243; 514/269; 544/298; 544/299
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 509 OF 549 USPATFULL on STN
AN 1998:104752 USPATFULL
TI Amine substituted compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
Ridgers, Lance H., Bothell, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801182 19980901 <--
AI US 1995-485777 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1706
INCL INCLM: 514/269.000
INCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
NCL NCLM: 514/269.000
NCLS: 514/274.000; 544/310.000; 544/311.000; 544/312.000
IC [6]
ICM: A61K031-505
ICS: C07D239-02
EXF 544/312; 514/269; 514/274; 514/310; 514/311
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 510 OF 549 USPATFULL on STN
AN 1998:104751 USPATFULL
TI Amino alcohol substituted cyclic compounds
IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5801181 19980901 <--
AI US 1995-474820 19950607 (8)
RLI Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993
DT Utility

LN.CNT 2822
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/249.000; 514/259.000; 514/274.000; 514/309.000; 514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000; 514/626.000; 514/668.000; 514/669.000
NCL NCLM: 514/263.350
NCLS: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000; 514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000; 514/626.000; 514/668.000; 514/669.000
IC [6]
ICM: A01N043-00
ICS: A01N043-90; A01N043-58; A01N043-42
EXF 514/263; 514/249; 514/259; 514/265; 514/274; 514/309; 514/315; 514/418; 514/425; 514/617; 514/619; 514/626; 514/668; 514/669
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 511 OF 549 USPATFULL on STN
AN 1998:95545 USPATFULL
TI Enatiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5792772 19980811 <--
AI US 1995-458957 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now patented, Pat. No. US 5652243 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now patented, Pat. No. US 5648357 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1734
INCL INCLM: 514/263.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 512 OF 549 USPATFULL on STN
AN 1998:95232 USPATFULL
TI Gene transfer-mediated angiogenesis therapy
IN Hammond, H. Kirk, La Jolla, CA, United States
Giordano, Frank J., Del Mar, CA, United States
Dillmann, Wolfgang H., Solana Beach, CA, United States4)
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5792453 19980811 <--
AI US 1995-485472 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-396207, filed on 28 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1161
INCL INCLM: 424/093.210
INCLS: 435/172.300; 435/320.100; 435/366.000; 536/023.500
NCL NCLM: 424/093.210
NCLS: 435/320.100; 435/366.000; 536/023.500

ICM: A01N063-00
EXF 435/320.1; 435/369; 435/93.1; 435/172.3; 435/366; 514/44; 424/93.21; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 513 OF 549 USPATFULL on STN
AN 1998:88470 USPATFULL
TI ***VEGF*** gene transfer into endothelial cells for vascular prosthesis
IN Pratt, Richard E., Palo Alto, CA, United States
Dzau, Victor J., Los Altos Hills, CA, United States
PA The Board of Trustees of the Leland Stanford Junior Univ., Palo Alto, CA, United States (U.S. corporation)
PI US 5785965 19980728 <--
AI US 1996-647821 19960515 (8)
DT Utility
FS Granted
LN.CNT 905
INCL INCLM: 424/093.210
INCLS: 424/093.100; 424/093.200; 435/172.300; 435/325.000
NCL NCLM: 424/093.210
NCLS: 424/093.100; 424/093.200; 435/325.000; 435/455.000; 435/456.000
IC [6]
ICM: A01N063-00
ICS: C12N015-00
EXF 600/36; 623/1; 623/11; 623/12; 435/172.3; 435/240.2; 435/320.1; 435/325; 424/93.21; 424/93.1; 424/93.2; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 514 OF 549 USPATFULL on STN
AN 1998:82763 USPATFULL
TI Hydroxyl-containing xanthine compounds
IN Underiner, Gail E., Brier, WA, United States
Porubek, David, Seattle, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Woodson, Paul, Edmonds, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5780476 19980714 <--
AI US 1995-468660 19950606 (8)
RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16 Nov 1992, now patented, Pat. No. US 5473070
DT Utility
FS Granted
LN.CNT 1672
INCL INCLM: 514/263.000
INCLS: 544/267.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
ICS: C07D473-04
EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 515 OF 549 USPATFULL on STN
AN 1998:79344 USPATFULL
TI Method for preparing substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777117 19980707 <--

RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned , said Ser. No. US -152650 which is a continuation-in-part of Ser. No. US -40820
DT Utility
FS Granted
LN.CNT 3153
INCL INCLM: 544/267.000
INCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
NCL NCLM: 544/267.000
NCLS: 544/257.000; 544/285.000; 544/286.000; 544/287.000; 544/311.000; 546/141.000; 546/243.000; 546/246.000; 548/477.000; 548/546.000
IC [6]
ICM: C07D473-10
ICS: C07D239-80; C07D211-94; C07D209-48
EXF 544/267; 544/257; 544/285; 544/286; 544/287; 544/311; 546/141; 546/243; 546/246; 548/477; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 516 OF 549 USPATFULL on STN
AN 1998:79342 USPATFULL
TI Acetal-and ketal-substituted pyrimidine compounds
IN Leigh, Alistair, Brier, WA, United States
Underiner, Gail, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5777115 19980707 <--
AI US 1994-193331 19940207 (8)
RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 1632
INCL INCLM: 544/242.000
INCLS: 544/267.000; 514/269.000; 514/270.000; 514/256.000
NCL NCLM: 544/242.000
NCLS: 544/267.000
IC [6]
ICM: C07D239-26
ICS: A61K031-505
EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 517 OF 549 USPATFULL on STN
AN 1998:72634 USPATFULL
TI Prevention and treatment of cardiovascular pathologies
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
Kunz, Lawrence L., Redmond, WA, United States
Schroff, Robert W., Edmonds, WA, United States
Weissberg, Peter L., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5770609 19980623 <--
AI US 1995-486334 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993,

DT Utility
FS Granted
LN.CNT 4318
INCL INCLM: 514/319.000
INCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
NCL NCLM: 514/319.000
NCLS: 514/324.000; 514/422.000; 514/428.000; 514/444.000; 514/448.000; 514/651.000
IC [6]
ICM: A61K031-445
ICS: A61K031-40; A61K031-38; A61K031-135
EXF 514/651; 514/324; 514/212; 514/422; 514/428; 514/444; 514/448; 514/319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 518 OF 549 USPATFULL on STN
AN 1998:72620 USPATFULL
TI Oxime substituted therapeutic compounds
IN Klein, J. Peter, Vashon, WA, United States
Leigh, Alistair, Brier, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5770595 19980623 <--
AI US 1994-193344 19940207 (8)
RLI Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2183
INCL INCLM: 514/263.000
INCLS: 544/271.000; 544/273.000
NCL NCLM: 514/263.350
NCLS: 514/151.000; 544/271.000; 544/273.000
IC [6]
ICM: M61K031-52
EXF 514/263; 544/271; 544/273

L5 ANSWER 519 OF 549 USPATFULL on STN
AN 1998:51651 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5750575 19980512 <--
AI US 1995-475721 19950607 (8)
RLI Division of Ser. No. US 1994-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And a continuation-in-part of Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3115
INCL INCLM: 514/617.000
INCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
NCL NCLM: 514/617.000
NCLS: 514/653.000; 564/182.000; 564/355.000; 564/361.000
IC [6]
ICM: A61K031-165
ICS: A61K031-135; C07C233-35; C07C215-20
EXF 564/355; 564/182; 564/361; 514/617; 514/653

L5 ANSWER 520 OF 549 USPATFULL on STN
AN 1998:39529 USPATFULL
TI Enantiomerically pure hydroxylated xanthine compounds to treat autoimmune diabetes
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5739138 19980414 <--
AI US 1995-457703 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1734
INCL INCLM: 514/263.000
INCLS: 514/866.000
NCL NCLM: 514/263.360
NCLS: 514/866.000
IC [6]
ICM: A61K031-52
EXF 514/263; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 521 OF 549 USPATFULL on STN
AN 1998:27916 USPATFULL
TI Methods for identifying cardiovascular therapeutic agents
IN Mendelsohn, Michael E., Wellesley, MA, United States
Karas, Richard H., Franklin, MA, United States
PA New England Medical Center Hospitals, Inc., Boston, MA, United States (U.S. corporation)
PI US 5728534 19980317 <--
AI US 1996-684704 19960719 (8)
DT Utility
FS Granted
LN.CNT 1298
INCL INCLM: 435/007.100
INCLS: 435/007.800; 435/007.720; 435/244.000; 435/325.000; 435/375.000; 435/069.100
NCL NCLM: 435/007.100
NCLS: 435/007.720; 435/007.800; 435/069.100; 435/244.000; 435/325.000; 435/375.000
IC [6]
ICM: G01N033-53
ICS: G01N033-566; C12N015-09
EXF 435/325; 435/375; 435/7.1; 435/7.8; 435/244; 435/7.72; 435/7.2; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 522 OF 549 USPATFULL on STN
AN 97:86614 USPATFULL
TI Halogen, isothiocyanate or azide substituted xanthines
IN Leigh, Alistair, Brier, WA, United States
Michnick, John, Seattle, WA, United States
Kumar, Anil, Seattle, WA, United States
Underiner, Gail, Brier, WA, United States

PI US 5670506 19970923 <--
AI US 1993-42946 19930405 (8)
DT Utility
FS Granted
LN.CNT 1994
INCL INCLM: 514/258.000
INCLS: 514/263.000; 544/267.000; 544/272.000; 544/277.000
NCL NCLM: 514/141.000
NCLS: 544/267.000; 544/272.000; 544/277.000
IC [6]
ICM: A61K031-52
ICS: C07D473-00
EXF 544/267; 544/276; 544/272; 544/277; 514/258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 523 OF 549 USPATFULL on STN
AN 97:73601 USPATFULL
TI Compositions for inhibiting restenosis
IN Weisz, Paul B., State College, PA, United States
PA The Trustees of the University of Pennsylvania, Philadephia, PA, United States (U.S. corporation)
PI US 5658894 19970819 <--
AI US 1994-345011 19941123 (8)
RLI Continuation of Ser. No. US 1992-900592, filed on 18 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1991-790320, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-691168, filed on 24 Apr 1991, now abandoned which is a continuation of Ser. No. US 1989-397559, filed on 23 Aug 1989, now abandoned , said Ser. No. US -900592 which is a continuation-in-part of Ser. No. US 1990-480407, filed on 15 Feb 1990, now patented, Pat. No. US 5183809, issued on 2 Feb 1993
DT Utility
FS Granted
LN.CNT 1449
INCL INCLM: 514/058.000
INCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 536/103.000; 530/810.000; 530/812.000; 530/813.000
NCL NCLM: 514/058.000
NCLS: 514/021.000; 514/023.000; 514/054.000; 514/060.000; 530/810.000; 530/812.000; 530/813.000; 536/103.000
IC [6]
ICM: A61K031-735
ICS: C08B037-16
EXF 514/21; 514/23; 514/54; 514/58; 514/60; 536/103; 530/810; 530/812; 530/813
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 524 OF 549 USPATFULL on STN
AN 97:66130 USPATFULL
TI Methods of using enantiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5652243 19970729 <--
AI US 1994-343810 19941122 (8)
RLI Division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1731

INCLS: 514/262.000; 514/265.000; 514/814.000
NCL NCLM: 514/263.360
NCLS: 514/814.000
IC [6]
ICM: A61K031-52
EXF 514/262; 514/263; 514/265
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 525 OF 549 USPATFULL on STN
AN 97:61689 USPATFULL
TI Enatiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5648357 19970715 <--
AI US 1994-307554 19940916 (8)
RLI Continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1748
INCL INCLM: 514/263.000
INCLS: 514/267.000; 514/270.000; 514/271.000
NCL NCLM: 514/263.360
NCLS: 514/267.000; 514/270.000; 514/271.000
IC [6]
ICM: A61K031-52
EXF 514/263; 514/267; 544/267; 544/270; 544/271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 526 OF 549 USPATFULL on STN
AN 97:54233 USPATFULL
TI Substituted amino alcohol compounds
IN Klein, J. Peter, Vashon, WA, United States
Underiner, Gail E., Brier, WA, United States
Kumar, Anil M., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5641783 19970624 <--
AI US 1994-303842 19940908 (8)
RLI Continuation-in-part of Ser. No. US 1993-152650, filed on 12 Nov 1993 And Ser. No. US 1993-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878
DT Utility
FS Granted
LN.CNT 3206
INCL INCLM: 514/263.000
INCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800; 514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800; 514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000; 514/247.000; 514/248.000; 514/249.000; 514/255.000; 514/256.000; 514/258.000; 514/259.000; 514/261.000; 514/262.000; 514/263.000; 514/270.000; 514/274.000; 514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000; 514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000; 514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000; 514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000; 514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000; 514/381.000; 514/383.000; 514/389.000;

514/404.000; 514/406.000; 514/413.000; 514/415.000; 514/416.000;
514/418.000; 514/423.000; 514/424.000; 514/425.000; 514/427.000;
514/428.000; 544/001.000; 544/002.000; 544/003.000; 544/008.000;
544/053.000; 544/063.000; 544/065.000; 544/066.000; 544/067.000;
544/090.000; 544/091.000; 544/162.000; 544/215.000; 544/216.000;
544/219.000; 544/220.000; 544/224.000; 544/235.000; 544/239.000;
544/254.000; 544/255.000; 544/257.000; 544/262.000; 544/272.000;
544/277.000; 544/278.000; 544/280.000; 544/283.000; 544/286.000;
544/301.000; 544/311.000; 544/335.000; 544/336.000; 544/350.000;
544/353.000; 544/385.000; 544/401.000; 546/102.000; 546/113.000;
546/114.000; 546/115.000; 546/117.000; 546/118.000; 546/119.000;
546/122.000; 546/138.000; 546/139.000; 546/150.000; 546/153.000;
546/157.000; 546/164.000; 546/176.000; 546/178.000; 546/242.000;
546/243.000; 546/246.000; 546/264.000; 546/300.000; 546/334.000;
548/100.000; 548/123.000; 548/125.000; 548/127.000; 548/128.000;
548/131.000; 548/134.000; 548/146.000; 548/153.000; 548/179.000;
548/186.000; 548/207.000; 548/214.000; 548/215.000; 548/217.000;
548/221.000; 548/225.000; 548/228.000; 548/229.000; 548/235.000;
548/237.000; 548/240.000; 548/241.000; 548/243.000; 548/247.000;
548/252.000; 548/267.200; 548/267.800; 548/303.700; 548/306.400;
548/307.100; 548/309.700; 548/319.100; 548/323.500; 548/340.100;
548/348.100; 548/349.100; 548/356.100; 548/370.100; 548/375.100;
548/379.400; 548/452.000; 548/453.000; 548/470.000; 548/482.000;
548/485.000; 548/486.000; 548/491.000; 548/503.000; 548/532.000;
548/543.000; 548/546.000; 548/550.000; 548/565.000; 548/566.000

NCL NCLM: 514/263.350

NCLS: 514/183.000; 514/222.500; 514/223.500; 514/224.200; 514/226.800;
514/227.500; 514/228.800; 514/229.200; 514/230.500; 514/230.800;
514/237.800; 514/241.000; 514/242.000; 514/243.000; 514/246.000;
514/247.000; 514/248.000; 514/249.000; 514/252.160; 514/256.000;
514/259.500; 514/264.100; 514/266.300; 514/270.000; 514/274.000;
514/297.000; 514/300.000; 514/301.000; 514/302.000; 514/303.000;
514/306.000; 514/307.000; 514/311.000; 514/312.000; 514/315.000;
514/345.000; 514/351.000; 514/357.000; 514/359.000; 514/360.000;
514/361.000; 514/362.000; 514/363.000; 514/364.000; 514/365.000;
514/367.000; 514/369.000; 514/372.000; 514/373.000; 514/374.000;
514/375.000; 514/376.000; 514/378.000; 514/379.000; 514/380.000;
514/381.000; 514/383.000; 514/389.000; 514/394.000; 514/395.000;
514/398.000; 514/399.000; 514/401.000; 514/404.000; 514/406.000;
514/413.000; 514/415.000; 514/416.000; 514/418.000; 514/423.000;
514/424.000; 514/425.000; 514/427.000; 514/428.000; 544/001.000;
544/002.000; 544/003.000; 544/008.000; 544/053.000; 544/063.000;
544/065.000; 544/066.000; 544/067.000; 544/090.000; 544/091.000;
544/162.000; 544/215.000; 544/216.000; 544/219.000; 544/220.000;
544/224.000; 544/235.000; 544/239.000; 544/254.000; 544/255.000;
544/257.000; 544/262.000; 544/272.000; 544/277.000; 544/278.000;
544/280.000; 544/283.000; 544/286.000; 544/301.000; 544/311.000;
544/335.000; 544/336.000; 544/350.000; 544/353.000; 544/385.000;
544/401.000; 546/102.000; 546/113.000; 546/114.000; 546/115.000;
546/117.000; 546/118.000; 546/119.000; 546/122.000; 546/138.000;
546/139.000; 546/150.000; 546/153.000; 546/157.000; 546/164.000;
546/176.000; 546/178.000; 546/242.000; 546/243.000; 546/246.000;
546/264.000; 546/300.000; 546/334.000; 548/100.000; 548/123.000;
548/125.000; 548/127.000; 548/128.000; 548/131.000; 548/134.000;
548/146.000; 548/153.000; 548/179.000; 548/186.000; 548/207.000;
548/214.000; 548/215.000; 548/217.000; 548/221.000; 548/225.000;
548/228.000; 548/229.000; 548/235.000; 548/237.000; 548/240.000;
548/241.000; 548/243.000; 548/247.000; 548/252.000; 548/267.200;
548/267.800; 548/303.700; 548/306.400; 548/307.100; 548/309.700;
548/319.100; 548/323.500; 548/340.100; 548/348.100; 548/349.100;
548/356.100; 548/370.100; 548/375.100; 548/379.400; 548/452.000;
548/453.000; 548/470.000; 548/482.000; 548/485.000; 548/486.000;

548/550.000; 548/565.000; 548/566.000
IC [6]
ICM: A61K031-415
ICS: A61K031-42; A61K031-425; A61K031-52
EXF 544/272; 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 527 OF 549 USPATFULL on STN
AN 97:51973 USPATFULL
TI Peptide mediated enhancement of thrombolysis methods and compositions
IN Lawrence, Daniel A., Ann Arbor, MI, United States
Ginsburg, David, Ann Arbor, MI, United States
Shore, Joseph D., Grosse Point Farms, MI, United States
Fay, William P., Ann Arbor, MI, United States
Olson, Steven T., Chicago, IL, United States
Francis-Chmura, Ann Marie, Warren, MI, United States
Eitzman, Daniel T., Ypsilanti, MI, United States
Paielli, Dell, Wyandotte, MI, United States
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)
Henry Ford Health System, Detroit, MI, United States (U.S. corporation)
PI US 5639726 19970617 <--
AI US 1994-315461 19940930 (8)
DT Utility
FS Granted
LN.CNT 4817
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
IC [6]
ICM: A61K038-00
ICS: A61K038-02; C07K005-00; C07K007-00
EXF 530/324; 530/325; 530/326; 530/327; 530/328; 514/12; 514/13; 514/14; 514/15; 514/16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 528 OF 549 USPATFULL on STN
AN 97:40793 USPATFULL
TI Treatment of diseases using enantiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5629315 19970513 <--
AI US 1995-456900 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1736
INCL INCLM: 514/263.000
INCLS: 514/866.000

NCLS: 514/866.000
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 529 OF 549 USPATFULL on STN
AN 97:31820 USPATFULL
TI Process for preparing enantiomerically pure xanthine derivatives
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5621102 19970415 <--
AI US 1995-456897 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1763
INCL INCLM: 544/267.000
INCLS: 514/340.000
NCL NCLM: 544/267.000
IC [6]
ICM: C07D473-06
ICS: C07D473-08; C07D473-12
EXF 544/267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 530 OF 549 USPATFULL on STN
AN 97:31706 USPATFULL
TI Enatiomerically pure hydroxylated xanthine compounds to treat inflammatory diseases
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5620984 19970415 <--
AI US 1995-456898 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1721
INCL INCLM: 514/263.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 97:22792 USPATFULL
TI Enantiomerically pure hydroxylated xanthine compounds to treat shock symptoms
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5612349 19970318 <--
AI US 1995-457062 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994, now abandoned which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1725
INCL INCLM: 514/263.000
INCLS: 514/921.000
NCL NCLM: 514/263.360
NCLS: 514/921.000
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 532 OF 549 USPATFULL on STN
AN 97:5708 USPATFULL
TI Method for identifying an agent which increases TGF-beta levels
IN Grainger, David J., Cambridge, England
Metcalfe, James C., Cambridge, England
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5595722 19970121 <--
AI US 1995-476735 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned And Ser. No. US 1994-241844, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-11669, filed on 28 Jan 1993, now abandoned
DT Utility
FS Granted
LN.CNT 4090
INCL INCLM: 424/009.200
NCL NCLM: 424/009.200
IC [6]
ICM: A61K049-00
EXF 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 533 OF 549 USPATFULL on STN
AN 96:111463 USPATFULL
TI Enatiomerically pure hydroxylated xanthine compounds
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5580874 19961203 <--

RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994, now abandoned which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1733
INCL INCLM: 514/263.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 534 OF 549 USPATFULL on STN
AN 96:111462 USPATFULL
TI Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5580873 19961203 <--
AI US 1995-456899 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1728
INCL INCLM: 514/263.000
NCL NCLM: 514/263.360
IC [6]
ICM: A61K031-52
EXF 514/263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 535 OF 549 USPATFULL on STN
AN 96:111313 USPATFULL
TI Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
IN Foulkes, J. Gordon, Huntington Station, NY, United States
Liechtfried, Franz E., Vienna, Austria
Pieler, Christian, Vienna, Austria
Stephenson, John R., Santa Cruz, CA, United States
Case, Casey C., Lynbrook, NY, United States
PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)
PI US 5580722 19961203 <--
AI US 1992-832905 19920207 (7)
RLI Continuation-in-part of Ser. No. US 1990-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-382712, filed on 18 Jul 1989, now abandoned
DT Utility
FS Granted
LN.CNT 4011

INCLS: 435/091.100; 435/091.200; 935/077.000; 935/078.000
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200
IC [6]
ICM: C12P019-34
ICS: C12Q001-68
EXF 435/6; 435/91; 435/91.1; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 536 OF 549 USPATFULL on STN
AN 96:97041 USPATFULL
TI R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
IN Bianco, James A., Seattle, WA, United States
Woodson, Paul, Bothell, WA, United States
Porubek, David, Edmonds, WA, United States
Singer, Jack, Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5567704 19961022 <--
AI US 1995-457683 19950601 (8)
RLI Division of Ser. No. US 1994-343810, filed on 22 Nov 1994 which is a division of Ser. No. US 1994-307554, filed on 16 Sep 1994 which is a continuation of Ser. No. US 1993-13977, filed on 4 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-926665, filed on 7 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-846354, filed on 4 Mar 1992, now abandoned
DT Utility
FS Granted
LN.CNT 1736
INCL INCLM: 514/263.000
INCLS: 514/262.000
NCL NCLM: 514/263.360
NCLS: 424/070.100
IC [6]
ICM: A61K031-52
EXF 514/263; 514/262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 537 OF 549 USPATFULL on STN
AN 96:72817 USPATFULL
TI Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IN Grainger, David J., Cambridge, United Kingdom
Metcalfe, James C., Cambridge, United Kingdom
Weissberg, Peter L., Cambridge, United Kingdom
PA NeoRx Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5545569 19960813 <--
AI US 1995-450520 19950525 (8)
RLI Division of Ser. No. US 1994-242161, filed on 12 May 1994 which is a continuation-in-part of Ser. No. US 1993-61714, filed on 13 May 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2263
INCL INCLM: 436/518.000
NCL NCLM: 436/518.000
IC [6]
ICM: G01N033-543
EXF 436/518; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 538 OF 549 USPATFULL on STN
AN 95:105868 USPATFULL

IN Michnick, John, Seattle, WA, United States
Underiner, Gail E., Brier, WA, United States
Klein, J. Peter, Vashon Island, WA, United States
Rice, Glenn C., Seattle, WA, United States
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 5470878 19951128 <--
AI US 1993-164081 19931208 (8)
RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned
DT Utility
FS Granted
LN.CNT 2665
INCL INCLM: 514/558.000
INCLS: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000; 554/055.000; 554/061.000; 554/108.000; 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000; 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000
NCL NCLM: 514/558.000
NCLS: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/669.000; 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000
IC [6]
ICM: A61K031-20
ICS: C07C233-00
EXF 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198; 564/215; 564/201; 564/197; 514/625; 514/629; 514/613; 514/558; 514/552; 514/529; 514/561; 514/626; 514/669; 560/130; 560/145; 562/553; 562/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 539 OF 549 USPATFULL on STN
AN 94:93338 USPATFULL
TI Methods for treating arteriosclerosis
IN Halperin, Jose, Brookline, MA, United States
Brugnara, Carlo, Newton Highlands, MA, United States
PA President and Fellows of Harvard University, Cambridge, MA, United States (U.S. corporation)
PI US 5358959 19941025 <--
AI US 1993-18835 19930218 (8)
DT Utility
FS Granted
LN.CNT 539
INCL INCLM: 514/396.000
INCLS: 514/399.000; 514/824.000
NCL NCLM: 514/396.000
NCLS: 514/399.000; 514/824.000
IC [5]
ICM: A61K031-415
EXF 514/396; 514/399; 514/824
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 540 OF 549 USPATFULL on STN
AN 91:84437 USPATFULL
TI Method for preventing tissue damage after an ischemic episode
IN Sheffield, Warren D., Lebanon, NJ, United States
PA Ethicon, Inc., Somerville, NJ, United States (U.S. corporation)
PI US 5057494 19911015 <--
AI US 1988-227579 19880803 (7)
DT Utility

LN.CNT 487
INCL INCLM: 514/012.000
INCLS: 514/021.000
NCL NCLM: 514/012.000
NCLS: 514/021.000
IC [5]
ICM: A61K037-02
ICS: A61K037-36
EXF 514/12; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 541 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2001-025162 [03] WPIDS
CR 2001-041064 [05]
DNC C2001-007775
TI Enhancing biological activity of vascular endothelial growth factor by replacing a Cys residue, for producing variant useful for treating hypertension, stroke, diabetes, lupus, glomerulonephritis, meningitis, tumor, pneumonia, infections.
DC B04 D16
IN ABRAHAM, J A; POLLITT, N S
PA (SCIO-N) SCIOS INC; (ABRA-I) ABRAHAM J A; (POLL-I) POLLITT N S
CYC 94
PI WO 2000071713 A1 20001130 (200103)* EN 57 C12N015-12 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000050233 A 20001212 (200115) <--
EP 1183352 A1 20020306 (200224) EN C12N015-12
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
US 6475796 B1 20021105 (200276) C12N015-87
JP 2003507006 W 20030225 (200317) 79 C12N015-09
US 2003096754 A1 20030522 (200336) A61K038-18
ADT WO 2000071713 A1 WO 2000-US13536 20000518; AU 2000050233 A AU 2000-50233 20000518; EP 1183352 A1 EP 2000-932525 20000518, WO 2000-US13536 20000518; US 6475796 B1 Provisional US 1999-135312P 19990520, US 2000-574708 20000518; JP 2003507006 W JP 2000-620090 20000518, WO 2000-US13536 20000518; US 2003096754 A1 Provisional US 1999-135312P 19990520, Div ex US 2000-574708 20000518, US 2002-268447 20021010
FDT AU 2000050233 A Based on WO 2000071713; EP 1183352 A1 Based on WO 2000071713; JP 2003507006 W Based on WO 2000071713; US 2003096754 A1 Div ex US 6475796
PRAI US 1999-135312P 19990520; US 2000-574708 20000518; US 2002-268447 20021010
IC ICM A61K038-18; C12N015-09; C12N015-12; C12N015-87
ICS A61K038-00; A61K038-22; A61K039-00; A61P007-00; A61P007-02; A61P009-00; A61P009-10; A61P009-12; A61P009-14; A61P043-00; C07K014-515; C07K014-52; C07K017-00

L5 ANSWER 542 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-619171 [59] WPIDS
CR 2000-619148 [58]
DNC C2000-185530
TI Enhancing collateral growth of collateral arteries and arteries from pre-existing arteriolar connections, using monocytes loaded with arteriogenic polypeptides, useful e.g. for treating cerebral occlusive and peripheral occlusive disease.
DC B04 D16 J04

PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN
CYC 90
PI WO 2000060054 A1 20001012 (200059)* EN 30 C12N005-10 <--
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
AU 2000045446 A 20001023 (200107) C12N005-10 <--
EP 1165754 A1 20020102 (200209) EN C12N005-10
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
ADT WO 2000060054 A1 WO 2000-EP3087 20000406; AU 2000045446 A AU 2000-45446 20000406; EP 1165754 A1 EP 2000-926832 20000406, WO 2000-EP3087 20000406
FDT AU 2000045446 A Based on WO 2000060054; EP 1165754 A1 Based on WO 2000060054
PRAI EP 1999-106800 19990406
IC ICM C12N005-10
ICS A61K048-00; C12N005-06

L5 ANSWER 543 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-365394 [31] WPIDS
DNC C2000-110292
TI Viral vascular endothelial growth factor-like proteins useful for stimulating cell proliferation, modulating vascular permeability while antagonists of the proteins are useful for treating pustular dermatitis.
DC B04 D16
IN FLEMING, S B; MERCER, A A; SAVORY, L J; STACKER, S A; WISE, L M
PA (LUDW-N) LUDWIG INST CANCER RES; (UYOT-N) UNIV OTAGO; (FLEM-I) FLEMING S B; (MERC-I) MERCER A A; (SAVO-I) SAVORY L J; (STAC-I) STACKER S A; (WISE-I) WISE L M
CYC 23
PI WO 2000025805 A1 20000511 (200031)* EN 76 A61K038-00 <--
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU JP NZ
AU 2000016053 A 20000522 (200040) A61K038-00 <--
EP 1126863 A1 20010829 (200150) EN A61K038-00
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6541008 B1 20030401 (200324) A61K039-00
JP 2003517275 W 20030527 (200344) 96 C12N015-09
US 2003211101 A1 20031113 (200382) A61K039-395
NZ 511119 A 20040430 (200431) A61K038-00
AU 775956 B2 20040819 (200474) A61K038-00
ADT WO 2000025805 A1 WO 1999-US25869 19991102; AU 2000016053 A AU 2000-16053 19991102; EP 1126863 A1 EP 1999-958757 19991102, WO 1999-US25869 19991102; US 6541008 B1 Provisional US 1998-106689P 19981102, Provisional US 1998-106800P 19981103, US 1999-431888 19991102; JP 2003517275 W WO 1999-US25869 19991102, JP 2000-579245 19991102; US 2003211101 A1 Provisional US 1998-106689P 19981102, Provisional US 1998-106800P 19981103, Div ex US 1999-431888 19991102, US 2003-352153 20030128; NZ 511119 A NZ 1999-511119 19991102, WO 1999-US25869 19991102; AU 775956 B2 AU 2000-16053 19991102
FDT AU 2000016053 A Based on WO 2000025805; EP 1126863 A1 Based on WO 2000025805; JP 2003517275 W Based on WO 2000025805; US 2003211101 A1 Div ex US 6541008; NZ 511119 A Based on WO 2000025805; AU 775956 B2 Previous Publ. AU 2000016053, Based on WO 2000025805
PRAI US 1998-106800P 19981103; US 1998-106689P 19981102; US 1999-431888 19991102; US 2003-352153 20030128
IC ICM A61K038-00; A61K039-00; A61K039-395; C12N015-09
ICS A61K031-727; A61K038-18; A61K045-00; A61P009-00; A61P017-00; C07H016-00; C07H021-04; C07K014-065; C07K016-08; C07K017-00; C12N001-21; C12N005-00; C12N005-06; C12N005-10; C12P021-02;

L5 ANSWER 544 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-317840 [27] WPIDS
CR 2000-256860 [22]; 2002-608416 [65]; 2003-101732 [09]; 2003-174592 [17]; 2003-746236 [70]
DNC C2000-096206
TI Novel unit dose comprising fibroblast growth factor, its angiogenically active fragment or mutein for inducing cardiac angiogenesis, treating ***coronary*** ***artery*** ***disease*** and reducing post myocardial infarction injury.
DC B04
IN KAVANAUGH, W M
PA (CHIR) CHIRON CORP; (WHIT-I) WHITEHOUSE M J
CYC 87
PI WO 2000021548 A2 20000420 (200027)* EN 66 A61K038-00 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW
AU 9964111 A 20000501 (200036) <--
EP 1121141 A2 20010808 (200146) EN A61K038-18
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
JP 2002527401 W 20020827 (200271) 72 A61K038-22
ADT WO 2000021548 A2 WO 1999-US22936 19991013; AU 9964111 A AU 1999-64111 19991013; EP 1121141 A2 EP 1999-951728 19991013, WO 1999-US22936 19991013; JP 2002527401 W WO 1999-US22936 19991013, JP 2000-575522 19991013
FDT AU 9964111 A Based on WO 2000021548; EP 1121141 A2 Based on WO 2000021548; JP 2002527401 W Based on WO 2000021548
PRAI US 1998-104103P 19981013
IC ICM A61K038-00; A61K038-18; A61K038-22
ICS A61K031-726; A61P009-10
ICA C07K014-50

L5 ANSWER 545 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-256866 [22] WPIDS
DNC C2000-078440
TI Hydrogel compositions useful for controlled delivery of growth factors e.g. in treatment of ischemia and in wound healing.
DC A11 A25 A96 B04 B07
IN JENNINGS, R N; PROTTER, A A; WANG, Y J; YANG, B
PA (SCIO-N) SCIOS INC
CYC 87
PI WO 2000013710 A2 20000316 (200022)* EN 27 A61K047-10 <--
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
AU 9959095 A 20000327 (200032) <--
EP 1107791 A2 20010620 (200135) EN A61K047-10
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
US 6331309 B1 20011218 (200205) A61F013-00
JP 2002524425 W 20020806 (200266) 33 A61K038-22
AU 758178 B 20030320 (200329) A61K047-10
ADT WO 2000013710 A2 WO 1999-US20382 19990903; AU 9959095 A AU 1999-59095 19990903; EP 1107791 A2 EP 1999-946759 19990903, WO 1999-US20382 19990903; US 6331309 B1 Provisional US 1998-99168P 19980904, US 1999-390164

19990903; AU 758178 B AU 1999-59095 19990903
FDT AU 9959095 A Based on WO 2000013710; EP 1107791 A2 Based on WO 2000013710; JP 2002524425 W Based on WO 2000013710; AU 758178 B Previous Publ. AU 9959095, Based on WO 2000013710
PRAI US 1998-99168P 19980904; US 1999-390164 19990903
IC ICM A61F013-00; A61K038-22; A61K047-10
ICS A61K009-10; A61K009-70; A61K038-18; A61K047-26; A61K047-32; A61K047-34; A61K047-36; A61P009-10; A61P017-02

L5 ANSWER 546 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-246641 [21] WPIDS
CR 2000-038600 [03]
DNN N2000-184459 DNC C2000-074681
TI Implantable device, carrying cells which produce and release therapeutic agent locally at site, and a monitor to detect unfavorable physiological change and signal the cells before damage occurs, use, e.g., in ***coronary*** ***artery*** ***disease*** .
DC A96 B07 D16 D22 P31 P32
IN DONOVAN, M G; SOYHAN, O; SOYKAN, O
PA (MEDT) MEDTRONIC INC
CYC 20
PI WO 2000012028 A1 20000309 (200021)* EN 52 A61F002-06 <--
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
EP 1027014 A1 20000816 (200040) EN A61F002-06 <--
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6206914 B1 20010327 (200119) A61F002-06
US 2001000802 A1 20010503 (200126) A61F002-06
EP 1426021 A1 20040609 (200438) EN A61F002-06
R: CH DE FR LI NL SE
EP 1027014 B1 20041124 (200477) EN A61F002-06
R: CH DE FR LI NL SE
US 6824561 B2 20041130 (200479) A61F002-06
DE 69922143 E 20041230 (200502) A61F002-06
ADT WO 2000012028 A1 WO 1999-US18719 19990823; EP 1027014 A1 EP 1999-942261 19990823, WO 1999-US18719 19990823; US 6206914 B1 CIP of US 1998-70480 19980430, US 1998-144420 19980831; US 2001000802 A1 CIP of US 1998-70480 19980430, Div ex US 1998-144420 19980831, US 2000-745144 20001220; EP 1426021 A1 Div ex EP 1999-942261 19990823, EP 2004-6105 19990823; EP 1027014 B1 EP 1999-942261 19990823, WO 1999-US18719 19990823, Related to EP 2004-6105 19990823; US 6824561 B2 CIP of US 1998-70480 19980430, Div ex US 1998-144420 19980831, US 2000-745144 20001220; DE 69922143 E DE 1999-622143 19990823, EP 1999-942261 19990823, WO 1999-US18719 19990823
FDT EP 1027014 A1 Based on WO 2000012028; EP 1426021 A1 Div ex EP 1027014; EP 1027014 B1 Related to EP 1426021, Based on WO 2000012028; US 6824561 B2 Div ex US 6206914; DE 69922143 E Based on EP 1027014, Based on WO 2000012028
PRAI US 1998-144420 19980831; US 1998-70480 19980430;
US 2000-745144 20001220
IC ICM A61F002-06
ICS A61B019-00; A61F002-02; C12N015-09

L5 ANSWER 547 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN
AN 2000-171083 [15] WPIDS
CR 1993-288089 [36]; 1997-319538 [29]; 1998-427937 [36]; 1998-582508 [49]; 1999-008650 [01]; 2000-171084 [15]; 2000-182219 [16]
DNN N2000-127157 DNC C2000-053204
TI Stimulating vascularization for e.g. promoting wound healing by contacting site with matrix comprising gelatin and nitric oxide inhibitor.
DC B03 B05 C02 C03 P32 P34
IN USALA, A; KLANN, R C
PA (ENCE-N) ENCELLE INC; (USAL-I) USALA A
CYC 87

```
      RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
          OA PT SD SE SL SZ UG ZW
       W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
          GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
          LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
          TT UA UG US UZ VN YU ZA ZW
    AU 9950952      A  20000201 (200028)                              <--
    EP 1094849      A1 20010502 (200125)  EN          A61L015-32
       R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
          RO SE SI
    US 6261587      B1 20010717 (200142)              A61F002-02
    US 2001007658   A1 20010712 (200143)              C12N005-00
    US 2001010826   A1 20010802 (200147)              A61K009-06
    AU 757968       B  20030313 (200328)              A61L015-32
    US 6713079      B2 20040330 (200423)              A61F002-00
    US 6730315      B2 20040504 (200430)#             A61F002-00
ADT WO 2000002596 A1 WO 1999-US15614 19990709; AU 9950952 A AU 1999-50952
    19990709; EP 1094849 A1 EP 1999-935483 19990709, WO 1999-US15614 19990709;
    US 6261587 B1 CIP of US 1998-113437 19980710, US 1999-337959 19990622; US
    2001007658 A1 CIP of US 1992-841973 19920224, CIP of US 1994-300429
    19940902, CIP of US 1995-568482 19951207, Div ex US 1998-113437 19980710,
    US 2001-758676 20010111; US 2001010826 A1 CIP of US 1992-841973 19920224,
    CIP of US 1994-300429 19940902, CIP of US 1995-568482 19951207, CIP of US
    1998-113437 19980710, Div ex US 1999-337959 19990622, US 2001-766330
    20010119; AU 757968 B AU 1999-50952 19990709; US 6713079 B2 CIP of US
    1992-841973 19920224, CIP of US 1994-300429 19940902, CIP of US
    1995-568482 19951207, CIP of US 1998-113437 19980710, Div ex US
    1999-337959 19990622, US 2001-766330 20010119; US 6730315 B2 CIP of US
    1992-841973 19920224, CIP of US 1994-300429 19940902, Div ex US
    1998-113437 19980710, CIP of US 1998-568482 19981207, US 2001-758676
    20010111
FDT AU 9950952 A Based on WO 2000002596; EP 1094849 A1 Based on WO 2000002596;
    US 2001007658 A1 CIP of US 5834005, Div ex US 6231881; US 2001010826 A1
    CIP of US 5834005, CIP of US 6231881; AU 757968 B Previous Publ. AU
    9950952, Based on WO 2000002596; US 6713079 B2 CIP of US 5834005, CIP of
    US 6231881, Div ex US 6261587; US 6730315 B2 CIP of US 5834005
PRAI US 1999-337959       19990622; US 1998-113437       19980710;
    US 1992-841973        19920224; US 1994-300429       19940902;
    US 1995-568482        19951207; US 2001-758676       20010111;
    US 2001-766330        20010119
IC  ICM  A61F002-00; A61F002-02; A61K009-06; A61L015-32; C12N005-00
    ICS  A61F013-00; A61K031-715; A61L015-44; A61L031-00; A61L033-00;
         C12N005-02

L5  ANSWER 548 OF 549  WPIDS  COPYRIGHT 2005 THE THOMSON CORP on STN
AN  2000-052684 [04]   WPIDS
DNC C2000-013542
TI  Use of angiogenic factors to stimulate angiogenesis for treatment of
    cardiovascular diseases.
DC  A96 B04 D16
IN  COLLEY, K J
PA  (ANGI-N) ANGIOGENIX INC; (COLL-I) COLLEY K J
CYC 87
PI  WO 9953943      A2 19991028 (200004)* EN   37    A61K038-18     <--
      RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
          OA PT SD SE SL SZ UG ZW
       W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
          GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU
          LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
          TT UA UG US UZ VN YU ZA ZW
    AU 9934955      A  19991108 (200014)                              <--
    BR 9909717      A  20001226 (200103)              A61K038-18      <--
```

R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
NO 2000005190 A 20001130 (200108) A61K038-18 <--
JP 2002512200 W 20020423 (200243) 48 A61K038-00
CN 1379681 A 20021113 (200317) A61K038-18
AU 760664 B 20030522 (200338) A61K038-18
US 2003185794 A1 20031002 (200365) A61K038-19
MX 2000010110 A1 20020801 (200367) A61K038-18
US 2003202960 A1 20031030 (200372) A61K038-19

ADT WO 9953943 A2 WO 1999-US8420 19990416; AU 9934955 A AU 1999-34955 19990416; BR 9909717 A BR 1999-9717 19990416, WO 1999-US8420 19990416; EP 1071445 A2 EP 1999-916697 19990416, WO 1999-US8420 19990416; NO 2000005190 A WO 1999-US8420 19990416, NO 2000-5190 20001016; JP 2002512200 W WO 1999-US8420 19990416, JP 2000-544346 19990416; CN 1379681 A CN 1999-806834 19990416; AU 760664 B AU 1999-34955 19990416; US 2003185794 A1 Provisional US 1998-82155P 19980417, Div ex US 1999-293287 19990416, US 2002-323533 20021218; MX 2000010110 A1 WO 1999-US8420 19990416, MX 2000-10110 20001016; US 2003202960 A1 Provisional US 1998-82155P 19980417, Cont of US 1999-293287 19990416, US 2003-457915 20030609

FDT AU 9934955 A Based on WO 9953943; BR 9909717 A Based on WO 9953943; EP 1071445 A2 Based on WO 9953943; JP 2002512200 W Based on WO 9953943; AU 760664 B Previous Publ. AU 9934955, Based on WO 9953943; MX 2000010110 A1 Based on WO 9953943

PRAI US 1998-82155P 19980417; US 1999-293287 19990416;
US 2002-323533 20021218; US 2003-457915 20030609

IC ICM A61K038-00; A61K038-18; A61K038-19
ICS A61K009-127; A61K009-26; A61K038-17; A61K038-22; A61K048-00; A61P009-00; A61P017-02; A61P019-00; A61P025-28; A61P043-00

ICA A61K035-76

L5 ANSWER 549 OF 549 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN

AN 1998-179057 [16] WPIDS

DNC C1998-057496

TI New isolated vascular endothelial growth factor-D - used to develop products for use in e.g. modifying angiogenesis or treating lung, heart or intestinal disorders.

DC B04 D16

IN ACHEN, M G; ALITALO, K; STACKER, S A; WILKS, A F

PA (LUDW-N) LUDWIG INST CANCER RES; (UYHE-N) UNIV HELSINKI LICENSING LTD OY; (UYHE-N) UNIV HELSINKI LICENSING LTD

CYC 79

PI WO 9807832 A1 19980226 (199816)* EN 90 C12N001-21 <--
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW
AU 9740796 A 19980306 (199830) C12N001-21 <--
EP 956339 A1 19991117 (199953) EN C12N001-21 <--
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
AU 729880 B 20010215 (200115) C12N001-21
US 6235713 B1 20010522 (200130) A61K038-18
JP 2001517075 W 20011002 (200172) 112 C12N015-09
EP 1283268 A2 20030212 (200312) EN C12N015-85
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 2003114658 A1 20030619 (200341) C07H021-04
US 2003125537 A1 20030703 (200345) A61K038-18
US 6689580 B1 20040210 (200413) C12N001-21
US 2004175730 A1 20040909 (200459) C12Q001-68

ADT WO 9807832 A1 WO 1997-US14696 19970821; AU 9740796 A AU 1997-40796 19970821; EP 956339 A1 EP 1997-938486 19970821, WO 1997-US14696 19970821; AU 729880 B AU 1997-40796 19970821; US 6235713 B1 Provisional US

1997-38814P 19970210, Provisional US 1997-51426P 19970701, US 1997-915795 19970821; JP 2001517075 W WO 1997-US14696 19970821, JP 1998-510953 19970821; EP 1283268 A2 Div ex EP 1997-938486 19970821, EP 2002-18842 19970821; US 2003114658 A1 Provisional US 1996-23751P 19960823, Provisional US 1996-31097P 19961114, Provisional US 1997-38814P 19970210, Provisional US 1997-51426P 19970701, Div ex US 1997-915795 19970821, Div ex US 1999-296275 19990422, US 2002-274953 20021022; US 2003125537 A1 Provisional US 1996-23751P 19960823, Provisional US 1996-31097P 19961114, Provisional US 1997-38814P 19970210, Provisional US 1997-51426P 19970701, Div ex US 1997-915795 19970821, Div ex US 1999-296275 19990422, US 2002-161694 20020605; US 6689580 B1 Provisional US 1996-23751P 19960823, Provisional US 1996-31097P 19961114, Provisional US 1997-38814P 19970210, Provisional US 1997-51426P 19970701, Div ex US 1997-915795 19970821, US 1999-296275 19990422; US 2004175730 A1 Div ex US 1997-915795 19970821, Div ex US 1999-296275 19990422, Cont of US 2002-161694 20020605, US 2003-705476 20031112

FDT AU 9740796 A Based on WO 9807832; EP 956339 A1 Based on WO 9807832; AU 729880 B Previous Publ. AU 9740796, Based on WO 9807832; JP 2001517075 W Based on WO 9807832; EP 1283268 A2 Div ex EP 956339; US 2003114658 A1 Div ex US 6235713; US 2003125537 A1 Div ex US 6235713; US 6689580 B1 Div ex US 6235713; US 2004175730 A1 Div ex US 6235713, Div ex US 6689580

PRAI US 1997-51426P 19970701; AU 1996-1825 19960823;
US 1996-23751P 19960823; AU 1996-3554 19961111;
US 1996-31097P 19961114; AU 1997-4954 19970205;
US 1997-38814P 19970210; AU 1997-7435 19970619

IC ICM A61K038-18; C07H021-04; C12N001-21; C12N015-09; C12N015-85; C12Q001-68

ICS A61K038-00; A61K038-19; A61K038-22; A61K039-395; A61K045-00; A61K048-00; A61P043-00; C07K001-14; C07K007-08; C07K014-47; C07K014-475; C07K014-49; C07K014-515; C07K014-52; C07K016-22; C07K016-24; C12N001-15; C12N001-19; C12N005-06; C12N005-10; C12N005-16; C12N015-18; C12N015-63; C12N015-64; C12P021-02; C12P021-08

STN INTERNATIONAL LOGOFF AT 15:29:45 ON 22 APR 2005